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ABSTRACT 
 
 
 Despite the scientific and medical communities’ best efforts, the incidence of 
fungal infections in susceptible populations continues to rise. The most common cause of 
these opportunistic fungal infections is Candida. In fact, Candida is the fourth most 
common pathogen associated with nosocomial blood stream infections. Reported 
mortality rates for patients with candidemia vary, but have not decreased in the past 
fifteen years and are reported to be as high as 50%. Candida glabrata, second only to 
Candida albicans among Candida infections, expresses high rates of resistance to 
treatment with arguably the best class of currently available antifungals - the azoles. 
Other available antifungals have associated toxicities, are not available as oral dosage 
forms or are cost prohibitive. As multidrug resistant C. glabrata have been reported, the 
need to find ways to overcome resistance to azoles is more pressing than ever. The work 
described here highlights our efforts to develop a better understanding of azole resistance 
in Candida, with a focus on C. glabrata, which can then be utilized to inform better 
strategies for decreasing or preventing resistance. 
 
 In C. glabrata clinical azole resistance is mediated almost exclusively by 
activating mutations in the zinc cluster transcription factor Pdr1, which controls the genes 
encoding the multidrug resistance transporters Cdr1, Pdh1, and Snq2. However, the 
specific relative contribution of these transporters to resistance is not known. In order to 
determine this, the SAT1 flipper method was used to delete CDR1, PDH1, and SNQ2 in a 
strain of C. glabrata engineered to carry a clinically relevant activating mutation in 
PDR1. Susceptibility testing was performed according to the CLSI guidelines with minor 
modifications and confirmed with Etest strips. Of the single transporter deletion strains, 
only CDR1 deletion resulted in decreased azole MIC. Deletion of PDH1 in combination 
with CDR1 resulted in a moderate decrease in MIC from that observed with deletion of 
CDR1 alone. SNQ2 deletion only decreased the MIC in the triple deletion strain in the 
absence of both CDR1 and PDH1. Deletion of all three transporters in combination 
decreased the MIC to the level observed in the PDR1 deletion strains for some, but not all 
of the azoles tested, which indicates additional Pdr1 targets likely play a minor role in 
this process. These results demonstrate that Cdr1 is the most important Pdr1-mediated 
multidrug resistance transporter for azole resistance in C. glabrata, suggesting that 
targeting this transporter alone might be sufficient to overcome this clinical problem. 
 
 Upc2 and Ecm22 in S. cerevisiae and Upc2 in C. albicans are the transcriptional 
regulators of ERG11, the gene encoding the target of azoles in the ergosterol biosynthesis 
pathway. Recently two homologs for these transcription factors, UPC2A and UPC2B, 
were identified in C. glabrata. One of these, UPC2A, was shown to influence azole 
susceptibility. We hypothesized that due to the global role for Upc2 in sterol biosynthesis 
in S. cerevisiae and C. albicans, disruption of UPC2A would enhance the activity of 
fluconazole in both azole-susceptible-dose dependent (SDD) and -resistant C. glabrata 
clinical isolates. To test this hypothesis, we constructed mutants disrupted for UPC2A 
and UPC2B alone and in combination in a matched pair of clinical azole-SDD and -
resistant isolates. Disruption of UPC2A in both the SDD and resistant isolates resulted in 
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increased susceptibility to sterol biosynthesis inhibitors, including a reduction in 
fluconazole minimum inhibitory concentration and minimum fungicidal concentration, 
enhanced azole activity by time-kill analysis, a decrease in ergosterol content, and 
downregulation of baseline and inducible expression of several sterol biosynthesis genes. 
Our results indicate that Upc2A is a key regulator of ergosterol biosynthesis and is 
essential for resistance to sterol biosynthesis inhibitors in C. glabrata. As such, the 
UPC2A pathway may represent a potential co-therapeutic target for enhancing azole 
activity against this organism. 
 
 The importance of Pdr1 in azole resistance in C. glabrata is well established. Our 
understanding of how Pdr1 is being regulated, however, is predominantly informed by 
regulation of similar systems in other organisms. In order to identify genes that interact 
with the Pdr1 transcriptional pathway, and influence the susceptibility of C. glabrata to 
fluconazole, we screened a collection of deletion mutants for those exhibiting increased 
resistance to fluconazole. Deletion of the gene coding for a protein homologous to the S. 
cerevisiae J protein Jjj1 resulted in decreased fluconazole susceptibility. We used the 
SAT1 flipper method to generate independent deletion mutants for JJJ1 in a SDD clinical 
isolate. Expression of both CDR1 and PDR1 was increased in the absence of JJJ1. In the 
absence of CDR1 or PDR1, deletion of JJJ1 had only a modest effect on fluconazole 
susceptibility. Transcriptional profiling using RNA-Seq revealed up-regulation of genes 
of the Pdr1 regulon in the absence of JJJ1. Jjj1 appears to be a negative regulator of 
fluconazole resistance in C. glabrata and acts primarily through up-regulation of the 
ABC transporter gene CDR1 via activation of the Pdr1 transcriptional pathway. 
 
 Unlike C. glabrata which has essentially one mechanism of resistance, in C. 
albicans clinical azole resistance can be attributed to multiple mechanisms, often in 
combination. The RTA3 gene, coding for a member of the Rta1p-like lipid-translocating 
exporter family, is coordinately upregulated with the ABC transporter genes CDR1 and 
CDR2 in azole-resistant clinical isolates of C. albicans that carry activating mutations in 
the transcription factor Tac1p. We show here that deleting RTA3 in an azole-resistant 
clinical isolate carrying a Tac1p activating mutation lowered fluconazole resistance by 
two-fold, while overexpressing RTA3 in an azole-susceptible clinical isolate resulted in 
enhanced fluconazole tolerance associated with trailing growth in a liquid microtiter plate 
assay. We also demonstrate that an Rta3p-GFP fusion protein localizes predominantly to 
the plasma membrane, consistent with a putative function for Rta3p as a lipid translocase. 
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PREFACE 
 
 
 The overarching theme of my graduate research has been development of a deeper 
understanding of azole resistance in Candida. The impetus for this being the currently 
limited antifungal treatment options and the paucity of new drugs in later stages of 
development. The azoles are the most widely used antifungal therapy due to their 
favorable side effect profile, dosage form options and low cost. However, the incidence 
of resistance to the azoles continues to increase, so much so, that the azoles are no longer 
recommended as first line therapy for candidiasis. In order to develop strategies for 
overcoming resistance and reestablishing the utility of the azole class of antifungals, we 
need to better understand the mechanisms of resistance to azoles in Candida. 
 
 My dissertation will begin with a general review of azole resistance in Candida 
with a focus on the differences between clinically relevant non-albicans species. The 
second chapter is a more comprehensive review of Candida glabrata, as that is the 
subject of the bulk of the research included here. This will be followed by chapters three 
to five, which detail three distinct projects related to C. glabrata azole resistance. The last 
chapter summarizes the findings from my graduate work and details my thoughts on 
possible future directions for these projects. My work in C. albicans is included in 
Appendix A. 
 
 In chapter three I investigated the hypothesis that each of the ABC transporters 
known to be involved in azole resistance in C. glabrata do not contribute equally. I show 
here that CDR1 codes for the transporter with the largest impact, while the transporters 
coded for by PDH1 and SNQ2 play a much-reduced role in azole resistance. 
 
 In chapter four I investigated the hypothesis that the transcription factor coded for 
by UPC2A influences azole susceptibility in a resistant clinical isolate, in addition to a 
susceptible dose dependent isolate. Prior to the work described here Upc2A had been 
shown to regulate key genes in the ergosterol biosynthesis pathway including the target 
for the azoles and deletion of UPC2A lead to increased azole susceptibility. We were able 
to show that deletion of UPC2A in a clinical isolate with a gain of function mutation in 
the transcription factor PDR1 that results in upregulation of the ABC transporters 
responsible for effluxing the azoles also lead to increased azole susceptibility. 
 
 In chapter five I investigated the hypothesis that the transcription factor Pdr1 is 
negatively regulated by the J protein coded for by JJJ1. Deletion of JJJ1 resulted in 
moderate increased expression of PDR1 and marked increased expression of CDR1. 
Additional ABC transporters do not appear to play a role. 
 
 My work in C. glabrata reiterates the importance of the transcription factor Pdr1 
in azole resistance. Activating mutations in PDR1 leading to increased efflux of azoles 
are essentially the only mechanism of resistance found in resistant clinical isolates. My 
work explores regulation of Pdr1 by Jjj1 and the relative importance of the downstream 
effectors of Pdr1 – the ABC transporters that efflux azoles from the cell. In addition, the 
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seemingly unrelated ergosterol biosynthesis pathway, which is controlled by the 
transcription factor Upc2A is also linked to Pdr1. Treatment with fluconazole in a strain 
lacking UPC2A does not result in upregulation of PDR1, CDR1, SNQ2 and PDH1 to the 
same extent as drug treatment in the presence of UPC2A. 
 
 Finally, in Appendix A I investigated the hypothesis that the putative lipid 
translocase, Rta3, contributes to the azole-resistant phenotype in C. albicans. Tac1 is a 
transcription factor that has a function in C. albicans similar to that of Pdr1 in C. 
glabrata. Activation of Tac1 leads to increased expression of the genes encoding the 
ABC transporters CDR1 and CDR2, as well as RTA3. Overexpression of RTA3 in a wild 
type strain increased tolerance to azoles and deletion of RTA3 in a resistant strain 
increased susceptibility to fluconazole.  
 
 In my exploration of azole resistance in both Candida albicans and Candida 
glabrata the theme has been transcriptional regulation. All three of the transcription 
factors discussed here are activated by treatment with fluconazole and regulate in the case 
of Upc2A key genes in the ergosterol biosynthesis pathway and in the case of Tac1 and 
Pdr1 ABC transporters, as well as other genes that play lesser roles in azole resistance. 
These transcriptional pathways are imperative for Candida to become resistant to the 
azoles class of antifungals and could potentially be targeted for development of new co-
therapeutics that would allow for successful treatment with the azoles. 
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CHAPTER 1.    AZOLE ANTIFUNGAL RESISTANCE IN CANDIDA ALBICANS 
AND EMERGING NON-ALBICANS CANDIDA SPECIES* 
 
 
INTRODUCTION 
 
 Candida albicans and emerging non-albicans Candida (NAC) species such as C. 
glabrata, C. parapsilosis, C. tropicalis, and C. krusei can cause superficial infections of 
the oral and vaginal mucosa as well as disseminated bloodstream and deep-tissue 
infections. Species involvement varies by infection site and by geography. Candida 
infections are most often caused by C. albicans as evidenced by epidemiological studies 
in the United States (1), Europe (2), and the Middle East (3). Of all the NAC species, C. 
glabrata is the most commonly isolated from patients with candidemia in North America 
(4-6), and Northern Europe (7, 8), as well as other geographic areas studied with the 
exception of Latin America (9). C. glabrata is also the most common NAC species found 
to be the causative agent in vulvovaginal candidiasis (VVC) (10-14) and candiduria (15, 
16). In some patient populations, for example, candidemia in patients with hematologic 
malignancy and VVC in diabetic patients, C. glabrata is even more common than C. 
albicans (17-19). C. parapsilosis is well known for its threat to the pediatric population, 
as it is responsible for 17–50% of all fungemia in infants and neonates (20, 21). C. 
parapsilosis is also second only to C. albicans in incidence as a cause of Candida 
endocarditis with mortality rates between 42 and 65% (22, 23). In the Asia-Pacific 
region, C. tropicalis has been reported to constitute 20–45% of Candida isolates (9, 24). 
C. tropicalis infections are commonly associated with malignancy, with some studies 
reporting higher prevalence among patients with hematologic diseases such as acute 
myeloid leukemia (25-29). Mortality associated with C. tropicalis candidemia in these 
populations unfortunately remains high, ranging from 30 to 70%, with the highest rates 
most commonly observed among the elderly (25, 26, 29-31). C. krusei is the fourth most 
common NAC species associated with invasive candidiasis and candidemia, accounting 
for approximately 2.7% of NAC species isolated across the United States (6). Moreover, 
the number of C. krusei isolates implicated in these types of infections has increased over 
time (6, 32). In particular, patients with hematologic malignancies and bone marrow 
transplants have been shown to be at increased risk of C. krusei infection (33-35). 
 
 
AZOLE RESISTANCE IN CANDIDA INFECTIONS 
 
 There are several classes of compounds that comprise the arsenal used to treat 
Candida infections. The polyenes, azoles, echinocandins, nucleoside analogs, and 
allylamines are used with varying efficacy depending on the type and site of infection and  
 
_________________________ 
* Reprinted with permission. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, 
Barker KS, Rogers PD. 2016. Azole Antifungal Resistance in Candida albicans and 
Emerging Non-albicans Candida Species. Front Microbiol 7:2173. (36)  
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the sensitivity of the Candida species (9, 37-39). The most commonly prescribed 
antifungal used for most C. albicans infections is fluconazole, a member of the azole 
class of antifungals (9). Azoles inhibit 14-α-sterol demethylase, encoded by the ERG11 
gene, which is an enzyme involved in the biosynthesis of the fungal-specific membrane 
sterol ergosterol. As some NAC species exhibit intrinsic resistance to azoles, their use is 
likely a contributing factor to the more frequent incidence of infections caused by these 
NAC species (40-42). Moreover, many studies have documented the ability of Candida 
to develop high-level resistance to azole antifungals (40, 41). A compilation of 
fluconazole MIC ranges and epidemiological cutoff values for Candida species is 
presented in Table 1-1. 
 
 Infections caused by C. albicans are associated with varying levels of fluconazole 
resistance depending on the type of infection. C. albicans isolates from candidemic 
patients have the lowest incidence of azole resistance (0–5%) (43-45). The incidence of 
fluconazole resistance in C. albicans isolates from oropharyngeal candidiasis (OPC) is 
higher and depends upon previous fluconazole treatment and prior OPC infections (46, 
47). C. glabrata has the highest incidence of azole resistance among Candida clinical 
isolates and exhibits intrinsic decreased susceptibility to the azole class of antifungals (6, 
40), including the newest addition to the class, isavuconazole (48). C. glabrata is also 
able to develop high-level resistance after exposure to azole antifungals (49, 50) and is 
one of the most frequent species isolated in breakthrough infections from patients 
receiving azole prophylaxis (19, 51, 52). Of increasing concern are the number of 
multidrug resistant isolates of C. glabrata that are being recovered clinically (53-57). In 
the Asia-Pacific region, fluconazole resistance in C. tropicalis ranges from 0 to as high as 
83% (58-60). The worldwide incidence of fluconazole resistance in C. parapsilosis 
disseminated infections ranges between 2 and 5% (44, 61, 62). As C. krusei exhibits 
intrinsic resistance to fluconazole, there is some controversy whether its increased 
infection rate is related to fluconazole prophylaxis or previous treatment (63-66). Clearly, 
an understanding of molecular mechanisms driving intrinsic and development of high-
level azole resistance is warranted. 
 
 
AZOLE ANTIFUNGAL RESISTANCE MECHANISMS 
 
 
Candida albicans 
 
 Resistance to azole antifungals in Candida (summarized in Figure 1-1) has been 
most extensively studied in C. albicans. One mechanism of resistance identified in this 
species is the presence of point mutations in ERG11. Previous studies have identified 
amino acid substitutions that result in decreased fluconazole susceptibility and have noted 
that several of these critical allelic variations cluster in three “hot spot” regions within 
Erg11p (67). Recently, 63 fluconazole-resistant C. albicans clinical isolates were 
examined for mutations within their ERG11 alleles, and 55 were found to carry at least 
one mutation that resulted in amino acid substitutions, with nine such predicted amino  
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Table 1-1. Fluconazole MIC ranges and epidemiological cutoff values for 
Candida species. 
 
Candida species (# of isolates 
tested) MIC range (mode)
1 Percent of resistant isolates 
C. albicans (5265) 0.06 - ≥128 (0.12) 3.5 
C. glabrata (7538) 0.12 - ≥128 (4) 7.8 
C. krusei (1075) 0.25 - ≥128 (16) 96.6 
C. parapsilosis (6023) 0.06 - ≥128 (0.5) 3.4 
C. tropicalis (3748) 0.06 - ≥128 (0.25) 2.3 
 
1MIC values are in mg/L 
 
Data sources: 
CLSI. 2012. Reference Method for Broth Dilution Antifungal Susceptibility Testing of 
Yeasts; Fourth Informational Supplement, 4th ed. Clinical Laboratory Standards Institute, 
Wayne, PA. 
Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez 
GM, Lass-Florl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-
Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J. 
2014. Multilaboratory study of epidemiological cutoff values for detection of resistance 
in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob 
Agents Chemother 58:2006-2012. 
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Figure 1-1. Comparison of documented fluconazole resistance mechanisms in 
Candida species. 
 
(A) Erg3 inactivation results in utilization of alternative sterols in the yeast membrane. 
(B) Uptake of exogenous sterols helps circumvent endogenous sterol production 
inhibition by fluconazole. Increased production of both (C) ATP-binding cassette efflux 
pumps and (D) major facilitator superfamily transporters reduces intracellular 
accumulation of azoles. (E) Inherently low affinity of fluconazole binding to species-
specific Erg11 may decrease fluconazole's potential to inhibit the protein. (F) Increased 
expression of Erg11 protein can help overcome azole activity and (G) aneuploidy may 
promote genetic adaptation to azole exposure. (H) Mutations in ERG11 can also result in 
proteins with reduced affinity for fluconazole binding. 
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acid substitutions being novel (68). Molecular modeling of the substitutions that resulted 
in decreased fluconazole susceptibility when expressed in a susceptible background 
revealed that the mutations clustered in either the predicted catalytic site, the fungus-
specific external loop, or on the proximal surface potentially interacting with the loop or 
near the heme. Additionally, a study involving site-directed mutagenesis of wild-type 
ERG11 to introduce mutations identified in 23 C. albicans clinical isolates demonstrated 
nine of these mutations result in increased fluconazole resistance (69). Five of the amino 
acid substitutions were predicted to be at or near the active site of Erg11p. 
 
 Another mechanism of fluconazole resistance in C. albicans is the increased 
expression of ERG11 due to activating mutations in the gene encoding the zinc-cluster 
transcriptional regulator Upc2p. C. albicans Upc2 is a homolog of the Saccharomyces 
cerevisiae ERG gene regulator pair Upc2/Ecm22. Initially, Upc2 involvement in 
fluconazole resistance in C. albicans was demonstrated when Δupc2 C. albicans strains 
were shown to be highly susceptible to azoles while those over-expressing Upc2 had 
increased fluconazole resistance (70). Further studies examining a matched set of 
fluconazole-susceptible and—resistant C. albicans clinical isolates in which fluconazole 
resistance was not associated with overexpression of drug efflux pumps revealed SNPs in 
one UPC2 allele and overexpression of several ERG genes and UPC2 in the resistant 
isolate (71). Expression of UPC2 alleles in fluconazole-susceptible strains resulted in 
increased fluconazole resistance (71-73). Interestingly, three additional matched sets of 
ERG11-overexpressing clinical C. albicans isolates have been described which have no 
sequence differences in UPC2 between the susceptible and resistant isolates in each pair 
(72), indicating that other mechanisms of ERG11 upregulation exist. While these studies 
were important in establishing Upc2p as a regulator of ERG11 expression in the context 
of fluconazole resistance, it was assumed that UPC2-mediated fluconazole resistance is a 
rare occurrence. However, a large study involving 63 fluconazole-resistant C. albicans 
clinical isolates demonstrated 47 of these isolates overexpressed ERG11 by at least 2-fold 
(74). Twenty-nine of these ERG11-overexpressing isolates contained a missense mutation 
in UPC2, and eight single amino acid substitutions were elucidated from their UPC2 
alleles. Seven of these alleles were found to be associated with increased ERG11 
expression, increased ergosterol production, and decreased fluconazole susceptibility. 
 
 Two other mechanisms of fluconazole resistance in C. albicans involve the 
overexpression of drug efflux pumps Mdr1p and Cdr1p/Cdr2p. TAC1 (transcriptional 
activator of CDR genes) is a zinc-cluster transcription factor whose regulon is hallmarked 
by the ATP-binding cassette (ABC) transporter-encoding genes CDR1 and CDR2 (75). 
Activation of expression of the TAC1 regulon is through binding of TAC1 to the DRE 
(drug response element) present in the promoters of TAC1-regulated genes (75, 76). At 
least nine hyperactive TAC1 alleles have been identified (77), and fluconazole minimum 
inhibitory concentrations (MIC) associated with the isolates from which these alleles 
have been discovered have revealed that TAC1 demonstrates codominance resulting in 
intermediate fluconazole MIC in TAC1-heterologous strains and high fluconazole MIC 
upon loss of heterozygosity (77, 78). Because TAC1 resides on the left arm of Chr5 with 
ERG11, such loss of heterozygosity in the presence of hyperactive TAC1 and mutated 
ERG11 results in high-level azole resistance (77, 79). 
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 Mdr1p is a major facilitator superfamily (MFS) efflux pump usually expressed at 
non-detectable levels in wildtype C. albicans strains, induced in the presence of benomyl, 
diamide, and hydrogen peroxide, and constitutively overexpressed in some fluconazole-
resistant C. albicans isolates (80). MRR1, multidrug resistance regulator 1, was identified 
by comparing the transcriptomes of sets of matched isolates in which the fluconazole-
resistant isolates overexpressed MDR1 (81). Disruption of MRR1 in these resistant 
isolates led to a decrease in fluconazole MIC, while introduction of each of the mutant 
alleles individually into a wildtype fluconazole-susceptible background in the native 
MRR1 locus conferred fluconazole resistance to the constructed strain. Another study 
examined additional MRR1 allelic variations in MDR1-mediated fluconazole resistance 
(82). In most cases the resistant isolates/strains were homozygous for the MRR1 allele 
containing the gain-of-function mutations due to mitotic recombination and chromosome 
loss. 
 
 A less common mechanism of azole resistance in C. albicans is inactivation of the 
ERG3 gene, which encodes the ergosterol biosynthesis enzyme sterol Δ5,6 desaturase. 
Erg3p catalyzes one of the final steps in the pathway and also converts nontoxic 14α-
methylated sterol intermediates, that accumulate during azole treatment, into the toxic 
sterol 14α-methylergosta-8,24(28)-dien-3β,6α-diol. Inactivation or deletion of the ERG3 
gene, therefore, prevents such toxic sterols from being synthesized. Only a handful of 
clinical C. albicans isolates have documented azole resistance due to ERG3 inactivation 
(83-88). 
 
 Aneuploidy plays a role in azole resistance in C. albicans as demonstrated by 
comparative genome hybridization (89). As alluded to earlier, a common aneuploidy 
found in azole-resistant strains involves Chr5. Similarly, loss of heterozygosity (LOH) 
has been shown to occur in azole-resistant C. albicans (78). Examination of TAC1 in a 
matched set of azole-susceptible and -resistant C. albicans isolates revealed that the 
susceptible isolate harbored two wildtype alleles of TAC1, while the resistant isolate 
contained only one of those alleles in which a single nucleotide polymorphism (SNP) 
translated into an activating amino acid substitution (N977D). 
 
 
Candida parapsilosis 
 
 Because azole resistance has been extensively studied in C. albicans, attempts to 
elucidate mechanisms of azole resistance in C. parapsilosis have involved examining 
orthologous genes and yielded mixed results. A study of a series of six isolates from a 
single patient found a single SNP in MRR1 present in the two fluconazole-resistant 
isolates (90). Nine fluconazole-resistant isolates were obtained from candidemia patients 
in a Brazilian hospital and examined for CDR1, MDR1, and ERG11 overexpression as 
well as the presence of SNPs in the ERG11 gene (91). Each of the resistant isolates 
possessed a single homozygous SNP (A395T) which corresponds to a Y132F amino acid 
substitution. In addition, while none of the isolates overexpressed MDR1 as compared to 
the C. parapsilosis reference strain ATCC22019, CDR1 expression was between 3.3- and 
9.2-fold higher in these isolates as compared to the reference strain, and ERG11 was 
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overexpressed between 1.5- and 7.4-fold. While this study indicated an association 
between CDR1 and ERG11 and fluconazole resistance in C. parapsilosis, a causal link 
was not definitively proven. 
 
 In a larger-scale study, 30 resistant isolates, 37 susceptible-dose-dependent 
isolates, and 55 susceptible isolates were collected from hospitals in four U.S. cities, and 
their ERG11 genes were sequenced (92). Five SNPs were identified in 54 of the isolates; 
amino acid substitution Y132F, found in 17 resistant isolates, was the only one found 
exclusively in resistant isolates. Twenty-three isolates harbored SNPs in MRR1. Of the 
nine SNPs identified, only three were found exclusively in resistant isolates. Quantitative 
PCR measuring relative MDR1 expression revealed nine isolates (six with a SNP in 
MRR1, three without) with at least 5-fold increase in MDR1 expression compared to a 
composite expression level from a subset of susceptible isolates. However, the expression 
levels were a fraction of the levels achieved by MDR1-mediated azole resistance in C. 
albicans. Without definitive experiments in which introduction of a mutated ERG11 
allele confers azole resistance in a susceptible isolate, these results remain suggestive. 
 
 In an effort to identify potential mechanisms of azole resistance on a genome-
wide scale in C. parapsilosis, fluconazole-, voriconazole-, and posaconazole-resistant 
strains were developed experimentally by serial passage in liquid culture containing 
either fluconazole, voriconazole, or posaconazole (93). The fluconazole- and 
voriconazole-resistant strains were cross-resistant to both fluconazole and voriconazole 
and possessed similar transcriptional profiles as assessed by microarray analysis; 
however, the posaconazole-resistant strain was not cross-resistant to the other azoles and 
had a distinct transcriptional profile. Among the genes differentially expressed in 
fluconazole- and voriconazole-resistant strains were the stress response gene GRP2, as 
well as MDR1 and MRR1. ERG11 was not differentially expressed in these strains. 
However, in the posaconazole-resistant strain, the ergosterol biosynthesis genes ERG11 
and ERG6, as well as ERG gene regulator UPC2 were among the genes differentially 
expressed. 
 
 In a study using laboratory strains of C. parapsilosis in which previously-
determined gain-of-function alleles of CpMRR1 were introduced into the native locus, 
strains containing Mrr1p with a G583R amino acid substitution from a fluconazole-
resistant C. parapsilosis isolate led to resistant fluconazole and voriconazole MIC 
compared to strains harboring the wildtype allele (94). Similarly, strains with single SNP-
containing MRR1 alleles had a ~5-fold increase in MRR1 gene expression and ~70-fold 
increase in MDR1 gene expression. 
 
 In another study, 35 unrelated fluconazole-resistant and four unrelated susceptible 
isolates of C. parapsilosis were examined to elucidate mechanisms of fluconazole 
resistance in C. parapsilosis (95). Sixteen resistant isolates overexpressed CDR1, three 
other resistant isolates exhibited MDR1 overexpression, and eight resistant isolates 
demonstrated overexpression of ERG11 as compared to the susceptible isolates. When 
sequencing orthologues of UPC2, MRR1, and TAC1 in order to identify putative gain-of-
function mutations that would lead to overexpression of ERG11, MDR1, and CDR1, only 
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one heterozygous mutation in UPC2 was recovered from one isolate, suggesting that 
ERG11 overexpression in fluconazole-resistant C. parapsilosis is not mediated by UPC2. 
TAC1 mutations that were recovered did not fully correspond with CDR1 overexpression 
and those recovered were not analogous to those found in gain-of-function CaTAC1 
alleles. Similarly, MRR1 mutations recovered did not correspond to any mutations found 
in gain-of-function alleles of CaMRR1. Subsequently, CDR1 was deleted from three of 
the CDR1-overexpressing isolates which only resulted in a one-dilution decrease in 
fluconazole MIC. MDR1 deletion in three MDR1-overexpressing isolates revealed a one-
dilution decrease in fluconazole MIC in two isolates and no change in fluconazole MIC 
in the third. To address the role of alterations in the ergosterol biosynthesis pathway in 
azole resistance in C. parapsilosis, ERG11, and ERG3 were sequenced. No ERG3 
mutations were recovered, which was supported by the sterol profiles of the isolates. A 
single ERG11 mutation (Y132F) was recovered in one resistant isolate and a combination 
of Y132F and R398I mutations was found in an additional ten isolates. In nine of these 
eleven isolates there was a change in the sterol profile indicative of a change in Erg11 
functionality. This study indicates that while differential expression of efflux pumps is 
commonly found in azole-resistant C. parapsilosis isolates, the resistant phenotype is not 
solely due to their overexpression but instead is multifactorial and involves ERG11 
mutation and/or overexpression. 
 
 
Candida tropicalis 
 
 As compared with other species of Candida, relatively little is known about the 
mechanisms of azole resistance in C. tropicalis. An analysis of 52 clinical C. tropicalis 
isolates from China found the average ERG11 expression level more than 4-fold higher 
among fluconazole-resistant isolates than -susceptible isolates (96). Moreover, ERG11 
expression was even higher among a subset of fluconazole-resistant isolates also resistant 
to itraconazole and voriconazole. These results were recently echoed by a similar study 
characterizing 35 C. tropicalis isolates from Korean university hospitals, nine of which 
were fluconazole-non-susceptible (97). While considerable variability in ERG11 
expression (~150-fold) was observed in the highly fluconazole-susceptible group, ERG11 
expression was significantly higher among both less fluconazole-susceptible (MIC 1–2 
μg/ml) and fluconazole-non-susceptible (MIC ≥ 4 μg/ml) isolates. This study also 
sequenced the C. tropicalis UPC2 gene and found several heterozygous and homozygous 
mutations. However, many of these mutations have been observed in fluconazole-
susceptible isolates not found to overexpress ERG11, and further characterization of their 
impact on the regulatory function of UPC2 is needed. 
 
 Molecular characterization of azole-resistant clinical C. tropicalis isolates has also 
revealed alterations in the ergosterol biosynthetic pathway (96-99). A fluconazole-
resistant C. tropicalis isolate recovered from a clinical blood specimen from Tunisia was 
found to have mutations in both ERG3 and ERG11 which were individually observed to 
be detrimental to ergosterol biosynthesis when heterologously expressed in S. cerevisiae 
(99). Notably, the ERG11 mutation in this isolate consisted of a deletion of 132 
nucleotides resulting in a D275V amino acid substitution and the loss of 44 amino acids 
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near the N-terminus of Erg11p. Homozygous replacement of the wild-type C. tropicalis 
ERG11 with the truncated clinical variant, with or without the associated clinical ERG3 
mutation, resulted in high-level fluconazole resistance in a fluconazole-susceptible 
reference strain of C. tropicalis. Additionally, an ERG11 mutation resulting in decreased 
fluconazole susceptibility due to the amino acid substitution Y132F, has been well 
characterized in C. albicans and was recently observed in a fluconazole-resistant C. 
tropicalis isolate from a patient with candidemia (100). 
 
 One of the first studies to associate the overexpression of efflux pumps with azole 
resistance in C. tropicalis utilized serial passaging of a reference C. tropicalis isolate on 
media containing various concentrations of fluconazole to produce genetically-related 
isolates with reduced fluconazole susceptibility (101). After passaging, all isolates with 
reduced susceptibility to fluconazole demonstrated increased expression of both C. 
tropicalis MDR1 and a gene with high homology to C. albicans CDR1. In both cases, the 
increased expression was found to then be diminished in fluconazole-susceptible 
revertants obtained from further passaging on fluconazole-free media. The role of efflux 
pump overexpression in azole resistance among clinical C. tropicalis isolates has been 
less clearly defined. When the expression of MDR1 and CDR1 was examined in the 
aforementioned 52 clinical C. tropicalis isolates from China, no significant difference 
was observed between fluconazole-susceptible and -resistant isolates (96). In contrast, 
among the 35 clinical isolates from Korean university hospitals, expression of both 
MDR1 and CDR1 was observed to be significantly higher among both less-fluconazole-
susceptible and fluconazole-non-susceptible isolates. However, it is important to note the 
large degree of variability in the expression of MDR1 and CDR1 observed in the highly 
fluconazole-susceptible control group, ~50-fold and ~30-fold respectively (31). To date, 
experiments to directly delineate the potential role of these efflux pumps has yet to be 
performed in C. tropicalis, and the homologs of C. albicans MRR1 and TAC1 have not 
been examined. 
 
 
Candida krusei 
 
 C. krusei is intrinsically resistant to fluconazole, though the precise mechanism is 
not completely understood. Several studies have attributed C. krusei's innate azole 
resistance to efflux pump activity, namely through the ATP-binding cassette transporter 
Abc1p, and reduced drug accumulation (102-104) in combination with reduced azole 
affinity for Erg11p (102, 104-107). Changes in the cell membrane affecting membrane 
fluidity may be implicated in azole resistance as well since there is evidence to suggest 
that intracellular azole accumulation occurs through one or possibly both mechanisms of 
passive and facilitated diffusion (108, 109). Additionally, the discovery of a trisomy in 
the ERG11-containing chromosome in a C. krusei strain suggests aneuploidy may not be 
uncommon in this species, though the effects as it relates to azole resistance are not yet 
known (104). 
 
 Resistance mechanisms against other azoles are also not clearly defined. For 
example, analysis of itraconazole-resistant C. krusei isolates revealed that reduced 
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intracellular content of the drug and not altered affinity for the drug target likely drives 
itraconazole resistance (102, 110). However, more recently it has been suggested that 
overexpression of genes encoding both Erg11p and the efflux pump Abc2p may also play 
a role with itraconazole resistance (111, 112). Despite its fungicidal activity in C. krusei 
(113) resistance to voriconazole has also emerged, and current research supports a theory 
where overexpression of the genes encoding the efflux pump Abc2 and Erg11 impart 
more transient resistance properties, while increased expression of Abc1p and point 
mutations in ERG11 predominate as time progresses to yield a stably resistant pathogen 
in the prolonged presence of voriconazole (114). Erg11p amino acid substitutions have 
been observed in azole-resistant C. krusei and, in the case of Y166S, have been predicted 
to interfere with Erg11p function (114, 115). While the newer antifungal agents 
posaconazole and isavuconazole have shown good activity against C. krusei (116, 117), 
reports of resistance against these agents are relatively sparse (44, 118). However, in a 
recent analysis examining NAC strains in the U.S. by region, Candida krusei resistance 
to posaconazole was highest in the eastern United States, with posaconazole resistance 
occurring in 13–16.7% of isolates (6). Nevertheless, the mechanisms of resistance in C. 
krusei against these agents remain to be investigated. 
 
 
Candida glabrata 
 
 C. glabrata is unique among the Candida species discussed here as it is a haploid 
yeast more closely related to S. cerevisiae. Development of azole resistance in clinical 
isolates of C. glabrata has been almost exclusively linked to the presence of activating 
mutations in the zinc cluster transcription factor Pdr1 (119) that lead to differential 
expression of downstream targets. Nearly all clinical isolates have been found to have 
PDR1 mutations, with such mutations found in the inhibitory domain, activating domain, 
middle homology region, and xenobiotic binding region. The rapid acquisition of PDR1 
mutations could be due to the high incidence of mutations in the mismatch repair gene 
MSH2, which results in a hypermutable phenotype (120). The activating mutations 
exhibit distinct expression patterns of the downstream effector genes, with the exception 
of increased expression of CDR1 and PUP1, and no correlation has been found between 
location of the mutation and altered gene expression (121-125). Among the genes whose 
pleiotropic drug response element (PDRE) is directly bound by Pdr1 (126), only three, 
the ABC transporters CDR1 (127), PDH1 (CDR2) (128, 129), and SNQ2 (130, 131), have 
been linked directly to azole resistance. Recent work has shown increased expression of 
four MFS transporters in clotrimazole resistant isolates compared to clotrimazole 
susceptible clinical isolates. Disruption of one of these, TPO3, moderately increased 
susceptibility to clotrimazole and fluconazole (132). These findings suggest MFS 
transporters may have a minor role in azole resistance in C. glabrata. 
 
 Surprisingly, ERG11 does not appear to play an important role in clinical azole 
resistance in C. glabrata (119, 127, 130). Increased expression of ERG11 has been 
observed in only two clinical isolates of C. glabrata (133, 134). The upregulation in one 
isolate was later found to be due to duplication of the entire chromosome containing 
ERG11 and the phenotype was lost with subsequent passaging in azole-free media (135). 
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A single resistant clinical isolate of C. glabrata has been shown to have a nonfunctional 
14-α-sterol demethylase due to a missense mutation in ERG11, which led to the complete 
absence of ergosterol in the cell membrane (55). No additional clinical isolates have been 
identified to have resistance mechanisms related to the azole target. 
 
 C. glabrata has the ability to grow with altered cell membrane sterols, which 
allows for evasion of azole treatment. C. glabrata is able to take up exogenous sterols 
(136), both when the ergosterol biosynthesis pathway is blocked and under normal 
conditions in wild type strains (137, 138). Aus1p has been identified as the sterol 
transporter responsible for tolerance to azoles in the presence of exogenous sterols (139). 
C. albicans has recently been shown to take up sterols under aerobic conditions; 
however, C. glabrata is more liberal in its ability to take up sterols and does so in both 
aerobic and anaerobic conditions and, in the presence of serum and fluconazole, enhances 
uptake under aerobic conditions (140). 
 
 Azole resistance in C. glabrata has also been attributed to the formation of petite 
mutants, which are cells that have lost mitochondrial function resulting in respiratory 
deficiency (141, 142). Petite mutants can be generated in the laboratory by treatment with 
azoles or ethidium bromide. This mutant phenotype has been recovered clinically (143, 
144), but is not common among clinical isolates. Azole resistance in petite mutants has 
been attributed to upregulation of the ABC transporters CDR1, CDR2, and SNQ2 (129, 
144), which is dependent on Pdr1 (121). Petite mutants exhibit altered sterol profiles with 
a disproportionate amount of ergosterol and very little of ergosterol intermediates; 
however, no changes in the sequence of ERG11 or its expression have been detected 
(145). 
 
 
CONCLUSIONS 
 
 Candida species are responsible for a majority of superficial and disseminated 
fungal infections in humans. While azole antifungals have long provided effective 
treatment for such infections, recent epidemiological studies indicate that intrinsic azole 
resistance in some Candida species as well as development of high-level azole resistance 
is a problem of critical importance in the clinical setting. While extensive studies to 
elucidate molecular mechanisms of high-level azole resistance in C. albicans has 
uncovered the role of ergosterol biosynthesis gene mutation and ERG gene and drug 
efflux pump upregulation as key mediators of azole resistance, there are clearly other 
factors at play that contribute significantly to such resistance. Similarly, while NAC are 
closely related to C. albicans, that does not necessarily translate to analogous molecular 
mechanisms of azole resistance. 
 
 Of the NAC species highlighted in this review, C. parapsilosis, C. tropicalis, C. 
krusei, and C. glabrata all express ABC transporter and/or MFS genes orthologous to 
CaCDR1 and CaMDR1. However, as discussed, the altered expression of these genes in 
azole-resistant NAC appear to contribute differently to resistance in different species. 
Moreover, the transcriptional regulators and genetic mutations governing azole efflux and 
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sterol biosynthesis in C. tropicalis, C. parapsilosis, and C. krusei have not been fully 
examined. Finally, there exist clear differences in the mutations in ERG11 that are found 
to influence azole resistance in clinical isolates among these species. As azole resistance 
continues to emerge in these species, a more complete understanding of the important 
differences among resistance mechanisms employed by these species will be needed in 
order to circumvent this important clinical problem. 
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CHAPTER 2.    AZOLE RESISTANCE IN CANDIDA GLABRATA* 
 
 
INTRODUCTION 
 
 The incidence of fungal infections continues to rise in susceptible populations, 
which include transplant patients, those with AIDS, patients with malignancy, those on 
immunosuppressive therapy, patients receiving total parenteral nutrition and premature 
infants (146). The most common cause of these opportunistic fungal infections is 
Candida (5). Collectively Candida species are the fourth most common cause of 
nosocomial blood stream infections in the United States (147, 148). Reported mortality 
rates for patients with candidemia vary, but are as high as 40% and have not decreased in 
the past fifteen years (5, 149-151). Candida glabrata is the second most common cause 
of Candida infections in most geographic populations studied (5, 7, 8, 152-158) and in 
some clinical populations is the most common, surpassing Candida albicans among 
patients with hematologic malignancies (19), diabetics (152, 159), and patients with an 
abdominal source of infection (152, 159). 
 
 Currently there are three classes of antifungals used clinically for the treatment of 
candidiasis. Amphotericin B, which targets ergosterol, the primary sterol in the fungal 
cell membrane, has long represented the gold standard for therapy, but is hampered by 
significant infusion-related adverse events and nephrotoxicity. As such, its use has 
decreased in recent years. The azole antifungals target lanosterol 14-α-demethylase which 
represents a key step in the biosynthesis of ergosterol. One member of this class, 
fluconazole is the most widely prescribed antifungal agent, is inexpensive, and is 
available for both oral and intravenous administration. While fluconazole is acceptable as 
first line therapy for invasive candidiasis in patients who are not critically ill and have not 
had prior azole exposure, its utility has been hindered by the emergence of resistance, 
particularly in C. glabrata. Multiple studies have shown a link between azole prophylaxis 
and increased rates of infection with C. glabrata (19, 52, 160, 161) and in one study azole 
prophylaxis was only a risk factor for resistant isolates of C. glabrata (50). The 
echinocandins, which target the fungal cell wall, have therefore become first line agents 
for treatment of this indication (39). However, resistance to this class of antifungal has 
also begun to emerge. In addition many reports of multidrug resistant isolates of C. 
glabrata have emerged in recent years (54, 55, 57, 162-164). It is therefore imperative to 
understand the basis of azole antifungal resistance in order to preserve this class of 
antifungal and overcome this clinical problem. In this review we will provide an 
overview of the mechanisms of azole antifungal resistance in C. glabrata with a focus on 
recent important discoveries in the field. 
 
 
 
 
_________________________ 
* Reprinted with permission. Whaley SG, Rogers PD. 2016. Azole Resistance in 
Candida glabrata. Curr Infect Dis Rep 18:41.  
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MULTIDRUG TRANSPORTERS 
 
  Pdh1, which stands for pleomorphic drug resistance homolog (also known as 
Cdr2 for Candida drug resistance), was the first drug transporter identified as 
participating in azole resistance in C. glabrata. This ATP binding cassette (ABC) 
transporter was discovered independently by two groups. Initially a series of isolates 
taken from a patient being treated with fluconazole for oral candidiasis was studied. 
Azole resistance was observed in the later isolates of this series and was associated with a 
decrease in intracellular fluconazole. There was also a significant increase in the 
transcript level of a gene with 72.5% identity with the Saccharomyces cerevisiae ABC 
transporter PDR5 (pleiotropic drug resistance), which was called PDH1. Treatment with 
fluconazole also increased expression of PDH1 in the susceptible isolate, but did not 
further increase expression in one of the later resistant isolates from the series (128). The 
same group continued their work on PDH1 later demonstrating that deletion of PDH1 in 
a mutant C. glabrata strain already lacking CDR1 resulted in an increase in fluconazole 
susceptibility. When PDH1 was overexpressed in the CDR1 deletion strain fluconazole 
minimum inhibitory concentration (MIC) was restored to that of the wild type (165). 
 
 A second group identified the same gene by observing that a strain in which 
CDR1 was deleted was still able to become resistant to azoles in vitro. A search for 
additional transporters potentially responsible for this observation led to the discovery of 
two such transporters. These were PDH1 (which these investigators named CDR2) and 
SNQ2. CDR2 exhibited very low levels of expression in azole susceptible strains, but was 
upregulated as much as 100-fold in resistant strains. Heterologous expression of CDR2 in 
S. cerevisiae decreased susceptibility to azoles, whereas SNQ2 was not examined further 
(129). 
 
 A second ABC transporter in C. glabrata, named Cdr1, was later found to have a 
significant role in azole resistance. Initial studies of two sets of matched isolate pairs 
from patients receiving fluconazole treatment for oral candidiasis revealed that there was 
a decrease in fluconazole accumulation in the resistant isolates as compared to the 
susceptible parent isolates. Expression analysis of candidate genes revealed CDR1 to be 
the only transporter tested that was upregulated in both resistant isolates. CDR1 stands for 
Candida drug resistance and was named due to homology with the C. albicans gene of 
the same name. The sequence shares 75% identity with S. cerevisiae PDR5, which 
encodes an ABC transporter well established as a cause of pleiotropic drug resistance in 
this organism. Deletion of CDR1 in a resistant isolate reduced susceptibility to azoles and 
increased fluconazole accumulation as compared to the resistant isolate (127). When 
CDR1 and PDH1 (CDR2) were constitutively expressed in S. cerevisiae, the level of 
resistance to azoles was higher in the strain expressing CDR1. This implies that CDR1 is 
the most important of these transporters in high-level azole resistance in C. glabrata 
(129). Like PDR5 in S. cerevisiae and PDH1 in C. glabrata, expression of CDR1 has also 
been shown to increase upon exposure to azole antifungals (119). 
 
 The ABC transporter Snq2 (sensitivity to 4-nitroquinoline-n-oxide), named due to 
its similarity to the S. cerevisiae gene with the same name, was initially thought to play a 
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minor role in azole resistance if any (129). Subsequent analysis of C. glabrata isolates 
from hospital infections over a three-year period solidified the importance of SNQ2 in 
azole resistance. In addition to the expected upregulation of CDR1 and PDH1 in the 
resistant isolates, several also exhibited upregulation of SNQ2 although to a lesser extent. 
The increased expression was often in combination with upregulation of the other ABC 
transporters, but was the only ABC transporter with increased expression in two isolates 
that were resistant to the tested azoles (130). Further analysis of one resistant clinical 
isolate with basal levels of CDR1 and PDH1 and increased expression of SNQ2 
demonstrated the importance of SNQ2 in azole resistance. Disruption of SNQ2 in this 
isolate resulted in an azole susceptible phenotype. Reintroduction of SNQ2 restored the 
resistant phenotype (131). 
 
 In C. albicans the major facilitator superfamily (MFS) transporter Mdr1 also 
plays a significant role in azole resistance (166, 167). In C. glabrata the MFS transporter 
gene QDR2 (quinidine resistance) was shown to be upregulated in a resistant strain 
compared to a susceptible matched isolate by microarray analysis and confirmed by 
qPCR (168). Later studies showed QDR2 was upregulated in a second resistant isolate 
compared to its parent (124). Subsequent investigation of QDR2 in azole resistance 
showed a weak link that likely does not have clinical significance for systemic fungal 
infections. Disruption of QDR2 increased sensitivity to the imidazoles - ketoconazole, 
miconazole, and clotrimazole, but had no effect on fluconazole or itraconazole 
sensitivity. Overexpresssion of QDR2 decreased sensitivity to ketoconazole, miconazole, 
and clotrimazole (169). 
 
 
TRANSCRIPTIONAL REGULATION OF AZOLE RESISTANCE 
 
 In S. cerevisiae there are two transcription factors that regulate expression of 
efflux pumps, Pdr1 and Pdr3. In C. glabrata after observing that the known efflux 
transporters at the time were coordinately upregulated with azole treatment the closest 
homolog for Pdr1 and Pdr3 was identified as Pdr1 (119). In S. cerevisiae the PDR3 
promoter contains binding sites for both Pdr1 and Pdr3, which allows for autoregulation. 
These binding sites are called pleiotropic drug response elements (PDRE). An initial 
study showed upregulation of PDR1 in a lab derived resistant strain of C. glabrata, but 
not in the resistant clinical isolates and additional laboratory derived resistant strains 
(119). Later work showed that the promoter regions of Pdr1, as well as the efflux 
transporters contain the PDRE (125). Pdr1 was shown to bind directly to the PDRE in the 
promoters of CDR1, PDH1, SNQ2 and QDR2 as well as additional members of the Pdr1 
regulon (126). 
 
 The most important mechanism of resistance in C. glabrata is the acquisition of 
activating mutations in the gene encoding the transcription factor Pdr1 that lead to 
upregulation of ABC transporters. Other than a few rare instances that will be discussed 
later in this review practically all clinical isolates that have developed high level azole 
resistance have been found to have Pdr1 activating mutations. Many different PDR1 
mutations that affect azole susceptibility have been identified in every region of the gene. 
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These mutations result in distinct patterns of altered gene expression among Pdr1 target 
genes and no correlation between location of the mutation and gene expression has been 
identified (51, 119, 121-125, 131, 168). 
 
 
REGULATION OF PDR1 
 
 
Mediator complex 
 
 The mechanism for activation of Pdr1 by fluconazole and other xenobiotics is 
similar to activation of pregnane X receptor in mammalian systems and Pdr1/Pdr3 in S. 
cerevisiae. Ketoconazole was found to bind directly to Pdr1. Gal11A was identified as a 
co-activator for drug dependent activation and interacts with Pdr1 through a binding 
domain that is similar to the KIX domain in humans. Gal11A is a component of the tail 
portion of the Mediator complex, which interacts with RNA polymerase II to regulate 
transcription. Infection with strains lacking Pdr1 and strains lacking Gal11A resulted in 
comparable increased survival with fluconazole treatment compared to wild type in a 
Caenorhabditis elegans model of infection (170). An inhibitor for the interaction between 
the KIX domain on Gal11A and Pdr1 was identified through a high throughput screen. 
This compound named iKIX1 prevented ketoconazole-induced upregulation of efflux 
pumps, as well as upregulation due to activating mutations in Pdr1 (171). This suggests 
that it may be possible to overcome Pdr1-mediated azole resistance in C. glabrata by 
chemically interfering with Pdr1 activity. 
 
 In addition to Gal11A three additional subunits of the Mediator complex have 
been implicated in azole resistance. Screening a transposon mutagenesis library for genes 
that when deleted resulted in increased susceptibility to azoles identified MED2 
(mediator complex) and PGD1 (polyglutamine domain), both genes code for members of 
the tail portion of the Mediator complex (172). Subsequent deletion of MED2 predictably 
also resulted in increased sensitivity to azoles. Similar to results seen for a Gal11A 
mutant strain described above, deletion of MED2 prevented fluconazole-induced 
upregulation of CDR1. Med2, as well as two additional components of the Mediator 
complex, Nut1 (negative regulation of URS2) and Srb8 (suppressor of RNA polymerase 
B) were required for induced fluconazole resistance due to expression of an ectopic 
vector expressing PDR1 with an activating mutation. However, two additional 
components of the tail portion of Mediator were not required. No direct interaction was 
observed between Pdr1 and Med2 in co-immunoprecipitation experiments (173). 
 
 
Negative regulators of azole resistance 
 
 One of the homologs for Pdr1 in S. cerevisiae forms a heterodimer with the 
transcription factor Stb5 (Sin3 binding protein) before binding to the promoter of ABC 
transporters (174). The homolog for Stb5 was identified in C. glabrata and further 
studied for a potential role in azole resistance. Deletion of Stb5 resulted in a minimal 
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increase in voriconazole MIC, but no difference was observed with fluconazole. 
Microarray studies revealed of the 68 genes upregulated in a strain with STB5 deleted 34 
were also upregulated in a strain overexpressing PDR1. The upregulation of PDR1, 
CDR1, and PDH1 in the Stb5 deletion strain was confirmed by qPCR analysis. These 
findings indicate a role in for Stb5 as a negative regulator of Pdr1 in C. glabrata (175). 
 
 Sirtuins, found in all organisms, are regulatory proteins that are dependent on 
nicotinamide adenine dinucleotide (NAD+) and function as deacetylases. In C. glabrata 
there are five members of this family. NAD+ is limited in certain niches in the host, such 
as the urinary tract and C. glabrata is unable to synthesize it. Under these conditions 
sirtuins are inactivated resulting in derepression of target genes. Previous work has 
focused on derepression of genes involved in host adaptation, for example adhesins, 
which are important for virulence. More recently one of the members of the sirtuin class 
of proteins in C. glabrata, Hst1 (homologues of Sir2), has been shown to participate in 
regulation of Pdr1. An initial microarray study showed increased expression of efflux 
pumps regulated by Pdr1 in an Hst1 deletion strain (176). 
 
 Additional work by a second group further elucidated the importance of the 
regulation by Hst1. Resistance to fluconazole increased in the presence of nicotinamide 
(NAM), which is an inhibitor of the sirtuin class of proteins. Deletion of Hst1 resulted in 
a six-fold increase in fluconazole MIC, while none of the other sirtuin deletion strains 
shared this phenotype. In Pdr1 and Cdr1 deletion strains, the deletion of Hst1 resulted in 
a minimal increase in MIC. PDR1 expression was moderately increased and CDR1 was 
increased approximately 20 fold in the Hst1 deletion strain. As in other organisms, Hst1 
was found to function in complex with Sum1 (suppressor of mar1-1) and Rfm1 
(repression factor of middle sporulation element). Deletion of any member of the 
complex resulted in the same altered fluconazole susceptibility. These experiments 
indicate a role for the Hst1-Rfm1-Sum1 complex in the negative regulation of Pdr1 (177). 
 
 
ALTERATION OF DRUG TARGET 
 
 The azole target, lanosterol 14-α-demethylase has been implicated in resistance in 
other species of Candida, both through alteration of the azole binding site and increased 
expression due to activating mutations in the transcription factor responsible for its 
regulation. In a comprehensive analysis of 29 resistant C. glabrata clinical isolates, none 
had increased ERG11 expression and none were found to carry a mutation in ERG11 
suggesting that alterations in this gene are not important for clinical resistance in C. 
glabrata (130). Anecdotal incidents of a role for ERG11 have been reported. Activity of 
lanosterol 14-α-demethylase was increased in a resistant clinical isolate (133) and was 
later attributed to a chromosomal duplication (135). ERG11 expression was found to be 
increased in a single azole-resistant oral isolate after recurrent infection in a patient 
receiving treatment for neck cancer (134). The first clinical isolate possessing a mutation 
in ERG11 in C. glabrata was reported in 2012 in an isolate recovered from a urine 
sample. A missense mutation resulted in the glycine at position 315 being replaced with 
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aspartic acid. ERG11 in this isolate was nonfunctional as exhibited by its sterol profile 
which had no detectable ergosterol and >80% lanosterol (55). 
 
 
STEROL HOMEOSTASIS 
 
 The sterol biosynthesis pathway is a focus of antifungal therapy due to its unique 
components in yeast versus the human host. The sterol composition of the cell is 
influenced by regulation of the sterol biosynthesis pathway, drug treatment, and 
exogenous sterol uptake. Altered sterols in the cell membrane can lead to altered 
membrane fluidity, which affects membrane proteins and can lead to static growth. 
Expression of the enzymes in the sterol biosynthesis pathway including the azole target 
Erg11 are regulated by the zinc cluster transcription factor, Upc2A (178). Deletion of 
UPC2A in C. glabrata results in decreased expression of ergosterol biosynthesis genes 
and prevents the induction of ergosterol biosynthesis when treated with inhibitors of the 
pathway. UPC2A also plays a role in azole susceptibility. Disruption of UPC2A in both 
susceptible and resistant isolate decreased fluconazole minimum inhibitory concentration 
(MIC), minimum fungicidal concentration (MFC), and enhanced fluconazole activity by 
time-kill analysis.  This suggests the Upc2A pathway might represent the key to 
overcoming azole resistance in this organism (179). 
 
 Treatment with the azole class of antifungals inhibits the synthesis of ergosterol 
resulting in static growth. One potential explanation for C. glabrata’s inherent reduced 
susceptibility to the azole antifungals is the ability to take up exogenous sterols. While 
the ability to take up sterols had previously been shown in S. cerevisiae, the first 
description of this phenomenon in C. glabrata was in Erg9 deletion strains. ERG9 was 
placed under the control of a tet promoter, such that upon treatment with doxycycline 
ERG9 was depleted. In lab media depletion of ERG9 resulted in rapid cell death, but in 
mice ERG9 depletion had a negligible effect on C. glabrata growth. Serum from multiple 
sources was able to recover the growth defect in vivo and the effect was shown to be 
attributable to cholesterol (136). Additional studies from a separate group confirmed the 
ability of C. glabrata to take up exogenous sterols in a strain with a transposon inserted 
into Erg1 (137). Further work on the conditions required for sterol uptake in C. glabrata 
revealed that sterols can be taken up in aerobic conditions in a Upc2A independent 
manner or anaerobic conditions in a Upc2A dependent manner. In aerobic conditions 
sterol uptake can also be induced by the presence of bovine serum or fluconazole in a 
Upc2A dependent manner (140). 
 
 The realization that identification of C. glabrata as the causative agent in some 
infections (mainly urinary tract) was missed because the isolates required media 
containing bile for growth lead to further studies in sterol uptake. Cholesterol was 
identified as the probable component in bile responsible for growth in these isolates. Bile 
supplementation was also found to decrease azole susceptibility in clinical isolates not 
dependent on bile for growth (180). A subsequent study of the same isolates revealed that 
four of the five were defective in sterol synthesis and the remaining isolate was defective 
in heme synthesis. These isolates were able to grow in the presence of cholesterol, human 
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serum or bovine serum. C. albicans mutants for similar pathways were unable to grow in 
the presence of exogenous sterols. Cholesterol was also taken up in an isolate that had no 
growth defect or deficiency in sterol synthesis (138). 
 
 A better understanding of how exogenous sterols are taken up could potentially 
lead to development of a co-therapeutic that would allow the azoles and other antifungals 
that act on the ergosterol pathway to be more effective against C. glabrata. AUS1 was 
identified as the transporter responsible for exogenous sterol uptake due to its similarity 
to sterol transporters that act in anaerobic conditions in S. cerevisiae. Depletion of AUS1 
prevented the recovery of ERG9 mutants by exogenous sterols (139). UPC2A and its 
homolog UPC2B were both shown to be important for AUS1 expression (178). Recent 
work also demonstrated a role for iron in the function of AUS1 sterol transport (181). 
 
 
VIRULENCE 
 
 Increased resistance in microbial pathogens results in decreased fitness and 
virulence in the majority of cases. In C. albicans azole resistance is often associated with 
a fitness cost in vitro, but in vivo there appear to be compensatory mechanisms that 
decrease or eliminate the growth defect (182). However, in C. glabrata recent work has 
demonstrated that the most common mechanism for resistance to the azole class of 
antifungals, activating mutations in PDR1, results in increased fitness and virulence both 
in vivo and in vitro. 
 
 Initial in vivo experiments conducted in a murine model of infection 
demonstrated an increased fungal load in the kidney, liver and spleen for strains altered to 
possess different GOF mutations in PDR1 compared to the wild type. These alleles were 
also associated with reduced survival of the mice tested. When PDR1 was disrupted there 
was no difference in fungal load or virulence compared to wild type. This initial study 
demonstrated that Pdr1 is not required for infection and basal level of virulence, but GOF 
mutations do offer a competitive advantage (123). PDR1 activating mutations did not 
influence replication or survival inside macrophages in culture and were not associated 
with increased cytokine production. However, strains with activating mutations in PDR1 
displayed greater adhesion to epithelial cells and reduced uptake by macrophages (183). 
The reduced uptake by macrophages in strains with a PDR1 activating mutation was 
dependent on the background strain and the increased adhesion was dependent on the 
specific activating mutation (184). 
 
 Mutations in PDR1 are known to result in different transcriptional profiles that do 
not appear to be explained by location of the mutation (122, 124, 185). A large analysis 
of multiple mutations found from clinical isolates of C. glabrata revealed only two genes 
that were coordinately regulated with all PDR1 activating mutations – CDR1 and PUP1 
(Pdr1 upregulated) were both upregulated. Since the increased virulence phenotype is 
seen with all PDR1 GOF mutations, these genes were suspected to be involved. Cdr1 is 
an ABC transporter known to be associated with azole resistance that has been discussed 
previously in this review. PUP1 codes for a protein of unknown function. A highly 
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similar protein in S. cerevisiae is thought to be located in the mitochondria, but also has 
no known function. Deletion of CDR1 and PUP1 in an azole-resistant clinical isolate 
revealed that both genes were required for the increased virulence seen in the strain with 
a GOF mutation in PDR1. In the susceptible clinical isolate with wild type PDR1 the 
deletion of PUP1 resulted in decreased fungal burden in kidney, but no decrease in 
survival. Similarly, when CDR1 and PUP1 were overexpressed in a strain disrupted for 
PDR1 there was an increased tissue fungal burden, but no increase in virulence (185). 
 
 Adherence is an important virulence factor for C. glabrata. Members of the 
glycosylphosphatidylinositol-dependent class of proteins called adhesins are known to be 
involved in host interaction. Expression of various adhesins was measured, but only 
EPA1 expression correlated with increased adherence of the different activating 
mutations. EPA1 has a PDRE in its promotor region, but Pdr1 did not bind by ChIP 
analysis. Disruption of EPA1 in a strain expressing an activating mutation in PDR1 
decreased adhesion back to the level of strains with a wild type PDR1. In a mouse urinary 
tract infection model EPA1 was required for PDR1 mediated increased fungal burden in 
the bladder and kidneys (184). Med2 discussed above in relation to potentially regulating 
Pdr1 has also been implicated in adherence to epithelial cells. Med2 deletion strains 
display increased adherence to ovary epithelial cells and increased expression of EPA1 
and EPA7 (173). 
 
 
GENETIC INSTABILITY 
 
 
Petite mutants 
 
 In S. cerevisiae, strains with mitochondrial defects form small, or petite colonies. 
Such petite mutants exhibit upregulation of the pleiotropic drug response through Pdr3 
(186, 187). Petite mutants of C. glabrata were first identified after the observation that 
resistant colonies consistently appeared in the zone of inhibition when assessing azole 
susceptibility by the disc diffusion method. These colonies were found to be respiratory 
deficient and lacked mitochondrial DNA. Petite mutants generated by selection on 
ethidium bromide exhibited resistance to azoles (141). Expression of ABC transporters 
CDR1 and PDH1 were shown to be upregulated in petite mutants generated by ethidium 
bromide exposure (129) and the azole resistance pattern was dependent on Pdr1 (121). 
No alteration in ERG11 expression or sequence have been identified, however petite 
mutants contain only small amounts of the intermediates from the ergosterol biosynthesis 
pathway – a disproportionate amount of ergosterol exists (145). Conflicting data exist 
about whether or not petite mutants have enhanced virulence in animal models (144, 
188). Most recently a petite mutant recovered from a patient showed increased virulence, 
but a petite mutant generated in the laboratory from the same wild type parent isolate 
using ethidium bromide did not have increased virulence (144). Relative to the number of 
invasive C. glabrata infections a very small number of petite mutants have been 
recovered clinically (143, 189). 
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Mutator phenotype 
 
 The ability of C. glabrata to develop multidrug resistance has been attributed to 
its haploid phenotype allowing for rapid genetic changes. DNA repair machinery has 
been implicated in bacteria and in C. albicans that possess a hyper mutation phenotype. A 
recent study evaluated the potential for DNA repair machinery to play a role in C. 
glabrata multidrug resistance. Mutants were made for homologs for genes involved in 
mismatch repair and double-strand break repair in other organisms. Disruption of the 
genes themselves did not alter antifungal susceptibility, however alteration in both 
pathways resulted in generation of more antifungal resistant mutants than wild type. 
Mutations in MSH2 (MutS homolog), which is involved in mismatch repair, were found 
in greater than 50% of clinical C. glabrata isolates. The increased mutation rate in these 
isolates leads to a higher rate of antifungal resistance in vivo and in vitro (120). 
 
 
Chromosomal changes 
 
 Karyotyping of C. glabrata clinical isolates has previously revealed genetic 
rearrangements in sequential isolates taken from the same patient, but the importance of 
these changes with regards to resistance was not well understood (190, 191). Along with 
typical rearrangements and duplications, C. glabrata has the ability to form new 
chromosomes. Although previously shown in C. albicans (89), subsequent analysis of a 
group of C. glabrata clinical isolates revealed that genes associated with azole resistance 
were among the regions found to be duplicated. Subsequent growth in vitro in the 
presence of azole resulted in retention of the extra chromosome, while growth without 
drug resulted in loss of the chromosome in 70% of daughter cells (192). A second study 
from the same group confirmed the previous association between chromosomal changes 
and resistance with a larger collection of isolates (193). The stability of these changes and 
their true impact on clinical resistance in C. glabrata are not well understood at this time. 
 
 
Heteroresistance 
 
 Heteroresistance, which was first described in 1947 has been seen in both gram 
positive and gram negative bacteria, as well as Cryptococcus. The term refers to clonal 
cell populations that vary in susceptibility to an antibiotic. This phenomena can result in 
treatment failure and selection for resistant populations due to inappropriate drug therapy 
from mistaking the entire population as susceptible (194). The ability of C. glabrata to 
develop resistance during azole therapy suggests heteroresistance occurs in this pathogen 
as well. 
 
 Recent analysis of a collection of C. glabrata clinical isolates indicates that 
heteroresistance is indeed widespread among this pathogen. Of the 52 isolates tested for 
fluconazole susceptibility 30 exhibited heteroresistance. No heteroresistance was 
observed when testing susceptibility to echinocandins. Activity of ABC transporter 
activity measured by rhodamine 6G efflux correlated with degree of heteroresistance to 
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fluconazole. However, none of the strains exhibiting heteroresistance had an activating 
mutation in PDR1. In animal studies persistent infection was more common in mice 
infected with strains with the heteroresistant phenotype compared to strains with no 
heteroresistance. This phenotype is still not well understood in C. glabrata, but this initial 
study reveals heteroresistance may be playing an important role in clinical azole 
resistance (195). 
 
 
CONCLUSION 
 
 While azole resistance in C. glabrata remains an important clinical threat, the 
work described in this review is reason to be optimistic about reclaiming the azoles as an 
effective treatment option in the future.  As the molecular and genetic basis of azole 
resistance in this fungal pathogen is better understood, it will be possible to design 
inhibitors of sterol demethylase that circumvent the relevant multidrug transporters and to 
discover compounds that can serve as co-therapeutic agents to overcome azole resistance. 
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CHAPTER 3.    RELATIVE CONTRIBUTION OF THE ABC TRANSPORTERS 
CDR1, PDH1, AND SNQ2 TO AZOLE RESISTANCE IN CANDIDA 
GLABRATA 
 
 
INTRODUCTION 
 
 The ATP-binding cassette (ABC) transporters are a large family of clinically 
relevant proteins found across prokaryotic and eukaryotic organisms. ABC transporters 
act as drug efflux pumps in Candida glabrata as well as in the related yeasts 
Saccharomyces cerevisiae and Candida albicans. Additional members of the ABC 
transporter family play a role in lipid homeostasis, which may also influence antifungal 
treatment, as the drug targets are influenced by lipid content in the cell (196). 
 
 In C. albicans, contributions of different mechanisms of resistance to the azole 
class of antifungals have been well characterized (197). There are two ABC transporters 
known to contribute to the resistance phenotype in C. albicans, Cdr1 and Cdr2. Deletion 
of each transporter in a clinical isolate with an activating mutation in the gene encoding 
the transcription factor Tac1, which results in increased expression of CDR1 and CDR2, 
established Cdr1 as most important in azole resistance (198). In C. glabrata resistance in 
clinical isolates is due primarily to activating mutations in the transcription factor Pdr1 
that lead to increased expression of the genes encoding one of three ABC transporters, 
Cdr1, Pdh1 or Snq2 (127-131, 165). CDR1 was found to be upregulated in a resistant 
clinical isolate of C. glabrata when compared to the susceptible paired isolate. Deletion 
of CDR1 in the resistant isolate resulted in decreased susceptibility to the level of the 
susceptible matched isolate. Reintegration of CDR1 into the deletion mutant restored the 
azole-resistant phenotype (127). PDH1 was also first implicated when its expression was 
found to be increased in azole-resistant clinical isolates of C. glabrata (128) and then 
further study showed deletion of PDH1 results in decreased susceptibility to fluconazole 
(129). The most recent ABC transporter that has been shown to contribute to azole 
resistance is Snq2. It was found to have increased expression in two azole-resistant 
clinical isolates that did not overexpress CDR1 or PDH1 (130) and subsequently shown 
in one of the same isolates to be required for the azole-resistant phenotype (131). 
 
 In order to overcome azole resistance in C. glabrata it is first important to 
thoroughly understand the mechanisms by which it develops resistance to the azoles. 
While it is known that in C. glabrata the vast majority of clinical resistance has been 
attributed to upregulation of ABC transporters, the relative importance of each of these 
remains unclear. Based on previous work in C. glabrata and C. albicans we predicted 
that Cdr1 plays the largest role in azole resistance. In this study we used a strain 
engineered to carry an activating mutation in PDR1 from an azole-resistant clinical 
isolate that results in upregulation of all three ABC transporters that have been shown to 
influence azole susceptibility in C. glabrata. By generating deletion strains of each 
transporter alone and in combination we were able to characterize their individual 
contributions to the phenotype. 
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MATERIALS AND METHODS 
 
 
Strains and growth media 
 
 All strains used in this study are listed in Table 3-1. The clinical isolates and the 
PDR1 replacement strain have been described previously. (124, 199) All strains were 
stored as frozen stocks at -80°C with 40% glycerol. Strains were routinely grown in YPD 
(1% yeast extract, 2% peptone, and 2% dextrose) broth at 30°C in a shaking incubator 
except as indicated for specific experimental conditions. 
 
 PX5-α Escherichia coli chemically competent cells (Protein Express, Cincinnati, 
OH) were used as the host for plasmid construction and propagation. These strains were 
grown at 37°C in Luria-Bertani (LB) broth or on LB plates supplemented with 100 μg/ml 
ampicillin (Sigma, St. Louis, MO) or 50 μg/ml kanamycin (Fisher BioReagents, Fair 
Lawn, NJ). 
 
 
Plasmid construction 
 
 For deletion of CDR1, PDH1 and SNQ2 we modified plasmid pSFS2. (200) 
Upstream homology regions approximately 800 - 1000 bp long were amplified using 
primer pairs CgCDR1A/CgCDR1B, CgPDH1/CgPDH1B or CgSNQ2A/CgSNQ2B and 
digested with ApaI/XhoI or KpnI/ApaI as indicated for insertion into their respective 
plasmids. Downstream homology regions approximately 800 - 1000 bp long were 
amplified using primer pairs CgCDR1C/CgCDR1D, CgPDH1C/CgPDH1D or 
CgSNQ2C/CgSNQ2D and digested with SacII/SacI or NotI/SacII as indicated for 
insertion into their respective plasmids. The disruption cassettes consisting of the SAT1 
flipper cassette and upstream and downstream flanking sequences of either CDR1, PDH1 
or SNQ2 were excised from the final plasmids pCgCDR1, pCgPDH1 or pCgSNQ2 and 
gel purified. Primers used to construct the cassettes are listed in Table 3-2. 
 
 
Strain construction 
 
 C. glabrata cells were transformed by the lithium acetate method using 
approximately 1 μg of DNA. The ApaI/SacI fragments from pCgCDR1 and pCgSNQ2 
and the KpnI/SacII fragment from pCgPDH1 were excised and gel purified prior to 
transformation. The transformed cells were allowed to recover 6 h in YPD at 30oC before 
being plated on YPD-agar plates containing 200 μg/ml nourseothricin (Jena Biochemical, 
Germany) and incubated at 30oC. Positive transformants were selected within 24 h and 
successful insertion of the disruption cassette at the target gene locus was confirmed by 
Southern hybridization using gene specific probes. Subsequently, induction of the flipper 
recombinase gene in the disruption cassette was performed by overnight growth of the 
positive transformant clones in YPD at 30oC with shaking (under no selective pressure). 
Selection for excision of the SAT1 flipper cassette was then performed by plating on
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Table 3-1. Strains used in the ABC transporter study. 
 
Strain Parent Genotype or description Reference 
SM1  Azole-susceptible clinical isolate (199) 
SM3  Azole-resistant clinical isolate (199) 
SM1RPDR1(SM3) SM1∆pdr1 pdr1∆::FRT-PDR1SM3 (124) 
S1RPS3CDR1M2A and -B SM1RPDR1(SM3) pdr1∆::FRT-PDR1SM3/cdr1∆::FRT This study 
S1RPS3PDH1M2A and -B SM1RPDR1(SM3) pdr1∆::FRT-PDR1SM3/pdh1∆::FRT This study 
S1RPS3SNQ2M2A and -B SM1RPDR1(SM3) pdr1∆::FRT-PDR1SM3/snq2∆::FRT This study 
S1RPS3CAPDH1M2A S1RPS3CDR1M2A pdr1∆::FRT-PDR1SM3/cdr1∆::FRT/ pdh1∆::FRT This study 
S1RPS3CBPDH1M2A S1RPS3CDR1M2B pdr1∆::FRT-PDR1SM3/cdr1∆::FRT/ pdh1∆::FRT This study 
S1RPS3CASNQ2M2A S1RPS3CDR1M2A pdr1∆::FRT-PDR1SM3/cdr1∆::FRT/ snq2∆::FRT This study 
S1RPS3CBSNQ2M2A S1RPS3CDR1M2B pdr1∆::FRT-PDR1SM3/cdr1∆::FRT/ snq2∆::FRT This study 
S1RPS3CAPASNQ2M2A S1RPS3CAPDH1M2A pdr1∆::FRT-PDR1SM3/cdr1∆::FRT/ pdh1∆::FRT/snq2∆::FRT This study 
S1RPS3CBPASNQ2M2A S1RPS3CBPDH1M2A pdr1∆::FRT-PDR1SM3/cdr1∆::FRT/ pdh1∆::FRT/snq2∆::FRT This study 
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Table 3-2. Primers used in the ABC transporter study. 
 
Primer name  Primer sequence1 
CgCDR1A  5’- CATAGATCAGGGCCCATTACATTAGCACAG - 3’ 
CgCDR1B 5’- CTCAGTGTTGCTCGAGATAGGGTTGATAC - 3’ 
CgCDR1C 5’- GTTCTGTTAGTTCCGCGGACTCTCGTAGAT - 3’ 
CgCDR1D 5’- GTGAATACAAACAAGAGCTCCACAATAATA - 3’ 
CgPDH1A 5’- AAACAGTCTATGGTACCACAAGTTTGCACA - 3’ 
CgPDH1B 5’- CCGTATACGTTTCGGGCCCTTGTCATCAA - 3’ 
CgPDH1C 5’- ACAGAAGATGCGGCCGCTATGGTATATTTATT - 3’ 
CgPDH1D 5’- ATTCCTTAATAACCGCGGAAGTTGACTTTA - 3’ 
CgSNQ2A 5’- TTGAGTATCTTAGGGCCCTTGTTTTCAGTT - 3’ 
CgSNQ2B 5’- GATAGAATACTCGAGTTGTCGCTGTGCGC - 3’ 
CgSNQ2C 5’- GCTATTTATTACCGCGGCCATGTCAGAG - 3’ 
CgSNQ2D 5’- AGACAGATATTGAGCTCCACTACTGCTGAG - 3’ 
 
1Underlined bases indicate introduction of restriction enzyme cloning sites to allow   
directional cloning into the SAT1-flipper cassette. 
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YPD-agar plates and incubating for up to 24 h at 30oC. Clones were selected and 
confirmed by Southern hybridization using gene specific probes. 
 
 
Isolation of genomic DNA and Southern hybridization 
 
 Genomic DNA from C. glabrata was isolated as described previously. (201) For 
confirmation by Southern hybridization, approximately 10 μg of genomic DNA was 
digested with the appropriate restriction enzymes, separated on a 1% agarose gel 
containing ethidium bromide, transferred by vacuum blotting onto a nylon membrane and 
fixed by UV-crosslinking. Hybridization was performed with the Amersham AlkPhos 
Direct Labeling and Detection System (GE Healthcare, Pittsburg, PA) as per 
manufacturer instructions. 
 
 
Susceptibility testing 
 
 Susceptibility testing was performed by microbroth dilution assay and by 
Epsilometer test strips (Etest). Microbroth dilution was performed according to the CLSI 
guidelines outlined in M27-A3 with a few modifications. (202) Fluconazole (MP 
Biomedicals, Salon, OH) stock solution was prepared by reconstitution in water to 5 
mg/mL. Colonies grown overnight on Sabouraud dextrose plates were diluted to 2.5x103 
cells/ml in RPMI 1640 (Sigma, St. Louis, MO) with 2% glucose, MOPS, pH 7.0. Plates 
were incubated at 35°C for 48 h. Absorbance at 600 nm was read with a BioTek Synergy 
2 microplate reader (BioTek, Winooski, VT); background due to medium was subtracted 
from all readings. The MIC was defined as the lowest concentration inhibiting growth by 
at least 50% relative to the drug-free control after incubation with drug for 48 h. Etest 
(bioMerieux) susceptibility assay was performed per manufacturer instructions with some 
modifications. Colonies were selected from cultures grown overnight on Sabouraud 
dextrose plates and diluted in water to 0.5 McFarland standard. Sterile cotton swabs were 
used to streak plates prior to Etest strip placement. Plates were incubated at 35°C and 
read at 24 and 48h. 
 
 
RESULTS 
 
 
CDR1 deletion alone alters fluconazole susceptibility in a resistant C. glabrata strain 
 
 The SAT1 flipper strategy for gene disruption was used to generate deletion 
strains in C. glabrata. Single gene deletion mutants were made for each ABC transporter 
known to contribute to azole resistance (CDR1, SNQ2, and PDH1). The azole-resistant 
strain SM1RPDR1(SM3) was used as the parent strain for the mutants. This strain was 
made in our laboratory previously by replacing the PDR1 allele in fluconazole 
susceptible doses dependent clinical isolate SM1 with the PDR1 allele from azole-
resistant isolate SM3, which contains the well characterized L946S activating mutation 
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(124). Isolate SM1 was recovered from a patient with an abdominal abscess prior to 
antifungal treatment. SM3 was recovered from an abscess from the same patient 46 days 
later after a course of fluconazole, followed by caspofungin and then amphotericin B. 
Pulsed field gel electrophoresis of the two isolates was indistinguishable (199). 
 
 Susceptibility testing was performed by broth dilution for a panel of azoles, as 
well as Etest for fluconazole. Both assays confirmed susceptibility data published 
previously for SM1, SM3 and SM1RPDR1(SM3). The fluconazole MIC for SM1 is 8 
(Table 3-3 and Figure 3-1A), which would be considered susceptible dose dependent 
according to the most recent breakpoints. The fluconazole MIC for both SM3 and 
SM1RPDR1(SM3) is 256. Deletion of CDR1 in strain SM1RPDR1(SM3) resulted in a 
decreased fluconazole MIC from 256 to 16. However, neither PDH1 nor SNQ2 single 
deletion mutants exhibited a change in fluconazole MIC. Fluconazole Etest susceptibility 
testing confirmed the results from the broth microdilution assay (Figure 3-1C). The same 
trend was seen with additional azoles tested (Table 3-3). Among single ABC transporter 
deletion mutants CDR1 alone was able to alter azole susceptibility. 
 
 
PDH1 and SNQ2 contribute to fluconazole resistance to a lesser extent than CDR1 
 
 Previous studies have demonstrated a role for Pdh1 and Snq2 in resistance to 
azoles. However, we show here that deletion of PDH1 or SNQ2 in an azole-resistant 
strain overexpressing all three transporters resulted in no change in fluconazole 
susceptibility (Table 3-3 and Figure 3-1A). In order to determine if PDH1 and SNQ2 
impact fluconazole resistance in the absence of CDR1, double and triple deletion strains 
were made using the SAT1 flipper method described above. 
 
 When PDH1 and CDR1 were deleted in combination, the MIC is consistently 
one-fold lower than the MIC for the strain in which CDR1 alone is deleted (Table 3-3 
and Figure 3-1B). When SNQ2 and CDR1 were deleted in combination, the MIC is the 
same as that observed for the CDR1 single deletion strain. To investigate the possibility 
that the presence of PDH1 is masking the effect of SNQ2 we constructed a strain with all 
three transporters deleted. The MIC for the triple deletion strain was consistently one-fold 
less than that of the CDR1 and PDH1 deletion strain. The patterns seen by microbroth 
dilution were confirmed by Etest susceptibility testing (Figure 3-1C). 
 
 
CDR1, PDH1, and CDR1 mutants exhibit similar susceptibility patterns to other 
azole antifungals 
 
 Of interest is the potential for these transporters to affect members of the azole 
class of antifungals differently. Newer triazoles in the class have improved spectrum of 
activity against additional fungal pathogens. The differences in chemical structure could 
influence the interaction with efflux pumps resulting in different ABC transporters 
preferentially effluxing different azoles. However, overall the patterns for all azoles 
tested are similar with few differences (Table 3-3). The magnitude of changes in MIC are 
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Table 3-3. Azole susceptibilities performed by microbroth dilution for selected 
strains. 
 
 MIC (μg/ml) 
Strain FLC1 ITC KTC MC VRC 
SM1 8 0.5 0.063 0.125 0.125 
SM3 256 32 4 1 8 
SM1RPDR1(SM3) 256 32 4 1 8 
∆cdr1 16 0.5 0.25 0.25 0.25 
∆pdh1 256 32 4 1 8 
∆snq2 256 32 4 1 8 
∆cdr1∆pdh1 8 0.125 ≤0.031 0.063 0.063 
∆cdr1∆snq2 16 0.5 0.25 0.25 0.25 
∆pdh1∆snq2 256 32 4 1 8 
∆cdr1∆pdh1∆snq2 2 0.125 ≤0.031 ≤0.016 0.031 
 
1Fluconazole (FLC), Itraconazole (ITC), Voriconazole (VRC), Ketoconazole (KTC), 
Miconazole (MC) 
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Figure 3-1. Fluconazole susceptibility testing. 
 
Microbroth dilution assays were setup as described above for single deletion strains (A) 
or double and triple deletion strains (B). Cultures were resuspended at 48h and 
absorbance at 600nm was measured and background subtracted. Data is represented as 
percent of no drug treatment control. Etest assays (C) were performed per manufacturer 
instructions with some modifications as described.   
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different among the azoles for the different ABC transporters. In general however, the 
differences from the parent strain and the triple ABC transporter deletion strain were 6 to 
8 drug dilutions for all azoles tested. Among the single deletion mutants, Cdr1 was the 
only transporter able to influence the MIC for all azoles tested. Interestingly, deletion of 
SNQ2 had no impact on itraconazole or ketoconazole MIC. No notable differences were 
observed in susceptibilities to echinocandins and amphotericin B in the mutant strains 
(data not shown). 
 
 
CDR1, PDH1, and SNQ2 explain most, but not all of Pdr1’s contribution to azole 
resistance 
 
 All three ABC transporters in this study are known targets of Pdr1. All three 
transporters are upregulated in strains that possess an activating mutation in PDR1 (123, 
124, 131). Pdr1 has also been shown to bind to the promoter regions of each transporter 
by Chip-Seq (126). In order to determine if these three transporters account for the 
entirety of Pdr1’s importance to azole resistance we compared PDR1 deletion strains to 
the triple ABC transporter deletion strain. Both the susceptible dose dependent and 
resistant clinical isolates lacking PDR1 have similar growth patterns (Figure 3-2). There 
is a distinctly different growth pattern for the triple deletion mutant, which indicates that 
there are likely additional genes of the Pdr1 regulon that contribute to azole resistance. 
 
 
DISCUSSION 
 
 Activating mutations in the zinc cluster transcription factor Pdr1 that result in 
upregulation of ABC transporters are found in the vast majority of azole-resistant clinical 
isolates of C. glabrata. Similarly to the transcription factors Pdr1 and Pdr3 in the closely 
related yeast S. cerevisiae (203), Pdr1 in C. glabrata exerts its regulatory effects by 
binding a pleiotropic drug response element (PDRE) (125, 126). Pdr1 is also auto 
regulated due to a PDRE in its promotor region (125). Developing a better understanding 
of this mechanism of azole resistance is important for discovering new treatment 
strategies. For example, a small molecule that could inhibit efflux by the ABC 
transporters would allow clinicians to once again successfully treat C. glabrata with 
azoles. 
 
 Many different activating mutations have been found throughout the coding 
sequence for PDR1 that result in similar decreases in azole susceptibility (121-125, 204). 
However, there are differences in the gene expression patterns of the Pdr1 regulon for the 
various mutations. Of particular interest are the patterns of expression of the three ABC 
transporters known to influence azole susceptibility, which do not appear to correlate 
with location of the mutation (123). 
 
 ABC transporter expression profiles in clinical isolates reveal a wide distribution 
of expression patterns. CDR1, PDH1 or both CDR1 and PDH1 were found to be highly  
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Figure 3-2. Comparison of fluconazole susceptibilities in PDR1 deletion strains 
versus the ABC transporter triple deletion strain. 
 
Microbroth dilution assays were setup as described above. Cultures were resuspended at 
48h and absorbance at 600nm was measured and background subtracted. Data is 
represented as percent of no drug treatment control. 
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expressed in 18 of 20 resistant clinical isolates from one study. The two remaining 
resistant isolates overexpressed SNQ2 alone. The susceptible dose dependent isolates 
overexpressed the ABC transporters to a lesser extent than the resistant isolates (130). 
Another group showed 10 of 12 resistant clinical isolates and 6 of 7 laboratory generated 
resistant mutants exhibited increased expression of CDR1 or both CDR1 and PDH1 
(119). A third study of resistant clinical isolates found CDR1 or PDH1 overexpression in 
the resistant isolate of 12 of 14 matched clinical isolates (51). A study in which 
expression of CDR1, PDH1 and PDR1 were measured in a panel of clinical isolates for 
the purpose of developing a qPCR based assay for determination of resistance in C. 
glabrata found that CDR1 expression alone could be used to predict resistance with 
100% sensitivity and 95% specificity. The same was not true for PDH1 expression or 
PDR1 expression (205). 
 
 Our experiments show that the three ABC transporters previously implicated in 
Pdr1 mediated azole resistance in C. glabrata are not able to fully explain the decrease in 
susceptibility in the absence of Pdr1. In addition to controlling expression of ABC 
transporters, Pdr1 also regulates expression of many other genes both directly and 
indirectly. We predict that there likely are genes among this group that make small 
contributions to azole resistance that in combination may explain the phenotypic 
difference between the PDR1 deletion strain and the triple ABC transporter deletion 
strain. 
 
 Among the list of genes whose promotors were found to be directly bound by 
Pdr1 are a major facilitator superfamily (MFS) transporter, QDR2, and two additional 
ABC transporters, YBT1 and YOR1 (126). Deletion of QDR2 in C. glabrata resulted in 
increased susceptibility to the imidazoles, clotrimazole, ketoconazole, miconazole, but 
had no effect on fluconazole or itraconazole susceptibility (169). YOR1 and YBT1 are 
frequently found among genes with altered expression in relation to azole susceptibility, 
but not direct relationship has been described. The effects of QDR2, YOR1 and YBT1 on 
fluconazole susceptibility could potentially be masked by the presence of the more 
dominant transporters CDR1, PDH1 and SNQ2 and therefore cannot be ruled out as 
contributing to azole resistance, albeit likely a minor contribution. 
 
 Other genes of interest shown previously to be upregulated in clinical isolates 
(122, 124) and laboratory derived strains (168) of C. glabrata with activating mutations 
in PDR1 are RSB1 and RTA1. Rsb1 is a putative sphingolipid flippase. The homolog for 
Rta1 in S. cerevisiae is a member of the fungal lipid-translocating exporter family of 
proteins. The promoter regions of both RSB1 and RTA1 possess a PDRE that is bound 
directly by Pdr1 (125). Recent work in C. albicans has implicated the putative lipid 
translocase encoded by RTA3 and the sphingolipid flippase encoded by RTA2 in azole 
resistance (Appendix A, Figures A-1 to A-4 and Tables A-1 to A-3) (206, 207). Rsb1 
and Rta1 may make similar contributions to azole resistance in C. glabrata.   
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CHAPTER 4.    UPC2A IS REQUIRED FOR HIGH-LEVEL AZOLE 
ANTIFUNGAL RESISTANCE IN CANDIDA GLABRATA* 
 
 
INTRODUCTION 
 
 Fungal infections caused by opportunistic organisms have continued to increase in 
recent decades and have become an important medical concern (208-210). Candida 
glabrata in particular has emerged over the past two decades as the predominant cause of 
yeast infections in diabetics (54%) and the elderly (51%) and is second to Candida 
albicans in most other patient populations (13, 17, 211, 212). Candidemia mortality rates 
continue to rise with rates for C. glabrata reported as high as 50% (151, 213, 214). The 
emergence of C. glabrata as a common pathogen is complicated by, and likely related to, 
its intrinsically low susceptibility to azole antifungals and its ability to rapidly develop 
high-level azole resistance during treatment (119, 134, 199, 205). 
 
 Ergosterol is an essential component of the fungal cell membrane and is an 
important signaling molecule in the cell. It helps maintain membrane integrity and 
fluidity, which facilitates several membrane-bound enzymatic reactions. Ergosterol is not 
synthesized by the host, so the ergosterol biosynthesis pathway has long been a target for 
antifungal agents (Figure 4-1). Compounds that inhibit this pathway are broadly 
categorized as sterol biosynthesis inhibitors (SBIs). The azole class of antifungals 
specifically targets lanosterol 14-alpha-demethylase (Erg11), which catalyzes the C-14 
demethylation of lanosterol (215-217). Statins, such as lovastatin, inhibit the gene 
products of HMG1 and HMG2, which convert 3-hydroxy-3-methyl-glutaryl (HMG)-CoA 
to mevalonate, resulting in a reduction in the synthesis of cholesterol in mammals and the 
synthesis of ergosterol in yeasts (Figure 4-1). 
 
 As has been observed in Saccharomyces cerevisiae and C. albicans, exposure to 
azoles also results in upregulation of genes from the ergosterol biosynthesis pathway 
(including ERG11) in C. glabrata (119, 215-217). The predominant mechanism of azole 
resistance in C. glabrata is the constitutive over-expression of ATP-binding cassette 
(ABC) transporter genes, CDR1, PDH1 and SNQ2, which are under the transcriptional 
regulation of a hyperactive form of the transcription factor Pdr1. ERG gene expression 
and regulation could also be important in acquired azole resistance, as is the case in C. 
albicans, or may potentially contribute to the intrinsic reduced azole susceptibility in C. 
glabrata (71-73, 119, 124, 178, 218-220). 
 
 Resistant isolates of S. cerevisiae often have increased expression of ERG11, as 
well as other ergosterol biosynthesis genes, which are under the control of the  
 
_________________________ 
*Reprinted with permission. Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, 
Toner G, Barker KS, Gygax SE, Rogers PD. 2014. UPC2A is required for high-level 
azole antifungal resistance in Candida glabrata. Antimicrob Agents Chemother 58:4543-
4554.  
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Figure 4-1. Representation of the ergosterol biosynthesis pathway in Candida 
glabrata. 
 
Genes (in italics) whose expression was monitored in this study are underlined. Site of 
action for specific drug classes indicated by dashed box. CoA, coenzyme A. 
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transcriptional regulators Upc2 and Ecm22 (221, 222). In C. albicans, a single homolog, 
Upc2, has been identified and found to be involved in ERG gene regulation (70, 217, 220, 
223, 224). These transcriptional regulators are members of the well-characterized fungal-
specific Zn(2)-Cys(6) family of transcriptional activators (218). ERG11 is not an essential 
gene in C. glabrata. Disruption of this gene or pharmacologic inhibition of its product 
prevents ergosterol production, which causes accumulation of alternate sterols including 
lanosterol, obtusifoliol, and 4, 14?-dimethyl zymosterol leading to decreased 
susceptibility to fluconazole, itraconazole, and amphotericin B (55, 225). Biosynthesis of 
these alternate sterols does not require ERG11, but does require other genes in the 
ergosterol biosynthesis pathway. 
 
 Nagi et al. recently described two Upc2 homologs in C. glabrata, Upc2A and 
Upc2B. Upc2A was shown to play a major role in the regulation of ERG2 and ERG3 in 
the ergosterol biosynthesis pathway (178). A strain disrupted for UPC2A also exhibited a 
4-fold and 16-fold increase in fluconazole and lovastatin (a member of the statin class of 
cholesterol lowering agents) susceptibility, respectively (178). Given the global role of 
Upc2 in regulation of sterol biosynthesis, we reasoned that disruption of UPC2A might 
enhance the activity of fluconazole in azole-resistant as well as -SDD clinical isolates. 
 
 
MATERIALS AND METHODS 
 
 
Strains and growth media 
 
 The matched fluconazole-SDD and -resistant clinical isolate set used in this study 
has been described previously (124, 199). All isolates/strains (Table 4-1) were 
maintained in YPD (1% yeast extract, 2% peptone, and 2% dextrose) broth at 30°C and 
stored as 40% glycerol stocks at −80°C. One Shot Escherichia coli TOP10 chemically 
competent cells (Invitrogen, Carlsbad, CA) were used as the host for plasmid 
construction and propagation. These strains were grown at 37°C in Luria-Bertani (LB) 
broth or on LB plates supplemented with 100 μg/ml ampicillin (Sigma, St. Louis, MO) or 
50 μg/ml kanamycin (Fisher BioReagents, Fair Lawn, NJ). 
 
 
Gene disruption 
 
 Mutant strains (Table 4-1) were generated by the SAT1-flipper gene disruption 
method (200). Briefly, approximately 900 bp of sequence immediately upstream of target 
gene plus the first 50 bp of the open reading frame (ORF), referred to as the 5’flanking 
region, was cloned upstream of the SAT1-flipper cassette in pSFS2A and the final 50 bp 
of the target gene ORF plus approximately 900 bp of sequence immediately downstream 
of the target gene, referred to as the 3’ flanking region, was cloned downstream of the 
SAT1-flipper cassette. The disruption cassettes consisting of the SAT1-flipper and 5’ and 
3’ flanking sequences of the either the UPC2A or UPC2B genes were excised from the 
final plasmid construct and gel purified. Primers used to construct the cassettes are listed 
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Table 4-1. Strains used in the UPC2 study. 
 
Strain Parent Genotype or description Reference 
SM1  Azole-SDD clinical isolate (199) 
SM1Δupc2A SM1 upc2AΔ::FRT This study 
SM1Δupc2B SM1 upc2BΔ::FRT This study 
SM1Δupc2AΔupc2B SM1 upc2AΔ::FRT/upc2BΔ::FRT This study 
SM1Δupc2A/UPC2A SM1 upc2AΔ::FRT-UPC2A This study 
SM1Δupc2AΔupc2B/UPC2A SM1 upc2AΔ::FRT-UPC2A/upc2BΔ::FRT This study 
SM3  Azole-resistant clinical isolate (199) 
SM3Δupc2A SM3 upc2AΔ::FRT This study 
SM3Δupc2B SM3 upc2BΔ::FRT This study 
SM3Δupc2AΔupc2B SM3 upc2AΔ::FRT/upc2BΔ::FRT This study 
SM3Δupc2A/UPC2A SM3 upc2AΔ::FRT-UPC2A This study 
SM3Δupc2AΔupc2B/UPC2A SM3 upc2AΔ::FRT-UPC2A/upc2BΔ::FRT This study 
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in Table 4-2. C. glabrata cells were transformed by the lithium acetate method using 
approximately 1 μg of DNA. The transformed cells were allowed to recover 6 h in YPD 
at 30oC before being plated on YPD-agar plates containing 200 μg/ml nourseothricin 
(Jena Biochemical, Germany) and incubated at 30oC. Positive transformants were 
selected within 24 h and successful insertion of the disruption cassette at the target gene 
locus was confirmed by Southern hybridization. Subsequently, induction of the flipper 
recombinase gene in the disruption cassette was performed by overnight growth of the 
positive transformant clones in YPD at 30oC with shaking (under no selective pressure). 
Selection of cassette excision was then performed by plating a series of dilutions of this 
culture on YPD-agar plates containing 25 μg/ml nourseothricin and incubating for up to 
24 h at 30oC. Clones were selected due to size differences (slower growing colonies 
usually indicated successful cassette excision) and confirmed by Southern hybridization 
(Figure 4-2). 
 
 Likewise, reintroduction of the UPC2A gene into the UPC2A locus was 
accomplished as above with a SAT1-flipper cassette in which the 5’ flanking sequence 
cloned upstream of the flipper cassette was replaced with a DNA fragment consisting of 
the 5’flanking sequence and full-length ORF of UPC2A. Isolate-specific constructs were 
prepared to reintroduce the native UPC2A alleles back into their original locus. This 
cassette was excised, gel purified, and used for cell transformation as above. Screening 
for positive clones was accomplished as described above (Figure 4-2). 
 
 
Isolation of genomic DNA and Southern hybridization 
 
 Genomic DNA from C. glabrata was isolated as described previously (201). For 
confirmation by Southern hybridization, approximately 10 μg of genomic DNA was 
digested with the appropriate restriction enzymes, separated on a 1% agarose gel 
containing ethidium bromide, transferred by vacuum blotting onto a nylon membrane and 
fixed by UV-crosslinking. Hybridization was performed with the Amersham ECL Direct 
Nucleic Acid Labeling and Detection System (GE Healthcare, Pittsburg, PA) as per 
manufacturer’s instructions. 
 
 
Susceptibility testing 
 
 Susceptibility testing was performed by microbroth dilution assay according to 
the CLSI guidelines outlined in M27-A3 with a few modifications (202). Antifungal 
agents were obtained from the following sources:  fluconazole (LKT Laboratories, St. 
Paul, MN), miconazole (MP Biomedicals, Inc., Solon, OH), anidulafungin and 
voriconazole (Pfizer, New York, N.Y.), ketoconazole, amphotericin B, lovastatin and 
terbinafine (Sigma, St. Louis, MO). All drugs were dissolved in dimethyl sulfoxide 
(DMSO) and diluted to give a final DMSO concentration of ≤ 0.5% in all experiments. 
Growth of C. glabrata was not affected at this concentration of DMSO (data not shown). 
Cultures were diluted to 2.5x103 cells/ml in RPMI 1640 (Sigma, St. Louis, MO) with 2% 
glucose, MOPS, pH 7.0. Plates were incubated at 35°C for 24, 48 and 72 h. Absorbance  
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Table 4-2. Primers used in the UPC2 study (grouped by application). 
 
Primer name and function Primer sequence1 
Cassettes for constructing 
mutants 
 
   CgUPC2A-A  5’-GTTAAAACGGGCCCATGATCGTCGTATCC-3’ 
   CgUPC2A-B 5’-AATAGCTTTGGCTCGGTATCCTCTATGT-3’ 
   CgUPC2A-C 5’-CTAGAGATGCGGCCGCTTATAGTGGTGGT-3’ 
   CgUPC2A-D 5’-TATCGATTTAACCGCGGTGATATTCTTCCA-3’ 
   CgUPC2A-E 5’-GTACCTAGTGGGCCCACCTTGATCTGT-3’ 
   CgUPC2A-F 5’-AATAAAGGAAGTAAATTGCATATTTCAGAG-3’ 
   CgUPC2B-A  5’-TGAGTTCAGTTTTATGGGCCCTTAGAAAG-3’ 
   CgUPC2B-B 5’-AGTTGTACTAACCTTCTTACCTCGAGTATCTA-3’ 
   CgUPC2B-C 5’-TAAGATATTGCCGCGGTTTACTAACGATGT-3’ 
   CgUPC2B-D 5’-CAAAACTATAGGAGCTCGAAGGAATATGTG-3’ 
qRT-PCR  
   ACT1F 5’-CGCTTTGGACTTCGAACAAGAA-3’ 
   ACT1R 5’-GTTACCGATGGTGATGACTTGAC-3’ 
   ERG1F 5’-GGTAAGAAGGTGCTGATTG-3’ 
   ERG1R 5’-GATGTTGTTGATGGACTGG-3’ 
   ERG2F 5’-AATCTGCTATTGCTGGTTGCC-3’ 
   ERG2R 5’-CGCTGCCGTTGTGTTTGG-3’ 
   ERG3F 5’-AAGCGTGTGAACAAGGAC-3’ 
   ERG3R 5’-TACAATAGCAGACCGAAGAC-3’ 
   ERG4F 5’-GCTGTACGCTAACGCTTGTG-3’ 
   ERG4R 5’-CAGTGGCAGTATGTGTATGGAAC-3’ 
   ERG5F 5’-CCCAGCCCTACACGACCCAGAAG-3’ 
   ERG5R 5’-GGACCACAGCCGAAGACCAACC-3’ 
   ERG6F 5’-TCCTCTTTCCACTTCTCCCGTTTC-3’ 
   ERG6R 5’-GCCACCGACACCGCAACC-3’ 
   ERG7F 5’-ATGCCTGATGGTGGTTGG-3’ 
   ERG7R 5’-TCTTCATTTGGACACTTAGCC-3’ 
   ERG9F 5’-CAGCACCAATGACACCAG-3’ 
   ERG9R 5’-CCTCAGAATCAGATAGAAGACC-3’ 
   ERG10F 5’-GTTATCGCTGGTGGTTGTG-3’ 
   ERG10R 5’-CATTGGTTGGTGGTCGTAAG-3’ 
   ERG11F 5’-TACCAAGCCATACGAGTTC-3’  
   ERG11R 5’-GGTCAAGTGGGAGTAAGC-3’  
   ERG24F 5’-ACTCGCTGGACTACTACTTC-3’ 
   ERG24R 5’-CAACTTAGTGCCGTCTCTTAG-3’ 
   ERG25F 5’-ATGTGTATGGATTACCTTGAGAC-3’ 
   ERG25R 5’-GTAGTTACCGATGAAGTAGTGG-3’ 
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Table 4-2. (Continued). 
 
Primer name and function Primer sequence1 
qRT-PCR (continued)  
   ERG27F 5’-CCAGGAAAGTAGCCGTTATCAC-3’ 
   18SF 5’-TCGGCACCTTACGAGAAATCA-3’ 
   18SR 5’-CGACCATACTCCCCCCAGA-3’ 
   PDR1F 5’-TTTGACTCTGTTATGAGCGATTACG-3’ 
   PDR1R 5’-TTCGGATTTTTCTGTGACAATGG-3’ 
   CDR1F 5’-CATACAAGAAACACCAAAGTCGGT-3’ 
   CDR1R 5’-GAGACACGCTTACGTTCACCAC-3’ 
   SNQ2F 5’-CGTCCTATGTCTTCCTTACACCATT-3’ 
   SNQ2R 5’-TTTGAACCGCTTTTGTCTCTGA-3’ 
   PDH1F 5’-ACGAGGAGGAAGACGACTACGA-3’ 
   PDH1R 5’-CTTTACTGGAGAACTCATCGCTGGT-3’ 
 
1 Underlined bases indicate introduction of restriction enzyme cloning sites to allow 
directional cloning into the SAT1-flipper cassette. 
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Figure 4-2. Construction of upc2aΔ and upc2bΔ mutants and complemented 
strains. 
 
Construction of upc2aΔ and upc2bΔ mutants and complemented strains. A. Structure of 
the deletion cassette from plasmid pCgUPC2A (top), which was used to delete the 
UPC2A ORF in strains SM1 and SM3 and genomic structure of the UPC2A locus in the 
parental strains (bottom). The UPC2A coding region is represented by the white arrow 
and the upstream and downstream regions (5’UPC2A and 3’UPC2A) by the solid lines. 
The SAT1 flipper cassette (SAT1-FLIP), in which the caFLP gene is expressed from the 
inducible SAP2 promoter (33), is represented by the grey rectangle bordered by FRT sites 
(black arrows). The 34 bp FRT sites are not drawn to scale. The probes used for Southern 
hybridization analysis of the mutants are indicated by the black bars. B. Structure of the 
deletion cassette from plasmid pCgUPC2B which was used to delete the UPC2B ORF in 
strains SM1 and SM3 and the genomic structure of the UPC2B locus in the parental 
strains. See A for further explanation. C. Structure of the DNA fragment from plasmid 
pCgUPC2Apb (top), which was used for reintegration of an intact UPC2A copy into the 
disrupted UPC2A locus in the upc2aΔ single and upc2aΔupc2bΔ double mutants 
(bottom) Only relevant restriction sites are given in panels A, B and C, as follows: A, 
ApaI; H, HindIII; N, NotI; S, ScaI; ScI, SacI; ScII, SacII; X, XhoI. D. Southern 
hybridization of ScaI-digested (top) or HindIII-digested (bottom) genomic DNA of SM1, 
SM3, upc2aΔ and upc2bΔ mutants, and complemented strains with the UPC2A-specific 
probe 2 (top) or UPC2B-specific probe 2 (bottom). The sizes of the hybridizing 
fragments (in kb) are given on the left side of the blot and their identities are indicated on 
the right. The genotype of the strains is given above the respective lanes. Only one of the 
two independently constructed series of strains is shown.  
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at 620 nm was read with a microplate reader (Beckman Coulter, Inc., Fullerton, CA); 
background due to medium was subtracted from all readings. The minimum inhibitory 
concentration (MIC) was defined as the lowest concentration inhibiting growth by at least 
80% (or no visible growth for amphotericin B) relative to the drug-free control after 
incubation with drug for 24 h. While CSI guidelines indicate an endpoint of 50% 
inhibition of growth, we chose to use a more stringent endpoint of 80% inhibition of 
growth in order to detect a more pronounced effect. Absorbance measured at 72 h was 
used to assess regrowth of the cultures (226). The minimum fungicidal concentration 
(MFC) was determined by spotting 5 μl from each well of the 48 h MIC plate onto YPD 
solid media and incubating at 30°C for an additional 24 h. The MFC was defined as the 
lowest concentration that exhibited complete inhibition of growth (227, 228). 
 
 
Spot assays 
 
 Colonies from cultures grown on Sabouraud dextrose (BD Biosciences, San Jose, 
CA) solid media for 24 h were diluted in sterile water to an optical density at 600 nm of 
0.1. Cultures were serially diluted one to four in sterile water. Two microliters of each 
dilution were spotted on each of three solid media: YPD, YPD with 5 μg/ml fluconazole, 
and YPD with 10 μg/ml fluconazole. The serial dilutions were incubated at 30°C for 24 
and 72 h. Plates were imaged at each time point and growth inhibition compared (71, 
127, 226). 
 
 
Time kill analysis 
 
 Time kill experiments were adapted from the methods described by Klepser et al. 
(229). Briefly, isolates started from freezer stocks were subcultured twice on potato 
dextrose agar (BD Biosciences, San Jose, CA). Colonies were picked from the plates into 
sterile water and the densities adjusted to that of a 0.5 McFarland standard. The 
suspensions were then diluted 1:10 in RPMI 1640 to a final volume of 3 ml with or 
without 10 μg/ml fluconazole. Cultures were incubated with agitation at 35°C. One 
hundred microliter samples were removed from each culture at 0, 6, 12, and 24 h time 
points, serially diluted in sterile water, and 50 μl aliquots were spread on potato dextrose 
agar. Plates were incubated at 35°C and colonies counted at 24 and 48 h. Each 
experiment was performed in triplicate. 
 
 
Ergosterol quantification analysis 
 
 Ergosterol was extracted and quantified as described by Arthington-Skaggs et al., 
1999 (230). Briefly a single colony of C. glabrata from a fresh YPD plate was used to 
inoculate 50 ml of RPMI-1640 (Sigma, St. Louis, MO) and incubated for 16 h shaking at 
35°C. Stationary-phase cells were collected by centrifugation for 5 minutes at 2700 rpm 
and washed twice with sterile distilled water. The net weight of the pellet was 
determined. To each pellet, 3 ml of 25% alcoholic potassium hydroxide solution (25 g of 
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KOH, 35 ml of sterile distilled water brought up to 100 ml with 100% ethanol) was 
added, then vortexed for 1 min. Cell suspensions were transferred to a sterile borosilicate 
glass screw cap tube and incubated at 85ºC for 1 h. Sterols were then extracted from cool 
tubes by the addition of the mixture of 3 ml n-heptane and 1 ml sterile distilled water 
followed by vortexing for 3 min. The heptane layer was transferred to a clean sterile 
borosilicate glass tube and stored at -20°C for up to 24 h. 100 μl of sterol/heptane mixture 
was scanned spectrophotometrically between 240 nm and 300 nm with a DU530 Life 
Sciences UV spectrophotometer (Beckman Coulter, Brea, CA). The presence of 
ergosterol in the extracted sample results in a characteristic four-peaked curve with peaks 
located at approximately 262, 270, 281, and 290 nm. The absence of detectible ergosterol 
was indicated by a flat line. All samples were blanked to n-heptane. A decrease in the 
height of the absorbance peaks correlates to a decrease in ergosterol content. Statistical 
significance was determined by using Student's t test (P < 0.05). 
 
 
RNA isolation 
 
 For RNA analysis, log phase cultures grown in YPD medium at 30°C were 
adjusted to an optical density of 0.2 measured at 600 nm. Indicated concentrations of 
drug or DMSO control were added and the cultures were incubated an additional 3 h to 
mid-log phase. RNA was extracted by the hot phenol method (231), as previously 
described (232). RNA was treated with RQ1 DNAse (Promega, Madison, WI). Quantity 
and purity were determined by spectrophotometer (NanoDrop Technologies, Inc., 
Wilmington, DE). 
 
 
Quantitative RT-PCR analysis 
 
 Quantitative RT-PCR was conducted as described previously (232). Single strand 
cDNA was synthesized from 2 μg of total RNA using the SuperScript First Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. Relative quantitative real-time PCR reactions were 
performed in triplicate using the 7000 Sequence Detection System (Applied Biosystems, 
Foster City, CA). Independent PCRs were performed using the primers listed in Table 2 
for both the genes of interest and either 18s ribosomal RNA or ACT1 using SYBR Green 
PCR Master Mix (Applied Biosystems). Relative gene expression was calculated by the 
comparative CT Method (ΔΔCT Method). For expression of PDR1, CDR1, SNQ2 and 
PDH1 samples were normalized first to 18S expression and then to the untreated SM1 
sample. For expression of genes in the ergosterol biosynthesis pathway, samples were 
first normalized to ACT1 and then to the untreated parent sample, SM1 or SM3. 
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RESULTS 
 
 
Disruption of CgUPC2A results in increased susceptibility to azole antifungals and 
other sterol biosynthesis inhibitors in C. glabrata 
 
 Using the C. glabrata genome database (www.genolevures.org/cagl.html), 
BLASTP analysis was performed to search for homologs of either ScUpc2 or ScEcm22. 
Two potential homologs were identified, CAGL0C01199g and CAGL0F07865g, which 
were recently reported by Nagi et al. as UPC2A and UPC2B, respectively (178). UPC2A 
(CAGL0C01199g) alone, UPC2B (CAGL0F07865g) alone, and both genes together were 
disrupted in fluconazole-SDD clinical isolate, SM1, and first tested against fluconazole 
(Table 4-3). As observed by Nagi et al., the disruption of UPC2A, alone or in 
combination with disruption of UPC2B, showed a marked increase in susceptibility to 
fluconazole, whereas the disruption of UPC2B alone did not. Complementation of 
UPC2A back into its native locus restored wild type susceptibility. In addition to 
fluconazole, strains were tested against a panel of azoles, non-azole SBIs (terbinafine and 
lovastatin), and antifungal agents not involved in sterol biosynthesis (amphotericin B and 
anidulafungin) (Table 4-3). The additional azoles tested exhibited similar susceptibility 
patterns as was observed with fluconazole. Terbinafine inhibits squalene epoxidase and 
lovastatin inhibits HMG-CoA reductase, both early enzymes in the ergosterol 
biosynthesis pathway (Figure 4-1). As was observed with the azole antifungals, strains 
disrupted for UPC2A exhibited increased susceptibility to both of these agents (Table    
4-3). As reported previously for C. albicans (223), disruption of either UPC2A or UPC2B 
had no effect on susceptibility to amphotericin B, which binds ergosterol in the fungal 
cell membrane. Likewise, disruption of UPC2 had no effect on susceptibility to the 
echinocandin, anidulafungin, which affects cell wall stability by targeting β-1,3-glucan 
synthase. (Table 4-3)  Finally, reintroduction of UPC2A was able to restore wild-type 
susceptibilities. These results demonstrate that UPC2A influences the susceptibility of C. 
glabrata to a range of clinically used azoles as well as other SBIs. 
 
 
Disruption of UPC2A results in enhanced activity of fluconazole against C. glabrata  
 
 Fluconazole remains the most widely used antifungal agent prescribed for the 
treatment of Candida infections (5). We therefore wished to further investigate the extent 
to which UPC2A influences fluconazole susceptibility in C. glabrata. In isolate SM1, 
disruption of UPC2A alone or in combination with disruption of UPC2B resulted not 
only in a reduction in fluconazole MIC (Table 4-3), but also in fluconazole MFC, 
whereas disruption of UPC2B had no effect on either of these parameters (Figure 4-3A). 
This phenotype reverted to that of the parent, SM1, when UPC2A was reintroduced. We 
used a 72 h endpoint for a broth microdilution assay in RPMI medium as a way to assess 
the ability of the organism to resume growth in the presence of fluconazole. The UPC2A 
mutant was unable to resume growth at this extended timepoint, whereas isolate SM1 was 
able to resume growth in concentrations up to 8 μg/ml (Figure 4-3B). Serial dilutions of 
the strains disrupted for UPC2A spotted on YPD solid medium containing 5 μg/ml or 10  
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Table 4-3. Broth microdilution susceptibility testing of the susceptible-dose dependent clinical parent isolate SM1, mutant 
strains disrupted for UPC2, and revertant. 
 
 MICs (μg/ml) 
Strain FLC1 ITC VRC KTC MC AMB LOVA TRB ANID 
SM1 8 2 2 2 0.5 2 200 512 0.016 
SM1Δupc2A 0.5 0.0078 0.125 0.0625 0.01563 2 25 32 0.016 
SM1Δupc2B 8 1 1 0.5 0.25 2 256 512 0.016 
SM1Δupc2AΔupc2B 0.5 0.0078 0.125 0.01563 0.01563 2 16 8 0.016 
SM1Δupc2A/UPC2A 8 2 2 2 0.5 2 200 512 0.016 
 
1Fluconazole (FLC), Itraconazole (ITC), Voriconazole (VRC), Ketoconazole (KTC), Miconazole (MC), Amphotericin B (AMB), 
Lovastatin (LOVA), Terbinafine (TRB), Anidulafungin (ANID) 
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Figure 4-3. Enhanced activity of fluconazole in a SDD clinical isolate, SM1, 
disrupted for UPC2A. 
 
(A) Minimum fungicidal concentrations (MFC) were determined by spotting cultures on 
solid media after 48 h of growth in liquid RPMI. The MFC is the lowest concentration of 
fluconazole that inhibited growth completely when transferred to solid medium. (B) 
Broth microdilution assays were conducted according to CLSI guidelines. As a measure 
of the ability of the strains to regrow the plates were allowed to incubate for 72 h prior to 
measuring optical density at 600 nm. (C) Serial dilutions of indicated strains were 
incubated for 24 or 72 h on YPD solid media containing 0, 5 or 10 μg/ml fluconazole. 
(D) Time kill curves for UPC2A disruptants and revertants in a susceptible clinical 
isolate, SM1, treated with 10 μg/ml fluconazole (open symbols) or DMSO control (closed 
symbols). Cultures were grown in RPMI media with aliquots removed at the indicated 
time points and plated on potato dextrose agar for colony counts.  
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μg/ml of fluconazole exhibited reduced growth, while SM1Δupc2B and the UPC2A 
revertants were no different than the parent, SM1. Moreover, the cultures were unable to 
recover after incubation for 72 h. (Figure 4-3C) Likewise, by time-kill analysis, 
disruption of UPC2A in isolate SM1 resulted in greater inhibition by 10 μg/ml 
fluconazole compared to the wild type isolate (Figure 4-3D). These results demonstrate 
that disruption of UPC2A greatly influences the ability of C. glabrata to grow in the 
presence of fluconazole. 
 
 
UPC2A is essential for resistance to sterol biosynthesis inhibitors in an azole-
resistant clinical isolate of C. glabrata 
 
 In order to determine if UPC2A or UPC2B influence resistance to SBIs, we 
disrupted these genes in a clinical isolate that exhibits high level azole resistance due to 
overexpression of the CDR1, PDH1, and SNQ2 transporter genes, as a result of an 
activating mutation in the transcription factor gene, PDR1. This isolate, SM3, was 
collected from the same patient as isolate SM1 after azole treatment failure and is 
described in detail elsewhere (124, 199). SM3 exhibited elevated MICs compared to SM1 
for fluconazole, itraconazole, voriconazole, ketoconazole, and miconazole, as well as 
lovastatin and terbinafine. As was observed in isolate SM1, disruption of UPC2A alone 
or in combination with UPC2B resulted in increased susceptibility to all azoles and sterol 
biosynthesis inhibitors tested (Table 4-4). Indeed, disruption of UPC2A reduced the 
susceptibility of fluconazole to that observed in the wild-type isolate SM1, 8 μg/ml. 
Fluconazole MFCs of the strains lacking UPC2A decreased to 16 μg/ml as compared to 
>256 μg/ml for isolate SM3 and the revertants (Figure 4-4A). After 72 h in RPMI 
medium, growth of this strain was unable to resume at a fluconazole concentration of ≥ 
16 μg/ml (Figure 4-4B). When serial dilutions of UPC2A disruptant strains were spotted 
on solid YPD medium containing 10 μg/ml fluconazole, growth was inhibited (Figure   
4-4C). The growth inhibition was maintained after incubation for 72 h. By time-kill 
analysis, fluconazole concentrations of 10 μg/ml had no effect on isolate SM3 after 24 h, 
whereas disruption of UPC2A resulted in approximately a log-fold reduction in growth 
after 24 h of fluconazole treatment (Figure 4-4D). This was roughly equivalent to the 
effect of fluconazole on isolate SM1. These results demonstrate that UPC2A is essential 
for high-level fluconazole resistance in C. glabrata. 
 
 
Disruption of UPC2A does not affect expression of PDR1, CDR1, SNQ2, and PDH1 
in an azole-resistant clinical isolate of C. glabrata 
 
 We observed that disruption of UPC2A not only increased susceptibility to 
fluconazole in clinical isolate SM1, but also in matched azole-resistant isolate SM3, 
which carries an activating mutation in PDR1 and overexpresses CDR1 and PDH1, as 
well as PDR1 itself. Recently CaUpc2 was shown to bind in vivo to the promoter of 
CDR1 suggesting that C. glabrata Cdr1 may also be a direct target of CgUpc2A (233, 
234). These authors found that CaUpc2 is involved in maintaining baseline expression of  
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Table 4-4. Broth microdilution susceptibility testing of the resistant clinical isolate SM3, mutant strains disrupted for 
UPC2, and revertant. 
 
 MICs (μg/ml) 
Strain FLC1 ITC VRC KTC MC AMB LOVA TRB ANID 
SM1 256 8 8 8 2 2 200 512 0.016 
SM1Δupc2A 8 0.125 0.25 0.25 0.062 2 25 32 0.016 
SM1Δupc2B 256 16 4 8 2 2 256 512 0.016 
SM1Δupc2AΔupc2B 8 0.25 0.25 0.25 0.062 2 64 16 0.016 
SM1Δupc2A/UPC2A 256 8 8 8 2 2 200 512 0.016 
 
1Fluconazole (FLC), Itraconazole (ITC), Voriconazole (VRC), Ketoconazole (KTC), Miconazole (MC), Amphotericin B (AMB), 
Lovastatin (LOVA), Terbinafine (TRB), Anidulafungin (ANID) 
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Figure 4-4. Enhanced activity of fluconazole in a resistant clinical isolate, SM3, 
disrupted for UPC2A. 
 
(A) Minimum fungicidal concentrations (MFC) were determined by spotting cultures on 
solid media after 48 h of growth in liquid RPMI. The MFC is the lowest concentration of 
fluconazole that inhibited growth completely when transferred to solid medium. (B) 
Broth microdilution assays conducted according to CLSI guidelines. As a measure of the 
ability of the strains to regrow the plates were allowed to incubate for 72 h prior to 
measuring optical density at 600 nm. (C) Serial dilutions of indicated strains were 
incubated for 24 or 72 h on YPD solid media containing 0, 5 or 10 μg/ml fluconazole. 
(D) Time kill curves for UPC2A disruptants and revertants in a resistant clinical isolate, 
SM3, treated with 10 μg/ml fluconazole (open symbols) or DMSO control (closed 
symbols). Cultures were grown in RPMI media with aliquots removed at the indicated 
time points and plated on potato dextrose agar for colony counts. 
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CDR1 in C. albicans and observed a slight decrease in CDR1 expression in the absence 
of UPC2. 
 
 To determine what role, if any, the deletion of UPC2A in C. glabrata has on the 
expression of the efflux pump genes CDR1, PDH1, SNQ2, as well as PDR1, we 
examined the expression of these genes by qRT-PCR in strains SM1 and SM3, as well as 
their respective mutants disrupted for UPC2A and the revertants grown for 3 h with or 
without 32 μg/ml fluconazole. Disruption of UPC2A had no effect on the expression of 
these genes in the absence of fluconazole (Figure 4-5). However, in fluconazole-treated 
cells, we did observe a reduction in the upregulation of all of the genes tested in the 
SM1Δupc2A mutant strain as compared to wild-type (Figure 4-5). Moreover, disruption 
of UPC2A in isolate SM3 had no effect on the constitutive overexpression of CDR1, 
PDH1, or SNQ2, suggesting that the reduced azole resistance observed in SM3 upon 
disruption of UPC2A is independent of these transporters. 
 
 
Disruption of UPC2A results in a reduction in ergosterol levels in azole-SDD and -
resistant C. glabrata isolates 
 
 Upc2 has previously been shown to be involved in the regulation of sterol 
biosynthesis and uptake in both S. cerevisiae and C. albicans (217, 222). To determine 
whether the observed decrease in susceptibility to SBIs corresponds to a decrease in 
ergosterol biosynthesis, we determined the effect of disruption of UPC2A and UPC2B on 
total ergosterol content in clinical isolates SM1 and SM3. Sterols were extracted from the 
mutant and parent strains and measured at an absorption spectra between 240 and 300 nm 
as described previously by Arthington-Skaggs et al., who demonstrated a direct 
correlation between ergosterol content and azole susceptibility in S. cerevisiae (230). As 
shown in Figure 4-6, disruption of UPC2A alone or in combination with UPC2B resulted 
in a reduction in ergosterol levels in both azole-SDD isolate, SM1, as well as azole-
resistant isolate, SM3. These results suggest that ergosterol biosynthesis is impaired in 
both SDD and resistant isolates of C. glabrata in the absence of UPC2A. 
 
 
UPC2 is essential for both baseline and sterol biosynthesis inhibitor-induced 
expression of ergosterol biosynthesis genes 
 
 Disruption of UPC2A resulted in increased susceptibility to SBIs and a significant 
decrease in total ergosterol content. In order to determine if disruption of UPC2A 
influences baseline expression of genes involved in sterol biosynthesis, thirteen ERG 
genes were examined by qRT-PCR. Disruption of UPC2A in both SM1 and SM3 resulted 
in ? 2-fold downregulation of all ERG genes examined. Reintroduction of UPC2A into its 
native locus partially or completely restored expression of most ERG genes (Figure 4-7). 
There was no significant difference between SM1 and SM3 in expression of any of the 
ERG genes tested. 
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Figure 4-5. Effect of UPC2A disruption on constitutive and fluconazole-induced 
gene expression. 
 
RNA was isolated from mid-log cultures in parent clinical isolates, Δupc2A mutants, and 
revertants and qRT-PCR analysis of relative gene expression was performed. Light bars 
represent untreated controls and dark bars represent treatment with 32 μg/ml fluconazole 
for 3 h. (A) PDR1 (B) CDR1 (C) SNQ2 and (D) PDH1 Data are shown as the mean ± SE 
(n=3). 
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Figure 4-6. Ergosterol quantification for UPC2A disruptants in a SDD clinical 
isolate, SM1 and matched resistant isolate SM3. 
 
Wild-type UPC2A allele (solid circles), Δupc2a (open squares) (A,B), Δupc2b (open 
triangles) (C,D) and Δupc2aΔupc2b ( open diamonds) (E,F). The results for the UPC2A 
disruptants shown in panels A, B, E, and F showed statistically significant lower 
ergosterol content than were found in the wild type (P < 0.05). Knockout strains with the 
wild type allele complemented back in showed no difference in ergosterol content 
compared to the wild type isolates (data not shown). Strains were grown in CSM medium 
for 48 h, followed by a heptane extraction and spectrophotometric scan between 240 – 
300 nm (41). Each isolate was extracted and analyzed in three independent experiments. 
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Figure 4-7. Effect of UPC2A disruption on both baseline and sterol biosynthesis 
inhibitor-induced expression of ergosterol biosynthesis genes. 
 
RNA was isolated from mid-log cultures in parent clinical isolates, Δupc2A mutants, and 
revertants. qRT-PCR analysis of relative gene expression was performed. A. SM1, 
Δupc2A mutant, and revertant gene expression. Gene expression was normalized to the 
untreated SM1 sample for each ergosterol biosynthesis gene. B. SM3, Δupc2A mutant, 
and revertant gene expression. Gene expression was normalized to the untreated SM3 
sample for each ergosterol biosynthesis gene.  
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 Multiple fungal pathogens, including C. glabrata, upregulate ergosterol 
biosynthesis genes in response to treatment with SBIs, which likely contributes to the 
decreased susceptibility observed with these agents (178, 235). We used qRT-PCR to 
determine the effects of SBI treatment on strains disrupted for UPC2A. Gene expression 
of ERG genes was measured for SM1 and SM3, as well as their respective UPC2A 
mutants and revertants, grown for 2 h in the presence or absence of 50 μg/ml lovastatin or 
128 μg/ml fluconazole. 
 
 Similar to S. cerevisiae (236), treatment of isolates SM1 and SM3 with lovastatin 
resulted in ? 2-fold upregulation of twelve of the thirteen ERG genes examined in SM1 
and all of the ERG genes examined in SM3. Treatment with fluconazole resulted in 
upregulation of all of these genes in SM1 and ten of the thirteen ERG genes examined in 
SM3. In the absence of UPC2A, lovastatin and fluconazole were unable to induce the 
expression of any of these ERG genes. Moreover, the majority of the thirteen ERG genes 
were downregulated ? 2-fold even in the presence of drug treatment. In most cases, 
reintroduction of UPC2A into its native locus in both SM1 and SM3 restored the ability 
of SBI treatment to induce ERG gene expression. (Figure 4-7) These data demonstrate 
that UPC2A is required for both baseline and SBI induction of ERG gene expression in C. 
glabrata. 
 
 
DISCUSSION 
 
 Despite the more recent development of the lipid-based formulations of 
amphotericin B and the echinocandins, fluconazole remains the most prescribed 
antifungal agent for the treatment of Candida infections. It is inexpensive, available as 
both intravenous and oral formulations and is associated with minimal adverse effects. 
Although its use is complicated by many drug-drug interactions, these are well 
understood and somewhat predictable. Indeed fluconazole maintains excellent activity 
against many common and clinically important Candida species such as C. albicans, C. 
parapsilosis, and C. tropicalis (38). Of particular concern however is C. glabrata which 
has emerged as the second-leading cause of candidiasis in the U.S. and which exhibits 
intrinsically low susceptibility to the azole antifungals (157, 160, 210, 237-240). 
 
 Furthermore, the development of high-level resistance to the azoles is common in 
C. glabrata and has been well documented in isolates from head and neck radiation 
patients, stem cell transplant patients, human immunodeficiency virus (HIV) patients, and 
in vulvovaginal candidiasis (12, 51, 127, 134, 205). The development of azole resistance 
has also been implicated in the fluconazole treatment failure and death of a patient 
suffering from C. glabrata candidemia (199). Such resistance appears to be almost 
exclusively due to activating mutations in the gene encoding the transcription factor Pdr1 
leading to overexpression of multidrug resistance transporters Cdr1, Pdh1, and Snq2 
(121, 123, 168). Strategies to preserve this antifungal class for use against C. glabrata by 
both enhancing activity and overcoming resistance are needed. 
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 The azoles exert their antifungal action by binding to and inhibiting the activity of 
the cytochrome P450 enzyme, lanosterol demethylase, which is a key enzyme in the 
ergosterol biosynthesis pathway that is encoded by ERG11. In both S. cerevisiae and C. 
albicans, the zinc cluster transcription factor Upc2 has been shown to be a central 
regulator of not only ERG11, but additional genes in the ergosterol biosynthesis pathway, 
as well. When lansosterol demethylase is inhibited genetically or pharmacologically in C. 
glabrata, alternate sterols and toxic sterol precursors such as lanosterol, 4,14α-dimethyl 
zymosterol, and 14?-methyl ergosta 8,24(28)-dien-3?,6?-diol are produced leading to 
reduced growth (55, 225) (Figure 4-1). In S. cerevisiae, C. albicans, and C. glabrata, 
Upc2 has been shown to be a central regulator of baseline and inducible expression of the 
genes encoding enzymes of the ergosterol biosynthesis pathway (178, 215, 222, 223, 
241). Moreover, disruption of UPC2 has been shown to increase the susceptibility of 
these organisms to the azole antifungals (178, 241, 242). 
 
 Given its global influence on sterol biosynthesis, we hypothesized that disruption 
of Upc2 might enhance the activity of the azole antifungals against azole-resistant, as 
well as, -SDD clinical isolates of C. glabrata. We have recently characterized a matched 
pair of azole-SDD and -resistant C. glabrata clinical isolates in which high-level azole 
resistance developed during fluconazole treatment (124). The resistant isolate in the pair 
carries an activating mutation in PDR1 leading to the overexpression of CDR1, PDH1, 
and SNQ2 and an increase in fluconazole MIC from 8 μg/ml to 256 μg/ml. Interestingly, 
disruption of UPC2A not only led to a reduction in fluconazole MIC from 8 μg/ml to 0.5 
μg/ml, but also a reduction in fluconazole MFC from >64 μg/ml to 1 μg/ml in the SDD 
isolate. Similar reductions in MIC were observed for other azoles and the SBIs, 
terbinafine and lovastatin, but not for amphotericin B or the echinocandin, anidulafungin, 
which act directly on ergosterol in the cell membrane or on the cell wall, respectively. 
Despite the reduction in ergosterol content we expected no change in amphotericin B 
susceptibility based on previous findings in C. albicans and C. glabrata (74, 178, 223). 
We agree with the hypotheisis of Silver et al. that this could potentially be due to the 
amount of remaining ergosterol being above the threshold necessary for amphotericin B 
to cause cell death (223). 
 
 As fluconazole is the most commonly prescribed azole antifungal, we examined 
its activity against these strains more closely. We used a 72 h endpoint in a broth 
microdilution assay to assess the ability of the organism to resume growth in the presence 
of fluconazole. Disruption of UPC2A greatly impeded the ability of isolate SM1 to 
resume growth in even relatively low concentrations of the drug. Likewise, when spotted 
on YPD plates containing either 5 or 10 μg/ml of fluconazole, isolate SM1 was unable to 
grow when UPC2A was disrupted. Similar results were observed by time-kill analysis in 
RPMI medium where isolate SM1 exhibited modest growth at 24 h in the presence of 10 
μg/ml fluconazole, whereas growth was inhibited in the absence of UPC2A. These results 
further demonstrate that UPC2A is required for optimal azole activity against C. glabrata. 
 
 We then examined the azole-resistant clinical isolate SM3 under the same 
conditions and observed remarkably similar results. Disruption of UPC2A led to 
increased susceptibility to fluconazole resulting in an MIC equal to that of SDD isolate 
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SM1. Moreover, the MFC for fluconazole was reduced from >256 μg/ml to 16 μg/ml. 
Disruption of UPC2A resulted in similar effects on susceptibility to other azoles and 
sterol biosynthesis inhibitors. Growth in the presence of fluconazole was likewise greatly 
reduced when measured at 72 h in liquid RPMI medium, on YPD plates containing 10 
μg/ml fluconazole and by time kill analysis at 24 h in 10 μg/ml fluconazole. These results 
demonstrate that UPC2A is required for high-level azole resistance in C. glabrata. 
 
 One possible explanation for the increased fluconazole susceptibility observed in 
these isolates is a change in expression of the genes encoding the multidrug resistant 
transporters Cdr1, Pdh1, and Snq2. Indeed, it has been shown that in C. albicans, Upc2 
binds the promoter of CDR1 suggesting it may contribute to its regulation (224). 
Interestingly, the sterol response element recognized by Upc2, as defined by Znaidi et al., 
is present in the promoter region of CDR1 in C. glabrata, as well (224). It has also been 
shown that fluconazole treatment activates the transcription factor Pdr1 and induces the 
expression of its targets, multidrug transporter genes (170). We therefore examined the 
influence of UPC2A on both baseline and inducible expression of PDR1, CDR1, PDH1, 
SNQ2 in isolates SM1 and SM3. Disruption of UPC2A had no effect on baseline 
expression of these genes in isolate SM1 or on their constitutive overexpression in isolate 
SM3. Interestingly, disruption of UPC2A reduced the inducible expression of all four 
genes in response to fluconazole. This suggests that Upc2A is required for optimal 
activation of the Pdr1 transcriptional pathway. The diminished capacity of isolate SM1 to 
respond to fluconazole stress by up-regulating these transporter genes may contribute to 
its increased susceptibility to the azoles and other sterol biosynthesis inhibitors. 
 
 Another possible explanation for the increased fluconazole susceptibility observed 
in these isolates is a change in the expression of genes involved in ergosterol biosynthesis 
that are regulated by UPC2A. Both SM1 and SM3 exhibited reduced cellular ergosterol 
when UPC2A was disrupted. Likewise, baseline expression as well as inducible 
expression by fluconazole or lovastatin of all ergosterol biosynthesis genes analyzed was 
reduced in the absence of UPC2A. Importantly, the azole target, ERG11, is included in 
this group of ergosterol biosynthesis genes, which would result in a reduced amount of 
target that would need to be inhibited in order to effectively inhibit ergosterol 
biosynthesis. These data suggest that the global impact on sterol biosynthesis in the 
absence of UPC2A greatly increases the vulnerability of C. glabrata to fluconazole, even 
in the setting of Pdr1 activation and overexpression of CDR1, PDH1, and SNQ2. 
 
 Additionally, the incorporation of alternate sterols into the cell membrane affects 
fluidity of the membrane and may compromise the ability of the efflux pumps to function 
properly. Krishnamurthy and Prasad demonstrated altered accumulation of various 
compounds when tested against a panel of S. cerevisiae ERG mutants expressing C. 
albicans Cdr1 (243). Altered membrane fluidity and asymmetry has also been associated 
with increased resistance to fluconazole in C. albicans independent of efflux pump 
function (244). Taken together, our findings suggest that Upc2A and the transcriptional 
activation pathway it regulates represents a potential target for overcoming azole 
antifungal resistance in C. glabrata. 
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CHAPTER 5.    JJJ1 IS A NEGATIVE REGULATOR OF PDR1-MEDIATED 
FLUCONAZOLE RESISTANCE IN CANDIDA GLABRATA 
 
 
INTRODUCTION 
 
 Candida glabrata is the second most common cause of human fungal infection 
(44). Fluconazole has long been among frontline therapies for the treatment of invasive 
candidiasis. However, C. glabrata exhibits intrinsic reduced susceptibility to fluconazole 
and often develops high-level resistance during fluconazole therapy (50, 161). As such, 
the most recent clinical guidelines for treatment of candidiasis now recommend empiric 
therapy with an echinocandin rather than fluconazole in large part due to the problem of 
fluconazole resistance in this Candida species (39). 
 
  In C. glabrata, resistance to fluconazole is almost exclusively due to activating 
mutations in the gene encoding the zinc cluster transcription factor Pdr1. Pdr1 is the 
homolog of Pdr1 and Pdr3 in Saccharomyces cerevisiae, which regulates genes involved 
in the pleiotropic drug resistance phenotype. In C. glabrata, Pdr1 activates the expression 
of the genes encoding the ABC transporters Cdr1, Pdh1, and Snq2. It has been proposed 
that fluconazole can activate Pdr1 by binding directly to its xenobiotic binding domain 
(170). Moreover, Pdr1 can be activated by mitochondrial loss as is observed in “petite” 
mutants (121). While activation of Pdr1 in the presence of xenobiotics is dependent on 
binding of the activation domain of Pdr1 to the KIX domain of the Mediator complex 
component Gal11a, our understanding of how Pdr1 is regulated in C. glabrata is 
incomplete (170). 
 
 In an effort to better understand this process, we screened a collection of 217 
single gene deletion strains of C. glabrata for increased resistance to fluconazole (245). 
Deletion of the putative J protein CAGL0J07370g resulted in fluconazole resistance. This 
gene shares greatest homology with the Saccharomyces cerevisiae gene JJJ1. We show 
here that disruption of JJJ1 in a wild-type C. glabrata clinical isolate results in increased 
resistance to fluconazole through a Pdr1-dependent increased expression of the ABC 
transporter gene CDR1. 
 
 
MATERIALS AND METHODS 
 
 
Strains and growth conditions 
 
 Strains used in this study are listed in Table 5-1. The parent clinical isolate and 
the PDR1 deletion strain have been described previously (124, 199). All strains were 
stored as frozen stocks at -80°C in 40% glycerol. Strains were routinely grown in yeast 
extract peptone dextrose (YPD; 1% yeast extract, 2% peptone, and 2% dextrose) broth at 
30°C in a shaking incubator except as indicated for specific experimental conditions. 
  
 61 
Table 5-1. Strains used in the JJJ1 study. 
 
Strain Parent Genotype or description Reference 
SM1  Azole-susceptible clinical isolate (199) 
SM1Δjjj1 SM1 jjj1Δ::FRT This study 
SM1Δjjj1::JJJ1 SM1∆jjj1 jjj1Δ::JJJ1-FRT This study 
SM1Δcdr1 SM1 cdr1Δ::FRT This study 
SM1Δpdr1 SM1 pdr1Δ::FRT (124) 
SM1Δjjj1Δcdr1 SM1∆jjj1 jjj1Δ::FRT/cdr1Δ::FRT This study 
SM1Δjjj1Δpdr1 SM1∆pdr1 jjj1Δ::FRT/pdr1Δ::FRT This study 
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 One Shot Escherichia coli TOP10 chemically competent cells (Invitrogen, 
Carlsbad, CA) were used as the host for plasmid construction and propagation. These 
strains were grown at 37°C in LB broth or on LB plates supplemented with 100 μg/ml 
ampicillin (Sigma, St. Louis, MO) or 50 μg/ml kanamycin (Fisher BioReagents, Fair 
Lawn, NJ). 
 
 
Deletion library screen 
 
 We obtained 217 C. glabrata single gene deletion strains from a previously 
published collection (245). These included genes encoding putative transcription factors 
and DNA binding proteins. The mutant strains were generated in a histidine auxotrophic 
mutant of C. glabrata strain ATCC 2001 (CBS138). Fluconazole MICs were determined 
for each deletion strain according to the CLSI reference method with minor modifications 
as described below (202, 246). Strains were tested at concentrations ranging from 64 
mg/L to 0.125 mg/L fluconazole in duplicate. 
 
 
Plasmid construction 
 
 For deletion of JJJ1 and CDR1 we modified plasmid pSFS2 (200). Upstream 
homology regions approximately 800 - 1000 bp long were amplified using primer pairs 
CgJJJ1-A/CgJJJ1-B or CgCDR1-A/CgCDR1-B and digested with ApaI and XhoI for 
insertion into their respective plasmids. Downstream homology regions approximately 
900 - 1000 bp long were amplified using primer pairs CgJJJ1-C/CgJJJ1-D or CgCDR1-
C/CgCDR1-D and digested with SacI and SacII for insertion into their respective 
plasmids. The disruption cassettes consisting of the SAT1 flipper cassette and upstream 
and downstream flanking sequences of either JJJ1 or CDR1 were excised from the final 
plasmids pCgJJJ1 or pCgCDR1 and gel purified. Primers used to construct the cassettes 
are listed in Table 5-2. 
 
 For reintegration of JJJ1 into ∆jjj1 mutants we modified plasmid pCgJJJ1. The 
open reading frame in addition to some upstream and downstream sequence was 
amplified using primer pair CgJJJ1-A/CgJJJ1-E and digested with ApaI and XhoI. This 
replaced the upstream homology region from plasmid pCgJJJ1, such that upon 
transformation and homologous recombination JJJ1 would be reintegrated into its 
original locus. The resulting plasmid is called pCgJJJ1pb. 
 
 
Strain construction 
 
 C. glabrata cells were transformed by the lithium acetate method using 
approximately 1 μg of DNA. The ApaI/SacI fragments from pCgJJJ1, pCgCDR1, and 
pCgJJJ1pb were excised and gel purified prior to transformation. The transformed cells 
were allowed to recover 6 h in YPD at 30oC before being plated on YPD-agar plates 
containing 200 μg/ml nourseothricin (Jena Biochemical, Germany) and incubated at  
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Table 5-2. Primers used in the JJJ1 study (grouped by application). 
 
Primer name and 
function Primer sequence
1 
Cassettes for 
constructing mutants 
 
   CgJJJ1-A  5’- AATTACAAAGGGCCCTATTTGAGTTACAGC -3’ 
   CgJJJ1-B 5’- ATTATCTGGATTCTCGAGAGGATGATAC -3’ 
   CgJJJ1-C 5’- AAGTAGGAATCCGCGGTTTAGTCATATACA -3’ 
   CgJJJ1-D 5’- TATTTATGCTACGAGCTCTATTGACGTTAT -3’ 
   CgJJJ1-E 5’- GTTTCCAAGCAACTCGAGATGATTAGT -3’ 
   CgCDR1-A  5’- CATAGATCAGGGCCCATTACATTAGCACAG -3’ 
   CgCDR1-B 5’- CTCAGTGTTGCTCGAGATAGGGTTGATAC -3’ 
   CgCDR1-C 5’- GTTCTGTTAGTTCCGCGGACTCTCGTAGAT -3’ 
   CgCDR1-D 5’- GTGAATACAAACAAGAGCTCCACAATAATA -3’ 
qRT-PCR  
   18SF 5’-TCGGCACCTTACGAGAAATCA-3’ 
   18SR 5’-CGACCATACTCCCCCCAGA-3’ 
   PDR1F 5’-TTTGACTCTGTTATGAGCGATTACG-3’ 
   PDR1R 5’-TTCGGATTTTTCTGTGACAATGG-3’ 
   CDR1F 5’-CATACAAGAAACACCAAAGTCGGT-3’ 
   CDR1R 5’-GAGACACGCTTACGTTCACCAC-3’ 
   SNQ2F 5’-CGTCCTATGTCTTCCTTACACCATT-3’ 
   SNQ2R 5’-TTTGAACCGCTTTTGTCTCTGA-3’ 
   PDH1F 5’-ACGAGGAGGAAGACGACTACGA-3’ 
   PDH1R 5’-CTTTACTGGAGAACTCATCGCTGGT-3’ 
 
1Underlined bases indicate introduction of restriction enzyme cloning sites to allow 
directional cloning into the SAT1-flipper cassette.  
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30oC. Positive transformants were selected within 24 h and successful insertion of the 
disruption cassette at the target gene locus was confirmed by Southern hybridization 
using gene specific probes. Subsequently, induction of the flipper recombinase gene in 
the disruption cassette was performed by overnight growth of the positive transformant 
clones in YPD at 30oC with shaking (under no selective pressure). Selection for excision 
of the SAT1 flipper cassette was then performed by plating on YPD-agar plates and 
incubating for up to 24 h at 30oC. Clones were selected and confirmed by Southern 
hybridization using gene specific probes. 
 
 
Genomic DNA isolation and Southern analysis 
 
 Genomic DNA from C. glabrata was isolated as described previously (201). For 
confirmation by Southern hybridization, approximately 10 μg of genomic DNA was 
digested with the appropriate restriction enzymes, separated on a 1% agarose gel 
containing ethidium bromide, transferred by vacuum blotting onto a nylon membrane and 
fixed by UV-crosslinking. Hybridization was performed with the Amersham ECL Direct 
Nucleic Acid Labeling and Detection System (GE Healthcare, Pittsburg, PA) as per 
manufacturer’s instructions. 
 
 
Susceptibility testing 
 
 Susceptibility testing was performed by microbroth dilution assay according to 
the CLSI guidelines outlined in M27-A3 with a few modifications (202, 246). 
Fluconazole (MP Biomedicals, Salon, OH) stock solution was prepared by reconstitution 
in water to 5 mg/mL. Cultures were diluted to 2.5x103 cells/ml in RPMI 1640 (Sigma, St. 
Louis, MO) with 2% glucose, MOPS, pH 7.0. Plates were incubated at 35°C for 48 h. 
Absorbance at 600 nm was read with a BioTek Synergy 2 microplate reader (BioTek, 
Winooski, VT); background due to medium was subtracted from all readings. The MIC 
was defined as the lowest concentration inhibiting growth by at least 50% relative to the 
drug-free control after incubation with drug for 48 h. 
 
 
RNA isolation 
 
 RNA isolation procedure was the same for both quantitative real time PCR and 
RNA-Seq experiments. Log phase cultures grown in YPD medium at 30°C were adjusted 
to an OD of 0.2 measured at 600 nm and the cultures were incubated an additional 3 h to 
mid-log phase. RNA was extracted by the hot phenol method (231), as previously 
described (232). RNA was treated with RQ1 DNAse (Promega, Madison, WI). Quantity 
and purity were determined by spectrophotometer (NanoDrop Technologies, Inc., 
Wilmington, DE) and verified using a Bioanalyzer 2100 (Agilent Technologies, Santa 
Clara, CA). 
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Quantitative real time PCR 
 
 Quantitative RT-PCR was conducted as described previously (232). Single strand 
cDNA was synthesized from 2 μg of total RNA using the SuperScript First Strand 
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. Relative quantitative real-time PCR reactions were 
performed in triplicate using the 7000 Sequence Detection System (Applied Biosystems, 
Foster City, CA). Independent PCRs were performed using the primers listed in Table   
5-2 for both the genes of interest and 18s ribosomal RNA using SYBR Green PCR 
Master Mix (Applied Biosystems). Relative gene expression was calculated by the 
comparative CT Method (ΔΔCT Method). For expression of PDR1, CDR1, SNQ2 and 
PDH1 samples were normalized first to 18S expression and then to the parent strain SM1. 
 
 
Protein isolation and Western analysis 
 
 Log-phase cells grown in YPD at 30°C were diluted to an OD of 0.2 measured at 
600nm and were grown in YPD for an additional 3 hours. Three OD600 units of culture 
were harvested per sample and two colonies of each strain were analyzed. Protein 
extracts were prepared as previously described (247). Protein pellets were resuspended in 
urea sample buffer (8 M urea, 1% 2-mercaptoethanol, 40 mM Tris-HCl pH 8.0, 5% SDS, 
bromophenol blue) and boiled at 90˚C for 10 min. An aliquot from each sample was 
resolved on a precast ExpressPlus™ 4-15% gradient gel (GenScript) following the 
manufacturer’s SDS-PAGE protocol. Proteins were electroblotted onto a nitrocellulose 
membrane, blocked with 5% nonfat dry milk, and then probed with anti-Pdr1 antibody 
(126) diluted 1:1500. All membranes were probed for tubulin as the loading control with 
12G10 anti-alpha-tubulin monoclonal antibody (Developmental Studies Hybridoma Bank 
at the University of Iowa) for 30 min at room temperature. The membrane was probed 
with secondary LI-COR antibodies IRDye 680LT goat anti-rabbit diluted 1:20,000 and 
IRDye 800CW goat anti-mouse diluted 1:10,000. Western blot signal was detected using 
the Li-Cor Odyssey infrared imaging system, application software version 3.0. 
 
 
RNA sequencing 
 
 Barcoded libraries were prepared using the Lexogen mRNA Sense kit for Ion 
Torrent according to manufacturer’s standard protocol. Libraries were sequenced on the 
Ion Torrent Proton sequencer. Individual sample fragments were concatenated to form 
the whole sample fastq file. Files were then run through FASTQC to check data quality. 
Any reads with a phred score <20 were trimmed. After trimming reads were aligned to 
the C. glabrata CBS138 reference transcriptome using RNA-Star long method. After 
alignment transcriptome alignment counts were gathered. The read counts for each 
sample were normalized using transcripts per kilobase million (TPM) method. 
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Accession number 
 
 The RNA sequencing data was submitted to the Gene Expression Omnibus 
(GEO) database (https://www.ncbi.nlm.nih.gov/geo/). The accession number is 
GSE104476. 
 
 
RESULTS 
 
 
Deletion of JJJ1 results in fluconazole resistance in a laboratory strain of C. glabrata 
 
 We screened 217 strains from a previously published collection of mutants 
deleted for genes encoding putative transcription factors and DNA binding proteins for 
increased resistance to fluconazole (245). Three strains exhibited fluconazole MICs that 
were greater than one dilution higher than that of the parent strain (Table 5-3). Two 
mutants, those deleted for CAGL0K05797g (EMI1) and CAGL0C00297g (ScSET2), 
exhibited a four-fold increase in fluconazole MIC. One strain, deleted for 
CAGL0J07370g, exhibited a sixteen-fold increase in fluconazole MIC. CAGL0J07370g 
has sequence homology to the gene encoding the type III J protein Jjj1 in S. cerevisiae. 
 
 
Deletion of JJJ1 in a susceptible-dose dependent clinical isolate of C. glabrata 
confers resistance to fluconazole 
 
 To confirm the phenotype of the JJJ1 mutant strain, we generated an additional 
JJJ1 deletion strain in clinical isolate SM1 using the SAT1 flipper method (200). Isolate 
SM1 was originally recovered from an antifungal naïve patient undergoing cancer 
chemotherapy (199). Deletion of JJJ1 in this susceptible-dose dependent clinical isolate 
resulted in a sixteen-fold increase in MIC to fluconazole from 4 mg/L to 64 mg/L (Table 
5-4, Figure 5-1). This increase was identical to that observed in the JJJ1 mutant strain 
from the deletion collection. We then constructed a complemented derivative strain using 
the SAT1 flipper method. The MIC of fluconazole upon reintroduction of JJJ1 was 
restored to that of parent, clinical isolate SM1. 
 
 
Jjj1-mediated fluconazole resistance is dependent upon Cdr1 
 
 In clinical isolates of C. glabrata fluconazole resistance is mediated by the ABC 
transporters Cdr1, Pdh1, and Snq2 (127-130). To determine if increased fluconazole 
resistance observed when JJJ1 is deleted is also mediated by these transporters, we first 
measured the expression levels of their respective genes using qRT-PCR. Deletion of 
JJJ1 in clinical isolate SM1 resulted in CDR1 expression over twenty-fold and PDH1 
expression over four-fold that observed in the parent strain (Figure 5-2A). There was no 
significant change in expression of SNQ2. 
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Table 5-3. Fluconazole MICs for single gene deletion mutant strains. 
 
C. glabrata 
designation 
C. glabrata 
gene name 
S. cerevisiae 
ortholog 
MIC50 
(mg/L) 
Parent   4 
CAGL0K05797g EMI1 EMI1 16 
CAGL0C00297g  SET2 16 
CAGL0J07370g JJJ1 JJJ1 64 
 
 
 
 
Table 5-4. Fluconazole MICs for indicated strains. 
 
Strain 
MIC50 
(mg/L) 
SM1 4 
SM1∆jjj1 64 
SM1∆jjj1::JJJ1 4 
SM1∆cdr1 1 
SM1∆pdr1 1 
SM1∆jjj1∆cdr1 2 
SM1∆jjj1∆pdr1 2 
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Figure 5-1. Deletion of JJJ1 in the susceptible dose dependent clinical isolate SM1 
results in decreased fluconazole susceptibility. 
 
Reintegration of JJJ1 to its original locus restored the susceptible dose dependent 
phenotype. Strains were grown in 96 well plates according to standard CLSI methods 
with minor modifications and optical density at 600nm was measured after 48 hours. 
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Figure 5-2. JJJ1 influences fluconazole susceptibility in a CDR1 dependent 
manner. 
 
(A) The effect of JJJ1 deletion on expression of the ABC transporters CDR1, SNQ2, and 
PDH1 was measured by qRT-PCR. Expression was normalized to 18S expression in the 
parent isolate SM1. (B) Strains were grown in 96 well plates according to standard CLSI 
methods with minor modifications and optical density at 600nm was measured after 48 
hours. 
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 We then deleted CDR1 in the JJJ1 deletion mutant. Deletion of CDR1 resulted in 
greater susceptibility to fluconazole than the wild-type parent isolate SM1 (Figure 5-2B). 
However, this mutant was not as susceptible as a CDR1 deletion mutant in the SM1 
background. These observations suggest that the increased fluconazole resistance 
observed upon deletion of JJJ1 is due in large part to CDR1, but that other determinants, 
possibly PDH1, contribute modestly to this phenotype as well. 
 
 
Jjj1-mediated fluconazole resistance and CDR1 expression is dependent on Pdr1 
 
 CDR1 is a direct target of the zinc cluster transcription factor Pdr1. The 
expression of CDR1 in response to fluconazole requires activation of Pdr1, and 
overexpression of CDR1 in fluconazole resistant clinical isolates is due to activating 
mutations in PDR1 (119, 121, 127). Of note, PDR1 is autoregulated (121, 125), so we 
predicted that deletion of JJJ1 would result in upregulation of PDR1 gene expression and 
concomitant increased Pdr1 protein expression. PDR1 expression increased 2.7-fold in 
the JJJ1 knockout compared to the parent strain (Figure 5-3A). As expected there is no 
PDR1 expression in the strain with PDR1 deleted alone or in the strain with JJJ1 and 
PDR1 deleted. Pdr1 protein levels followed the same pattern (Figure 5-3B). 
 
 To determine if the effects on CDR1 expression and fluconazole susceptibility 
observed upon deletion of JJJ1 is dependent upon activation of Pdr1, we deleted PDR1 in 
the JJJ1 deletion mutant and measured expression of CDR1 and susceptibility to 
fluconazole. Deletion of PDR1 reduced expression of CDR1 in the absence of JJJ1 to 
levels observed in the wild-type parent strain (Figure 5-4A). Deletion of PDR1 in the 
JJJ1 deletion mutant increased fluconazole susceptibility beyond what was observed in 
the wild-type parent strain (Figure 5-4B), but not to the extent of that observed in the 
PDR1 deletion mutant. This suggests that while most of the effect of deleting JJJ1 on 
fluconazole susceptibility is dependent upon Pdr1, some of the effects of Pdr1 on 
fluconazole susceptibility are not affected by Jjj1. 
 
 
Deletion of JJJ1 activates genes of the Pdr1 regulon 
 
 In order to determine what genes in addition to CDR1, PDH1, and PDR1 are 
differentially expressed when JJJ1 is deleted, we used RNA-seq to compare the 
transcriptional profiles of both the JJJ1 deletion mutant and the JJJ1/PDR1 deletion 
mutant to that of parent isolate SM1. In the JJJ1 deletion mutant as compared to the 
parent strain, 204 genes were up-regulated and 224 genes were down-regulated by 1.5-
fold or greater (Appendix B, Table B-1 and B-2). Up-regulation and down-regulation of 
119 and 149 of these, respectively, required PDR1 (Table B-1 and B-2, bolded genes). 
As expected, we observed CDR1, PDH1, and PDR1 to be among those genes whose up-
regulation upon deletion of JJJ1 required PDR1. Of the twenty-five targets of Pdr1 that 
have been previously confirmed by ChIP-seq (126), seven were found to be up-regulated 
when JJJ1 was deleted. These were CDR1, YBT1, YOR1, RSB1, RTA1, PDH1, and 
NCE103. One of these, NCE103, remained up-regulated in the absence of both JJJ1 and  
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Figure 5-3. JJJ1 deletion results in altered expression of PDR1 at both transcript 
and protein levels. 
 
(A) The effect of JJJ1 and PDR1 deletion alone and in combination on expression of the 
transcription factor PDR1 was measured by qRT-PCR. Expression was normalized to 
18S expression in the parent isolate SM1. (B) The effect of JJJ1 and PDR1 deletion alone 
and in combination on protein levels of the transcription factor Pdr1 was assessed by 
Western analysis. (Panel B contributed by W. Scott Moye-Rowley and Lucia 
Simonicova) 
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Figure 5-4. JJJ1 influences fluconazole susceptibility in a PDR1 dependent 
manner. 
 
(A) The effect of JJJ1 and PDR1 deletion alone and in combination on expression of the 
ABC transporter CDR1 was measured by qRT-PCR. Expression was normalized to 18S 
expression in the parent isolate SM1. (B) Strains were grown in 96 well plates according 
to standard CLSI methods with minor modifications and optical density at 600nm was 
measured after 48 hours.  
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PDR1. Of the eighty-five genes up-regulated in the absence of both JJJ1 and PDR1, 
seven are involved in methionine biosynthesis (MET6, MUP1, MET8, MET13, ScMET2, 
ScMXR1, and MET15). Seventeen genes predicted to have a role in adhesion were 
observed to be up-regulated in the absence of JJJ1, four of which required PDR1 (Table 
B-3). 
 
 
DISCUSSION 
 
 Unlike other species of Candida, azole resistance in clinical isolates of C. 
glabrata is almost exclusively due to activating mutations in the gene encoding the 
transcription factor Pdr1 that lead to increased expression of the genes encoding the ATP 
binding cassette (ABC) transporters CDR1, PDH1, and SNQ2. Single amino acid 
substitutions in Pdr1 can result in its activation and the effects on expression of 
downstream target genes vary depending on the mutation (123, 124, 185). This lends 
itself to a hypothesis that Pdr1 is negatively regulated and that single amino acid changes 
interfere with the negative regulation resulting in altered gene expression. The varied 
patterns of gene expression seen with the different activating Pdr1 mutations would 
indicate there may exist more than one negative regulatory mechanism. 
 
 Regulation of Pdr1 in C. glabrata is not fully understood, but recent work in this 
area provides some insight. The transcription factor Stb5 has been shown to be a negative 
regulator of Pdr1. Deletion of STB5 in a wild type background resulted in minimal 
decreased susceptibility, however in a ∆pdr1 mutant strain deletion of STB5 resulted in 
marked decreased susceptibility to the azoles. Overexpression of STB5 increased azole 
susceptibility. In addition, the expression profile of the STB5 deletion strain overlaps with 
that of a mutant strain overexpressing PDR1 (175). In the closely related nonpathogenic 
yeast Saccharomyces cerevisiae, Stb5 forms a heterodimer with the transcription factor 
Pdr1 and binds the promoter of the ABC transporter PDR5 directly (174). However, 
susceptibility to ketoconazole was not shown to be affected in an S. cerevisiae STB5 
deletion strain (248). 
 
 Pdr1 is also regulated at the level of transcription through the mediator complex. 
Deletion of GAL11A, which codes for a member of the mediator complex, results in 
decreased expression of the ABC transporter PDH1 and increased azole sensitivity. A 
direct interaction between the Gal11a KIX domain and Pdr1 has been demonstrated 
(170). Pdr1 was shown to act as a xenobiotic receptor and bind ketoconazole directly. 
Gal11a is important for drug induced Pdr1 activation, however it is dispensable for Pdr1 
activation in petite mutants (125). Pdr1 is also autoregulated through binding of the 
PDRE located in its promotor region (125, 126). 
 
 In S. cerevisiae two zinc finger transcription factors, Pdr1 and Pdr3, are 
responsible for regulation of the pleiotropic drug response. Understanding how this 
regulation occurs is informative for forming a model for regulation in C. glabrata, which 
has not been studied as thoroughly to date. Pdr1 and Pdr3 regulation occurs through 
similar, yet distinct pathways.  
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 Pdr1 function in S. cerevisiae is regulated by the Hsp70/Hsp40 co chaperone pair 
Ssz1/Zuo1. Ssz1 and Zuo1 are part of a ribosome associated complex that is involved in 
folding of newly synthesized proteins (249), however this activity is distinct from that 
involved in regulation of Pdr1 and the multidrug resistant phenotype (250, 251). Ssz1 and 
Zuo1 are both able to activate Pdr1 independently of one another indicating that they are 
not acting as chaperones in this case (250). A region at the C terminus of Zuo1 has been 
shown to bind directly to Pdr1 similar to xenobiotic direct binding of Pdr1 (251). 
Overexpression of Ssz1 leads to an increase in Pdr1 target genes, and increases tolerance 
to cyclohexamide and oligomycin indicating that it acts as a positive regulator (252). 
 
 Pdr3 in S. cerevisiae is also regulated by an Hsp70, however in this case it 
appears to be a negative regulation. Overexpression of the Hsp70 gene, SSA1 leads to 
increased sensitivity to cyclohexamide and decreased Pdr1 target gene expression (253). 
Previous work had shown Pdr3 is activated in mitochondrial deficient mutants (187). 
There is less Ssa1 associated with Pdr3 in these mutants indicating this regulatory 
pathway is involved in the altered drug susceptibility associated with mitochondrial 
insufficiency. Deletion of the nucleotide exchange factor Fes1, which is thought to inhibit 
Ssa1 activity also increased sensitivity to cyclohexamide, but no Hsp40 working in 
conjunction with the Hsp70, Ssa1 has been described (253). 
 
 The C. glabrata ORF CAGL0J07370g identified in our screen to affect 
fluconazole susceptibility has the characteristic J domain present in members of the 
Hsp40 class of proteins. The primary role for Hsp40 proteins attributed to the J domain is 
stimulation of adenosine triphosphate (ATP) hydrolysis through interaction of Hsp70 
ATPase domains (254, 255). The closest homolog to CAGL0J07370g is ScJJJ1 from S. 
cerevisiae, which shares 66.2% amino acid similarity and 51.2% identity as calculated 
with EMBOSS Needle (256). ScJJJ1 and ScZUO1 have the J domain in common, as well 
as another region thought to bind the ribosome, which is unique to these two genes 
among all Hsp40s in S. cerevisiae (257, 258). Importantly, deletion of ScJJJ1 results in 
increased sensitivity to the azoles, which is the opposite effect from that observed upon 
deletion of CAGL0J07370g in C. glabrata (259). 
 
 The experiments described here demonstrate a role for JJJ1 in fluconazole 
susceptibility in C. glabrata. Deletion of JJJ1 in a susceptible dose dependent isolate 
results in fluconazole resistance. This altered susceptibility is primarily a result of PDR1 
dependent activation of CDR1. Based on what is known in the closely related species S. 
cerevisiae as well as what is known in C. glabrata we propose a model for the role of the 
Hsp40 Jjj1 in Pdr1 regulation. Post transcriptionally Pdr1 is negatively regulated by Jjj1 
and may involve an Hsp70 a nucleotide exchange factor or both. When the Jjj1/Pdr1 
interaction is disrupted Pdr1 is activated and able to upregulate a distinct set of target 
genes. 
 
 Our transcriptional profiling data supports this proposed mechanism. Chromatin 
immunoprecipitation combined with sequencing has been used to determine the direct 
binding targets of Pdr1 (126). Eight genes whose altered expression in the JJJ1 mutant is 
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dependent on PDR1 are direct Pdr1 targets six exhibited upregulation (CDR1, YBT1, 
YOR1, RSB1, RTA1, and PDH1) and two were downregulated (ATF2 and ScBAG7). Only 
one known direct Pdr1 target, NCE103, showed altered expression that was independent 
of PDR1 expression. Additional indirect Pdr1 targets identified by previously published 
microarray data are also among the genes upregulated in the JJJ1 deletion strain in a 
PDR1 dependent manner (ScGPP1, ScCIS1, ScLAC1, ScMCP1, ScGUT2, ScPBI2, 
ScGSF2, GLK1, and ILV5) (122, 124, 168, 185). 
 
 While the Pdr1 pathway appears to be primarily responsible for the altered gene 
expression in the JJJ1 deletion strain there is a consistent one dilution change in MIC 
when JJJ1 is deleted in strains lacking CDR1 or PDR1. This finding allows for the 
possibility that there may be Pdr1 independent effects as well. 
 
 Among the genes upregulated in the JJJ1 deletion strain that were independent of 
PDR1 expression were many adhesion related genes. Five members of the EPA family 
were in this group. Three of these, EPA1, EPA2, and EPA3 are part of a cluster of genes 
whose transcription is controlled by subtelomeric silencing (260, 261). Adhesins are 
known to be upregulated when nicotinic acid is limited (262), however, that does not 
appear to be happening in this experiment. None of the genes known to exhibit increased 
expression under nicotinic acid limited conditions, for example TNA1, TNR1, and TNR2, 
have increased expression. Of particular interest among the adhesin genes found to be 
upregulated, EPA1 has a role in increased adhesion to epithelial cells in strains of C. 
glabrata with activating mutations in PDR1 (184). EPA1 has the putative PDRE site in 
its promoter (184), however Pdr1 does not bind tightly (126). EPA1 along with many 
other adhesins were still upregulated in the mutant strain lacking JJJ1 and PDR1. In 
addition to the EPA genes were PWP1 and PWP3, which belong to adhesin cluster II. In 
total there are 17 genes predicted to have a role in adhesion among the upregulated genes 
in the JJJ1 deletion strain, for 13 of these genes the increased expression is independent 
of Pdr1. 
 
 The experiments described here provide further insight into regulation of Pdr1 in 
the important fungal pathogen C. glabrata. Our data suggest that the J protein Jjj1 acts as 
a negative regulator of fluconazole resistance primarily through transcription factor Pdr1 
and its target ABC transporter Cdr1. 
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CHAPTER 6.    CONCLUSION 
 
 
 In the field of infectious disease fungal pathogens are often overlooked in 
discussions of difficult to treat infections. However, due to the increasing rates of patients 
with serious systemic fungal infections due to advances in medicine that have resulted in 
an increased population of immunocompromised patients and the increasing rates of 
resistance to available antifungals this is likely to change in the coming years. The 
current state of antifungal drug development, like all antibiotic drug development is 
worrisome. Emergence of multidrug resistant infecting fungal pathogens including 
multiple species of Candida is alarming when considering the lack of new drugs in 
development. The increasing threat of resistance has simply evolved more quickly than 
new drugs are being discovered and brought to market. One strategy to combat resistance 
in the race we are losing is to overcome resistance to current antifungals in order to 
reestablish their utility. In order to do that, we must first develop a thorough 
understanding of the mechanisms of resistance to current antifungals and then use that 
information to propose strategies to circumvent the resistance mechanisms. The focus of 
the work described here is resistance to the azole class of antifungals. While they are 
fungistatic, their side effect profile, dosage form options and affordability make them a 
desirable choice for treatment in most patient populations. The increasing rates of 
resistance to the azoles put them in danger of becoming obsolete. 
 
 While multiple mechanisms of azole resistance in C. albicans have been 
described, additional as yet unidentified contributors cannot be ruled out, as exhibited by 
the novel contributor to azole resistance described here. Admittedly the impact on 
resistance is minor, however RTA3 represents one of likely multiple genes in the Tac1 
regulon that contribute to resistance. Further characterization of these additional factors 
will better inform development of drug targeting strategies. 
 
 In C. glabrata clinical resistance to the azoles revolves around the transcription 
factor Pdr1 and the ABC transporters which it regulates. We were able to delineate the 
contributions of the relevant ABC transporters that had previously been shown to 
influence azole susceptibility. When all three are overexpressed the one that is most 
influential is CDR1, followed by PDH1 and then SNQ2, both of which have a much 
smaller impact compared to CDR1. This establishes CDR1 as the key to clinical azole 
resistance, which potentially simplifies the drug development strategy for overcoming 
resistance. If a small molecule could be targeted to block azole uptake by the pump coded 
for by CDR1 alone or perhaps CDR1 and PDH1, we would predict that majority of the 
clinical isolates of C. glabrata would again succumb to azole therapy. While this does 
strategy would be ineffective against isolates that do not overexpress CDR1, the literature 
reveals this would be a small percentage of the isolates currently recovered from patients 
and an assay to identify which susceptible isolates using a simple PCR based assay would 
be relatively easily developed an implemented.  
 
 Future directions for this work would include further characterization of the ABC 
transporters. The activating mutation in Pdr1 described here upregulates CDR1, PDH1, 
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and SNQ2. However, we know that there are many activating mutations and they do not 
all show the same patterns of expression for these three efflux pumps. Further 
characterization of representative mutations that result in alternative expression patterns, 
perhaps a mutation that only upregulates SNQ2 or PDH1 would provide important 
insight. In addition further characterization of what might be contributing to azole 
resistance other than the ABC transporters is necessary. Identification of alternative 
potential contributors, however minor they may be, will give us insight into strategies C. 
glabrata might utilize if we were able to prevent increased efflux.  
 
 Knowing that Pdr1 plays such a crucial role in azole resistance, it’s regulation is 
another potential source for discovering small molecule targets that would allow for 
continued use of the azoles. We describe here a novel negative regulator of Pdr1, the J 
protein encoded by JJJ1. Deletion of JJJ1 in C. glabrata results in decreased 
susceptibility to the azoles. While we can speculate on how Jjj1 is impacting 
susceptibility based on what is known about Pdr1 regulation in S. cerevisiae, we do not 
have a definitive answer. We do not know if Jjj1 interacts with Pdr1 directly or indirectly. 
The next steps would be to determine the exact mechanism involved, with the ultimate 
goal being to use that information to inform potential drug targeting. Our transcriptional 
profiling data also warrants a closer examination for additional genes affected by deletion 
of JJJ1 that are contributing to altered azole susceptibility. Another important area of 
investigation is whether or not overexpression of JJJ1 in a resistant isolate has any 
impact on azole susceptibility. In theory since deletion of JJJ1 results in decreased 
susceptibility, depending on the mechanisms at play, overexpression could potentially 
enhance azole susceptibility. 
 
 While Pdr1 is the main player in clinical azole resistance, exploration of the 
Upc2A pathway for additional potential druggable targets shows promise. Previous work 
had identified Upc2A in C. glabrata as vital for sterol homeostasis. Upc2A is the 
transcriptional regulator that controls expression of multiple genes in the ergosterol 
biosynthesis pathway, which includes the drug target for the azoles. Deletion of UPC2A 
had previously been shown to result in enhanced azole activity in susceptible isolates of 
C. glabrata. In the work described here deletion of UPC2A in an azole-resistant clinical 
isolate was shown to decrease susceptibility to that of the parent clinical isolate. 
 
 In order to best exploit the Upc2 regulatory pathway we need to better understand 
which genes are important for the effect on azole resistance. We know that many genes in 
the ergosterol biosynthesis pathway are upregulated in response to treatment with azoles, 
but we do not know what other genes may be involved. Further exploration of how the 
alterations in the sterol biosynthesis pathway are affecting the fungistatic versus 
fungicidal property of the azoles is also of interest. When the Upc2 pathway is altered the 
sterol composition of the cell is altered and the enzymes necessary for cell survival 
change. Understanding these compensatory changes will allow targeting strategies that 
could force the production of toxic sterols instead of the altered sterol profile that 
produces the fungistatic effect. 
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 Many questions remain unanswered with regard to C. glabrata. We do not fully 
understand why C. glabrata, which is so closely related to the benign yeast S. cerevisiae 
is pathogenic. The presence of adhesion genes that increase virulence has been 
implicated, but this remains largely a mystery. We also don’t have a good understanding 
of why C. glabrata has high intrinsic resistance to the azoles. One could speculate this 
could be related to the structure of the drug target, which has not been characterized. The 
evolved mechanism of resistance to the azoles itself provides unanswered questions as 
well. One would predict the necessity for multiple resistance mechanisms, as seen in C. 
albicans, however the reality is that clinical resistance is very simply attributable to 
activating mutations in PDR1. All of these questions warrant further thought and 
investigation. 
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APPENDIX A. THE RTA3 GENE, ENCODING A PUTATIVE LIPID 
TRANSLOCASE, INFLUENCES THE SUSCEPTIBILITY OF CANDIDA 
ALBICANS TO FLUCONAZOLE* 
 
 
INTRODUCTION 
 
 Invasive fungal infections are an increasing problem worldwide (263). Among 
fungal infections, those caused by Candida species are by far the most common (5). A 
recent study of health care associated infections in the U.S. found Candida species to be 
the 7th most common pathogen overall and the most common pathogen isolated from 
bloodstream infections in the population studied (264). Among Candida infections, 
Candida albicans is the most prevalent species and was responsible for 44.4% of all 
Candida infections in the U.S. between 2006-2011 (6). 
 
 Along with the increasing rates of Candida infection, there has also been an 
increase in resistance to fluconazole, which is the most commonly prescribed antifungal 
agent (5, 265). The Centers for Disease Control and Prevention (CDC) reports roughly 
3,400 cases of fluconazole resistant Candida infections with 220 associated deaths 
annually (266). Candida has evolved multiple mechanisms of resistance to fluconazole. 
One common mechanism of resistance found in clinical isolates is the overexpression of 
the CDR1 and CDR2 genes, encoding two homologous ATP-binding cassette (ABC) 
transporters functioning as multidrug efflux pumps and phospholipid translocases (267, 
268). Overexpression of CDR1 and CDR2 has been shown to be the result of activating 
mutations in the gene encoding the zinc cluster transcription factor Tac1p (75, 78). Our 
previous characterization of the Tac1p regulon by microarray RNA profiling revealed 
that azole-resistant clinical isolates carrying an activated Tac1p protein overexpress many 
genes in addition to CDR1 and CDR2, including PDR16 (a phospholipid transferase), 
LCB4 (a sphingolipid long chain base kinase) and RTA3 (a putative lipid translocase), 
suggesting a function for Tac1p in regulating lipid/phospholipid homeostasis (76). 
(75)Recently the ABC transporter gene ROA1, a known Tac1p target (76), was also 
shown to contribute to azole resistance (269). Genetic dissection of the roles of CDR1, 
CDR2, PDR16, and ROA1 showed that they all participate in the azole-resistant 
phenotype in C. albicans, although to different extents (198, 269, 270). RTA2 has been 
shown to be involved in calcineurin-mediated azole resistance and sphingolipid LCB 
release in C. albicans (271). Given the overexpression of RTA3 in azole-resistant clinical 
isolates carrying Tac1p activating mutations and its sequence homology to RTA2, we 
investigated its contribution to azole resistance. 
 
 
 
_________________________ 
* Reprinted with permission. Whaley SG, Tsao S, Weber S, Zhang Q, Barker KS, 
Raymond M, Rogers PD. 2016. The RTA3 Gene, Encoding a Putative Lipid 
Translocase, Influences the Susceptibility of Candida albicans to Fluconazole. 
Antimicrob Agents Chemother 60:6060-6066.  
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MATERIALS AND METHODS 
 
 
Strains and growth media 
 
 The C. albicans strains used in this study are listed in (Table A-1). All strains 
were routinely maintained in YPD (1% yeast extract, 2% peptone, and 2% dextrose) 
broth at 30°C (unless otherwise stated) and stored as 40% glycerol stocks at -80°C. One 
Shot Escherichia coli TOP10 chemically competent cells (Invitrogen, Carlsbad, CA) 
were used as the host for plasmid construction and propagation. These strains were grown 
at 37°C in Luria-Bertani (LB) broth or on LB plates supplemented with 100 μg/mL 
ampicillin (Sigma, St. Louis, MO) or 50 μg/mL kanamycin (Fisher BioReagents, Fair 
Lawn, NJ). 
 
 
Strain construction 
 
 RTA3 disruptants and revertant. The SAT1-flipper cassette was used to 
construct mutants as previously described (200). Fragments of the RTA3 sequence 
containing the 5’ region -453 to +96 relative to the start codon and the 3’ region +1260 to 
+1816 were amplified by PCR and cloned on each side of the SAT1-flipper cassette. Two 
rounds of transformation and induction of the flippase resulted in replacement of the 
region +96 to +1260 relative to the RTA3 start codon in both alleles with an FRT site. 
Primers are listed in Table A-2. For reintegration, the 5’ fragment in the disruption 
cassette was replaced with a fragment containing the RTA3 open reading frame (-453 to 
+2392). After one round of transformation and induction of the flippase, the resulting 
revertant strain has one allele of RTA3 reintroduced into the original locus with a 
downstream FRT site. The second allele remains disrupted for RTA3. 
 
 RTA3 overexpression. The RTA3 open reading frame (primers RTA3-5’ and 
RTA3-3’), ADH1 promoter region (primers ADH1 and ADH2) and 3’ fragment of ADH1 
(primers ADH8 and ADH11) were PCR amplified from SC5314. The ACT1 termination 
sequence and SAT1 selection marker were PCR amplified from vector pBSS2 (primers 
ACT16 and SAT2), which contains the SAT1 flipper construct in the pBluescript 
backbone. All primers used are listed in Table A-2. The assembled cassette was designed 
to replace one allele of ADH1 with the RTA3 open reading frame followed by the ACT1 
termination sequence and the SAT1 selection marker, which allowed expression of RTA3 
from the ADH1 promoter. 
 
 GFP tagged RTA3. A 3 kb fragment was amplified by PCR from the pNIM 
vector (272) using the primers listed in Table A-2. The final DNA product contained 95 
bp of homology to the 3’ end of RTA3 (just before the stop codon) followed by a 
fragment of the pNIM cassette (GFP, ACT1 termination sequence, ACT1 promoter, 
SAT1, URA3 termination sequence) and a 116-bp region homologous to the 3’ UTR 
immediately following the RTA3 ORF. This construct was transformed into the 5674  
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Table A-1. C. albicans strains used in the RTA3 study. 
 
Strain Parent  Genotype Reference 
5457  Azole-susceptible clinical isolate (270) 
5674 5457 Azole-resistant clinical isolate; 
Tac1pN972D 
(270), (273) 
SZY31 5674 tac1∆::FRT/tac1∆::FRT (273) 
5674RTA3M4A 5674 rta3∆::FRT/rta3∆::FRT This study 
5674RTA3M4B 5674 rta3∆::FRT/rta3∆::FRT This study 
5674RTA3R2A 5674RTA3M4A rta3∆::FRT/RTA3-FRT  This study 
5674RTA3R2B 5674RTA3M4A rta3∆::FRT/RTA3-FRT This study 
5674RTA3G2A 5674RTA3R2B rta3∆::FRT/RTA3-GFP-caSAT1 This study 
5674-GFP 5674 ADH1/adh1::Ptet-caGFP This study 
SC5314  Azole-susceptible clinical isolate (274) 
SCRTA3M4A SC5314 rta3∆::FRT/rta3∆::FRT This study 
SCRTA3OE1G SC5314 ADH1/adh1::PADH1-RTA3-
caSAT1 
This study 
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Table A-2. Primers used in the RTA3 study. 
 
Primer Sequence (5’ – 3’)1 
Northern blot  
RTA3 probe Forward ATGAATACTATGGATCTTGCGGTAATTAC 
RTA3 probe Reverse CGACCCAAATATCCGAGAAATTCTAATG 
RTA3 disruption 
and reintegration 
 
RTA3A AATTGGATTTCCTGGTGGTGGGCCCAAGATTA 
RTA3B TGGGGCATAAGTTGCAGCAATCTCGAGTAGAG 
RTA3C AACAAAGACCAAGCGGCCGCGGACAAAAGT 
RTA3D CTTTTAAACTATAAAAGTTTATGCCGCGGGTC 
RTA3E AAGGGTGGGAATCTCGAGGTACACCAAG 
GFP-tagged RTA3  
RTA3gfpA TTGTTAGGGGTGATCCTATTCAAGAGAATAAG
GAAGGTGCTGGAGCTGGAGCTATGAGTAAGGG
AGAAGAACTTTTCACT 
RTA3gfpB AAAAAACTAATAATGATATTGTTAGTGACAAT
GAAGAATCGACGTTGCAAGGTCAAAATATTGT
TAGGGGTGATCCTATT 
RTA3gfpC TTTCACTTGCATTTAAGTTGCTAGGAATCATAC
CACCCCTTAGTTAACATTCAAATCTGCAGGACC
ACCTTTGATTGTAA 
RTA3gfpD ACAAAAGCAAGTACAATTAATAAGCAAACATC
TATAAACATCTAATAACATAGCCACCTTTTTCA
CTTGCATTTAAGTTG 
RTA3 
overexpression 
 
ADH1 TGTCAAAGGATTGGTACCTTGAGATGGAG 
ADH2 TTTGTGGGCCCCATAATTGTTTTTGTATTTGTTG 
RTA3-5’ GAAAATCTAGAAGGCTCATGAATACTATGG 
RTA3-3’ CTTAGTTAAAGATCTAATTCATTCCTTATTC 
ACT16 TTCTAAGATCTAAATTCTGGAAATCTGG 
SAT2 CTAGTGATTTCTGCAGGACCACCTTTG 
ADH8 GGTGCTGAACCAAACTGCAGTGAAGCTGAC 
ADH11 GAACCTTTGATTTCCGCGGATTTGACAACAGC 
 
1Underlined bases indicate introduction of restriction enzyme cloning sites to allow 
directional cloning.  
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RTA3 revertant strain to allow expression of the Rta3p-GFP fusion protein from the 
endogenous RTA3 promoter. 
 
 GFP expression in 5674. The empty pNIM plasmid was digested with KpnI and 
SacII to release the GFP cassette and used to transform 5674, generating a strain in which 
GFP expression can be induced in the presence of doxycycline following integration at 
the ADH1 locus (272). 
 
 
C. albicans transformation 
 
 C. albicans transformations were performed either using a standard lithium 
acetate protocol (273) or as described previously (275), with minor modifications. 
Overnight cultures were diluted to an optical density at 600 nm (OD600) of 0.1 in 50 mL 
of fresh YPD and allowed to grow to an OD600 of approximately 2. The cells were 
harvested and resuspended in a 10 mL solution containing 100mM lithium acetate 
(LiAc), 10mM Tris-HCl, 1mM EDTA and then incubated with shaking for one hour at 
30°C. Next, 250 μL of 1M dithiothreitol was added and the cells were incubated for an 
additional 30 minutes with shaking. Cells were diluted with 40 mL H2O, centrifuged and 
washed with 25 mL H2O, then with 5 mL 1M sorbitol and resuspended in 50 μL 1M 
sorbitol. Plasmids were digested, separated by gel electrophoresis and purified using the 
Geneclean II kit (MP Biomedicals, Solon, OH). Then 5 μL of purified DNA or H2O 
control were added to 40 μL of electrocompetent cells. Electroporation was performed in 
a CelljecT Pro (Thermo Fisher, Waltham, MA) at 1.5 kV in a 2mm cuvette. Cells were 
immediately resuspended in 1 mL of 1 M sorbitol and transferred to a microcentrifuge 
tube. Transformed cells were allowed to recover in YPD at 30°C with shaking for 4-6 
hours then plated on YPD agar plates containing 200 μg/mL nourseothricin (Jena 
Biochemical, Germany). Transformants were selected after 24-48 hour growth and 
confirmed by Southern blot analysis. 
 
 
gDNA preparation and Southern blot analysis 
 
 Genomic DNA was isolated as described previously (201). For confirmation by 
Southern hybridization, approximately 10 μg of genomic DNA was digested with the 
appropriate restriction enzymes, separated on a 1% agarose gel containing ethidium 
bromide, transferred by vacuum blotting onto a nylon membrane and fixed by UV-
crosslinking. Hybridization was performed with the Amersham ECL Direct Nucleic Acid 
Labeling and Detection System (GE Healthcare, Pittsburg, PA) as per manufacturer’s 
instructions. 
 
 
RNA preparation and Northern blot analysis 
 
 C. albicans strains (50 mL cultures) were grown in YPD medium at 30˚C to an 
OD600 of 1.0.  Total RNA was extracted using a hot phenol method (276). Northern 
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blotting was performed as previously described (270). The RTA3 probe used for 
membrane hybridization was obtained by PCR amplification from SC5314 genomic 
DNA using primers corresponding to a region from +1 to +500 with respect to the RTA3 
start codon (Table A-2). After washing, the membrane was exposed to a Fujifilm 
imaging plate and the results were visualized using Multi Gauge software version 3.0 
(Fujifilm). 
 
 
Fluconazole susceptibility assays 
 
 Liquid microtiter plate assays were performed as described previously (198). 
Fluconazole (FLC; Sigma, St. Louis, MO) concentrations tested in the deletion strains 
were 1.5, 3, 9, 25, 37.5, 50, 62.5, 75, 87.5, 100 and 200 μg/mL; each strain was tested as 
four biological replicates, each with technical duplicates. FLC concentrations tested in 
the overexpression strain were 0.2, 0.4, 0.8, 1.6, 3.1, 6.3, 12.5, 25, 50, 100 and 200 
μg/mL; each strain was tested in triplicate. Cell growth was measured 
spectrophotometrically at OD620 after 48 hours of incubation at 30˚C in YPD. Data was 
plotted using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA) as a dose-
response curve where the X values are the logarithms of FLC concentrations and Y 
values are percent cell growth in the presence of FLC relative to cell growth in the 
absence of FLC. The data was fitted using non-linear regression allowing the 
determination of the IC50 for each strain in response to FLC treatment. 
 
 
Spot assay 
 
 Colonies from cultures grown on YPD solid media for 24 hours were diluted in 
YPD to OD600 of 1.0. Cultures were serially diluted one to five in YPD. Approximately 2 
μL of each dilution were applied to solid YPD containing the indicated concentrations of 
fluconazole using a handheld pin transfer tool. The serial dilutions were incubated at 
30°C for 24, 48, and 72 hours. Plates were imaged using an Epson Perfection V700 Photo 
scanner at each time point and growth inhibition was compared. 
 
 
Fluorescence microscopy 
 
 Cells were grown in synthetic complete medium (2% glucose, 0.67% Yeast 
Nitrogen base without amino acids (Difco, Sparks, MD), 0.2% amino acids). The 
5674/pNIM strain (5674-GFP) was treated with 50 μg/mL doxycycline (Sigma, St. Louis, 
MO) to induce expression of GFP as described (272). Cells were harvested at an OD600 
of 0.4, washed with 0.1 M potassium phosphate buffer pH 6.4 and resuspended in 0.1 M 
potassium phosphate buffer pH 7.4. The cells were then placed on a 15-well microscope 
slide pre-treated with poly-L-lysine (Sigma, St. Louis, MO). Non-adhering cells were 
aspirated and 0.05 μg/mL DAPI (Sigma, St. Louis, MO) was added to each well. Images 
were acquired using a Zeiss LSM 700 inverted confocal laser scanning microscope 
equipped with a 63x oil immersion objective (1.4 NA, DIC) at a 2x zoom. GFP images 
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were captured using a 488 nm diode laser for excitation and a beam splitter set to capture 
emission above 505 nm.  All images were acquired using the same laser strength, detector 
gain value and pixel dwell time to enable subsequent comparative analyses using ImageJ 
software (http://imagej.net; version 2.0.0-rc-29/1.49s) (277). Quantification of the 
autofluorescence intensity was achieved by analyzing 15 individual cells (one transverse 
line per cell), which determined the threshold value of 25 arbitrary units for background 
subtraction. 
 
 
RESULTS 
 
 
Increased RTA3 expression in an azole-resistant clinical isolate of C. albicans is 
Tac1p dependent 
 
 The SAT1 flipper method was used to delete both copies of RTA3 in a well-
characterized fluconazole-resistant clinical isolate 5674. This strain and its azole-
susceptible parental strain 5457 were isolated from the same patient 58 days apart (270). 
Compared to strain 5457, strain 5674 is resistant to several azole derivatives and 
overexpresses CDR1, CDR2 and many other genes, including RTA3, due to a strong gain-
of-function mutation (N972D) in Tac1p (76, 273). 
 
 Northern blot analysis was performed on all strains, using an RTA3-derived probe. 
The RNA detected was approximately 1.7 kb, consistent with the size of the RTA3 
transcript (Figure A-1) (278). As predicted from the microarray studies, RTA3 transcripts 
were strongly induced in strain 5674 as compared to strain 5457, in a Tac1p-dependent 
manner (76). RTA3 transcripts were undetectable in the 5674 rta3Δ/Δ strain, confirming 
the RTA3 deletion in this strain. Reintegration of one copy of RTA3 into its original locus 
in the 5674 rta3Δ/Δ strain gave rise to intermediate levels of RTA3 RNA (Figure A-1). 
 
 
Deletion of RTA3 in an azole-resistant clinical isolate of C. albicans results in 
increased susceptibility to fluconazole 
 
 The fluconazole sensitivity of clinical isolates 5457 and 5674 and the mutant 
strains was determined by microtiter plate assay. Cell growth was assessed by measuring 
optical density at 620 nm and normalized to the no fluconazole controls. This experiment 
showed that the deletion of RTA3 in isolate 5674 decreased the fluconazole resistance of 
the cells by 2-fold, an effect that was partially suppressed in the RTA3 revertant (Figure 
A-2A and Table A-3). A fluconazole resistance assay was also carried out on solid 
media, yielding similar results (Figure A-2B). These results demonstrate that RTA3 
contributes to the overall azole resistance of the 5674 clinical isolate. This contribution, 
although minor as compared to that of CDR1 in strain 5674 (6-fold), is similar in extent 
to that of CDR2 (1.5-fold) (198) and PDR16 (2-fold) (270).  Taken together, these data 
demonstrate that the high level of azole resistance in clinical isolate 5674 is achieved 
through the combined action of multiple Tac1p targets.  
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Figure A-1. Northern blot analysis of RTA3 expression. 
 
Total RNA was prepared from the indicated strains and analyzed by Northern blotting 
with an RTA3-specific probe. rRNAs are shown as loading controls (bottom) and the 
position of the 26S and 18S rRNAs is indicated on the left. 
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Figure A-2. Deletion of RTA3 in the azole-resistant clinical isolate 5674 results in 
decreased fluconazole resistance. 
 
(A) Strains were grown for 48 hours in YPD at the fluconazole concentrations tested and 
OD620 readings were measured and normalized to the no drug control wells. n=4. (B) 
Serial dilutions of the strains were incubated for 24, 48, or 72 hours on YPD solid media 
containing 0, 25, or 50 μg/mL fluconazole. 
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Table A-3. Fluconazole susceptibility of strains tested in the RTA3 study. 
 
Strain IC50a Fold changeb 
5457 2.79 (?0.08) 0.03 
5674 83.68 (?1.05) 1.00 
5674 rta3Δ/Δ 41.79 (?0.30) 0.50 
5674 rta3?/?+RTA3 53.70 (?1.05) 0.64 
 
a IC50 of each strain to FLC (μg/mL) 
b Relative to 5674  
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 The same strategy was used to delete RTA3 in the azole-susceptible clinical 
isolate SC5314. Assessment of the fluconazole sensitivity of the resulting strain by 
microtiter plate and spot assays revealed that it was identical to that of SC5314 (data not 
shown). This was consistent with the finding that RTA3 is not expressed in the azole-
susceptible strains SC5314 and 5457 (Figure A-1). 
 
 
Overexpression of RTA3 in an azole-susceptible C. albicans strain results in 
increased tolerance to fluconazole 
 
 We used an overexpression strategy to further test the role for RTA3 in azole 
resistance. One allele of the highly expressed ADH1 gene was replaced with RTA3 in the 
SC5314 background such that RTA3 expression was under the control of the strong 
ADH1 promoter. This resulted in high levels of RTA3 expression as determined by 
Northern blot analysis (Figure A-1). A liquid microtiter plate assay with the resulting 
strains showed that, in the presence of fluconazole, the strain overexpressing RTA3 
exhibited enhanced growth as compared to the parental strain, accompanied by growth 
trailing (Figure A-3A) (279); this trailing effect was also seen after 24 hours of growth 
and with another independently constructed RTA3-overexpressing strain (data not 
shown). Interestingly, the RTA3-overexpressing strain clearly demonstrated enhanced 
growth compared to SC5314 on solid YPD medium containing 5, 25, or 50 μg/mL 
fluconazole incubated for 24, 48, and 72 hours (Figure A-3B). These results indicate that 
an increased dosage of RTA3 expression can confer fluconazole tolerance in the absence 
of additional molecular alterations – i.e. activation of additional Tac1p targets. 
 
 
Rta3p localizes to the plasma membrane 
 
 Subcellular localization of Rta3p was assessed by tagging the protein with the 
green fluorescent protein (GFP) and analyzing the fluorescence of the resulting cells by 
confocal microscopy. Rta3p-GFP expressing cells exhibited a faint rim staining pattern 
consistent with plasma membrane localization, although intracellular staining was found 
to be strong, as shown in the GFP intensity plot (Figure A-4A). Interestingly, Rta3p-GFP 
also displayed a punctate distribution pattern, suggesting an association with lipid rafts, 
as previously shown for Cdr1p (280). Parental 5674 cells analyzed similarly to determine 
their level and pattern of autofluorescence exhibited a faint, diffuse signal that appeared 
mostly intracellular (Figure A-4B). Quantification of the autofluorescence intensity 
across individual cells allowed the autofluorescence threshold value to be set at 25 
arbitrary units (Figure A-4B, right panel). Subtracting autofluorescence from the Rta3p-
GFP signal decreased the intracellular staining and enhanced punctate staining at the cell 
periphery (Figure A-4A). Results obtained with the Rta3p-GFP cells were different from 
those obtained with cells expressing untagged GFP, which displayed primarily 
intracellular staining. Upon induction with doxycycline, cells expressing GFP were found 
to be very bright (Figure A-4C). The GFP intensity plot for these cells before and after 
autofluorescence correction showed similar bell-shaped distribution curves corresponding 
to an intracellular localization of GFP, confirming that the rim-like staining pattern  
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Figure A-3. Overexpression of RTA3 in the azole-susceptible clinical isolate 
SC5314 results in enhanced fluconazole tolerance. 
 
(A) Strains were incubated for 48 hours in YPD at the concentrations tested and OD620 
readings were measured and normalized to the no drug control wells. N = 3, in duplicate. 
(B) Serial dilutions of the strains were incubated for 24, 48, or 72 hours on YPD solid 
media containing 0, 5, 25, or 50 μg/mL fluconazole. 
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Figure A-4. Analysis of Rta3p-GFP sub-cellular localization. 
 
(A) Confocal microscope image of strain 5674 expressing Rta3p-GFP grown to log phase 
in synthetic complete medium. The DIC and corresponding fluorescence (GFP) images 
are shown. The fluorescence intensity of the selected transversal section of the cell (arrow 
line) was quantified using ImageJ software (GFP intensity plot, where the length and 
direction are expressed as increased distance on the x-axis). The threshold for 
autofluorescence signal (25 arbitrary units, AU) determined from 5674 cells is indicated 
as a dashed line in the intensity plots. An autofluorescence subtraction image and its 
corresponding intensity plot are also shown.  Two peaks in the intensity plot 
corresponding to plasma membrane (PM) fluorescence are indicated. (B) 5674 cells were 
analyzed as described in panel A. (C) 5674-GFP cells were analyzed as described in 
panel A.   
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observed with Rta3p-GFP is not due to the GFP moiety of the fusion protein. Taken 
together, these results demonstrate that Rta3p-GFP localizes predominantly to the plasma 
membrane, similar to S. cerevisiae Rsb1p and Rta1p (281, 282). 
 
 
DISCUSSION 
 
 Here we show that RTA3 participates along with CDR1, CDR2, and PDR16 in 
Tac1p-mediated azole resistance in C. albicans. Disruption of RTA3 in a resistant clinical 
isolate carrying a TAC1 activating mutation resulted in a modest increase in 
susceptibility. Such an effect is not surprising as this isolate still overexpresses CDR1, 
CDR2, and PDR16. Overexpression of RTA3 alone in the susceptible isolate SC5314 
resulted in an increase in fluconazole tolerance and in its ability to grow on solid medium 
in the presence of fluconazole.  While this Tac1p target gene clearly contributes to this 
phenotype, the mechanism by which it does so remains unclear. 
 
 The function of C. albicans RTA3 remains uncharacterized. The closest homologs 
to this gene in the yeast Saccharomyces cerevisiae are RSB1 and RTA1, both of which are 
members of the lipid-translocating exporter family (283). RSB1 encodes a translocase that 
moves sphingolipid long chain bases (LCB) from the cytoplasmic side of the plasma 
membrane to the external side and glycerophospholipids inward toward the cytoplasm, 
thus conferring plasma membrane lipid asymmetry (284, 285). RTA1 encodes a similar 
protein that is involved in 7-aminocholesterol resistance by a yet unknown mechanism 
(286). The C. albicans genome contains four genes encoding proteins belonging to this 
family: RTA2, RTA3, RTA4 and orf19.6224. While the other members of the C. albicans 
family are not yet functionally characterized, RTA2 has been shown to be involved in 
calcineurin-mediated azole resistance and sphingolipid LCB release in C. albicans (271). 
 
 In addition to CDR1 and CDR2, other target genes of Tac1p have been implicated 
in the azole resistance mediated by activating mutations in this transcription factor. 
Disruption of the phospholipid transferase gene PDR16 in an azole- resistant clinical 
isolate resulted in increased susceptibility to fluconazole, whereas overexpression of 
PDR16 increased resistance (270). Interestingly, the Tac1p target gene ROA1, which 
encodes a putative ABC transporter, was recently shown to influence azole susceptibility 
in C. albicans (269). Disruption of ROA1 increased tolerance to a panel of azoles. It is 
therefore tempting to speculate that other Tac1p target genes, in addition to PDR16, 
RTA3, and ROA1 may play a supporting role in this process. 
 
 Based on the plasma membrane localization of Rta3p and its homology to 
proteins involved in maintaining optimal membrane lipid asymmetry, its overexpression 
(ectopic or Tac1p-mediated) could attenuate plasma membrane alterations caused by 
azoles, as shown for Rta2p (271). Alternatively, it could also alter plasma membrane 
permeability and/or the activity of plasma membrane-associated azole transporters like 
Cdr1p. The determination of Rta3p molecular and cellular function(s) should help to 
answer these questions. 
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APPENDIX B. SUPPLEMENTAL DATA 
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Table B-1. Genes up-regulated by at least 1.5-fold in SM1∆jjj1 versus SM1. 
 
C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0M01760g CDR1 PDR5 9.22 11.59 
 
-4.81 -6.65 Multidrug transporter of ATP-binding cassette (ABC) 
superfamily, involved in resistance to azoles; expression 
regulated by Pdr1p; increased abundance in azole-resistant 
strains; expression increased by loss of the mitochondrial 
genome 
CAGL0K00170g EPA22 
 
7.06 2.98 
 
13.57 4.81 Putative adhesin-like protein; belongs to adhesin cluster I 
CAGL0L05434g SUN4 UTH1 6.01 4.74 
 
5.00 5.53 Ortholog(s) have role in fungal-type cell wall biogenesis, fungal-
type cell wall organization, mitochondrion degradation 
CAGL0E06688g EPA3 
 
5.21 3.96 
 
6.76 3.76 Epithelial adhesion protein; belongs to adhesin cluster I; GPI-
anchored 
CAGL0C03289g YBT1 YBT1 4.74 8.73 
 
1.35 -1.41 Putative ABC transporter involved in bile acid transport; gene 
is upregulated in azole-resistant strain 
CAGL0E06666g EPA2 
 
4.35 3.22 
 
6.57 4.38 Epithelial adhesion protein; predicted GPI-anchor; belongs to 
adhesin cluster I 
CAGL0G05544g 
 
HBT1 4.20 6.02 
 
4.21 40.23 Ortholog(s) have role in cell morphogenesis involved in conjugation 
with cellular fusion and cell surface, fungal-type cell wall, mating 
projection, plasma membrane localization 
CAGL0F00649g 
 
RCK2 4.03 1.54 
 
3.04 2.55 Ortholog(s) have protein serine/threonine kinase activity 
CAGL0I10147g PWP1 
 
3.83 5.07 
 
4.13 6.44 Protein with 32 tandem repeats; putative adhesin-like protein; 
belongs to adhesin cluster II 
CAGL0H02563g 
 
DDR2 3.80 7.00 
 
2.30 1.42 Predicted GPI-linked protein 
CAGL0F07777g 
 
ALD3 3.26 3.59 
 
2.15 14.73 Putative aldehyde dehydrogenase; expression upregulated in biofilm 
vs planktonic cell culture 
CAGL0J04202g HSP12 HSP12 3.18 8.68 
 
3.40 13.54 Heat shock protein; gene is upregulated in azole-resistant strain; 
expression upregulated in biofilm vs planktonic cell culture 
CAGL0K07854g DIB1 2.97 2.14 3.06 2.81 Ortholog(s) have role in mRNA splicing, via spliceosome and 
U4/U6 x U5 tri-snRNP complex, U5 snRNP localization 
CAGL0M11660g 
  
2.97 6.44 
 
2.75 -7.64 Has domain(s) with predicted hydrolase activity 
CAGL0J05159g 
  
2.96 1.79 
 
2.70 1.49 Putative adhesin-like protein 
CAGL0G02739g 
 
XBP1 2.95 4.82 
 
3.92 9.05 Ortholog(s) have sequence-specific DNA binding, sequence-specific 
DNA binding RNA polymerase II transcription factor activity 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0E06644g EPA1 
 
2.90 4.56 
 
2.46 2.59 Sub-telomerically encoded adhesin with a role in cell adhesion; GPI-
anchored cell wall protein; N-terminal ligand binding domain binds 
to ligands containing a terminal galactose residue; belongs to 
adhesin cluster I 
CAGL0K04785g 
 
MRX7 2.88 3.40 
 
2.04 2.85 Ortholog(s) have mitochondrion localization 
CAGL0L07832g 
 
YCR016W 2.82 1.58 
 
1.65 -1.18 Ortholog(s) have nucleolus localization 
CAGL0M07766g 
  
2.80 2.29 
 
2.40 2.71 Putative protein; gene is upregulated in azole-resistant strain 
CAGL0L00157g 
  
2.73 6.48 
 
2.82 3.72 Putative adhesin-like protein; multiple tandem repeats; predicted 
GPI-anchor; belongs to adhesin cluster III 
CAGL0J07502g 
 
YNL234W 2.63 3.46 
 
1.73 -1.67 Putative protein similar to globins with a heme-binding domain; 
gene is upregulated in azole-resistant strain 
CAGL0I10224g 
  
2.60 1.86 
 
-1.67 1.86 Unknown 
CAGL0G01540g NCE103 NCE103 2.57 2.81 
 
2.27 6.29 Beta carbonic anhydrase with a predicted role in non-classical 
protein export; upregulated in azole-resistant strain; enzyme activity 
increased by amines and amino acids; protein abundance decreased 
in ace2 cells 
CAGL0H00418g 
  
2.54 1.56 
 
1.96 2.84 Protein of unknown function 
CAGL0J01727g 
  
2.53 2.27 
 
2.21 1.89 Putative adhesion protein; predicted GPI-anchor; belongs to adhesin 
cluster VI 
CAGL0L00583g 
 
USV1 2.48 1.90 
 
2.08 2.43 Ortholog(s) have sequence-specific DNA binding, sequence-specific 
DNA binding transcription factor activity 
CAGL0K07007g 
  
2.46 3.45 
 
1.75 -1.28 Protein of unknown function 
CAGL0D02640g 
  
2.44 2.01 
 
2.06 3.30 Has domain(s) with predicted substrate-specific transmembrane 
transporter activity, transmembrane transporter activity, role in 
transmembrane transport and integral component of membrane, 
membrane localization 
CAGL0D02662g 2.44 2.01 2.06 3.30 Has domain(s) with predicted substrate-specific transmembrane 
transporter activity, transmembrane transporter activity, role in 
transmembrane transport and integral component of membrane, 
membrane localization 
CAGL0J01774g 
  
2.41 2.18 
 
2.80 2.62 Putative adhesin-like protein; has glycine and serine rich repeats; 
belongs to adhesin cluster VI 
CAGL0I04994g MET6 MET6 2.36 3.56 
 
2.99 8.43 5-methyltetrahydropteroyltriglutamate homocysteine 
methyltransferase; protein abundance increased in ace2 mutant cells 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0K04367g 
  
2.34 8.67 
 
1.85 1.63 Has domain(s) with predicted amino acid transmembrane transporter 
activity, role in amino acid transmembrane transport and membrane 
localization 
CAGL0G00242g YOR1 YOR1 2.34 2.74 
 
-1.79 1.03 Putative ABC transporter involved in multidrug efflux; gene is 
upregulated in azole-resistant strain 
CAGL0M01716g 
 
TEC1 2.31 2.35 
 
1.95 1.51 Ortholog(s) have RNA polymerase II core promoter proximal region 
sequence-specific DNA binding, more 
CAGL0K12254g 
 
VID24 2.30 2.19 
 
1.87 1.55 Ortholog(s) have role in negative regulation of gluconeogenesis, 
proteasome-mediated ubiquitin-dependent protein catabolic process, 
protein catabolic process in the vacuole, protein targeting to vacuole 
CAGL0L06666g YHB1 YHB1 2.25 2.93 
 
1.66 1.63 Putative flavohemoglobin, involved in nitric oxide detoxification 
CAGL0I09724g 
  
2.24 2.32 
 
2.43 -2.09 Has domain(s) with predicted role in transmembrane transport 
and integral component of membrane localization 
CAGL0E01155g 
 
RPA14 2.24 3.00 
 
-1.31 1.73 Ortholog(s) have RNA polymerase I activity, role in regulation 
of cell size, transcription of nuclear large rRNA transcript from 
RNA polymerase I promoter and DNA-directed RNA 
polymerase I complex localization 
CAGL0M06699g 
 
SDS3 2.24 1.67 
 
3.29 1.33 Ortholog(s) have histone deacetylase activity 
CAGL0G01738g 
 
PIL1 2.23 3.43 
 
1.67 7.37 Ortholog(s) have lipid binding activity and role in eisosome 
assembly, endocytosis, negative regulation of protein kinase 
activity, protein localization, response to heat 
CAGL0H06853g ADH6 
 
2.21 3.72 
 
1.83 1.55 Putative NADP-dependent alcohol dehydrogenase VI; protein 
abundance increased in ace2 mutant cells 
CAGL0L01287g UTR4 UTR4 2.18 1.96 
 
1.52 3.69 Haloacid dehalogenase-like hydrolase 
CAGL0G01122g 
 
CIS1 2.17 3.08 
 
-1.30 1.22 Putative protein; gene is upregulated in azole-resistant strain 
CAGL0D06666g 2.17 1.78 2.67 1.44 Protein of unknown function 
CAGL0M10219g 
 
LAC1 2.14 2.40 
 
1.40 -1.50 Putative ceramide synthase component; gene is upregulated in 
azole-resistant strain 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0M04587g 
 
RMP1 2.11 1.58 
 
1.47 -1.14 Ortholog(s) have rRNA primary transcript binding activity, role 
in mRNA cleavage, maturation of 5.8S rRNA from tricistronic 
rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) and 
cytoplasm, nucleolus, ribonuclease MRP complex localization 
CAGL0I00286g 
  
2.10 3.37 
 
1.47 1.17 Has domain(s) with predicted substrate-specific transmembrane 
transporter activity, transmembrane transporter activity, role in 
transmembrane transport and integral component of 
membrane, membrane localization 
CAGL0M14047g 
 
ADH6 2.10 6.39 
 
1.98 3.28 Putative NADPH-dependent cinnamyl alcohol dehydrogenase; gene 
is upregulated in azole-resistant strain 
CAGL0E00110g 
  
2.09 2.98 
 
3.01 2.30 Putative adhesin-like protein; ORF appears artificially broken into 
fragments due to sequencing errors; belongs to adhesin cluster III; 
predicted GPI anchor 
CAGL0J00275g 
 
RRP45 2.06 2.11 
 
2.30 3.72 Ortholog(s) have role in U1 snRNA 3'-end processing, U4 snRNA 
3'-end processing and U5 snRNA 3'-end processing, more 
CAGL0B02838g MUP1 MUP1 2.05 6.16 
 
2.10 3.95 Ortholog(s) have L-methionine secondary active transmembrane 
transporter activity and role in cysteine transport, methionine import 
CAGL0H04851g 
 
PPZ1 2.05 1.92 
 
2.15 12.37 Ortholog(s) have protein serine/threonine phosphatase activity, role 
in cellular protein localization, cellular sodium ion homeostasis, 
protein dephosphorylation and cytoplasm, extrinsic component of 
plasma membrane, nucleus localization 
CAGL0G03179g 
  
2.03 2.55 
 
1.81 4.26 Has domain(s) with predicted phospholipid binding activity 
CAGL0E00116g 
  
2.00 3.84 
 
2.77 2.08 Protein of unknown function 
CAGL0K06677g MET8 MET8 2.00 2.07 
 
1.63 6.71 Putative bifunctional dehydrogenase and ferrochelatase; gene is 
upregulated in azole-resistant strain 
CAGL0B00528g HLR1 1.99 1.65 1.81 1.65 Ortholog(s) have role in fungal-type cell wall organization and 
cytoplasm localization 
CAGL0E01529g 
 
PFK27 1.98 1.76 
 
1.63 1.56 Ortholog(s) have role in fructose 2,6-bisphosphate metabolic 
process, regulation of glycolytic process 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0J04884g 
 
UBX6 1.98 1.83 
 
1.31 3.94 Ortholog(s) have role in sporulation resulting in formation of a 
cellular spore, ubiquitin-dependent protein catabolic process 
and nucleus localization 
CAGL0A01804g HXT1 HXT1 1.98 1.86 
 
1.49 -3.43 Ortholog(s) have fructose transmembrane transporter activity, 
pentose transmembrane transporter activity, role in glucose 
transport, mannose transport and plasma membrane 
localization 
CAGL0K04675g 
  
1.94 1.59 
 
1.94 1.26 Protein of unknown function 
CAGL0L06094g STR3 STR3 1.94 8.16 
 
3.11 11.32 Putative cystathionine beta-lyase; gene is upregulated in azole-
resistant strain 
CAGL0E05522g 
 
YOR342C 1.94 2.81 
 
1.75 -1.07 Ortholog(s) have cytoplasm, nucleus localization 
CAGL0M01914g 
  
1.92 1.92 
 
1.61 2.21 Protein of unknown function 
CAGL0F07029g MET13 MET13 1.92 2.36 
 
2.17 5.70 Ortholog(s) have methylenetetrahydrofolate reductase (NAD(P)H) 
activity, role in methionine biosynthetic process, one-carbon 
metabolic process and cytosol, mitochondrion, nucleus localization 
CAGL0D04048g 
 
VMA7 1.92 1.67 
 
1.59 1.99 Ortholog(s) have role in cellular metal ion homeostasis, cellular 
response to biotic stimulus and cellular response to starvation, more 
CAGL0H05137g 
 
ALD6 1.92 1.71 
 
1.58 2.06 Ortholog(s) have aldehyde dehydrogenase [NAD(P)+] activity, role 
in NADPH regeneration, acetate biosynthetic process, response to 
salt stress and cytosol, mitochondrion localization 
CAGL0H03619g 
 
YNL011C 1.91 2.09 
 
1.56 8.14 Ortholog of S. cerevisiae : YNL011C, C. albicans SC5314 : 
C7_01230C_A, C. dubliniensis CD36 : Cd36_71090, C. parapsilosis 
CDC317 : CPAR2_300420 and Candida tenuis NRRL Y-1498 : 
CANTEDRAFT_111980 
CAGL0J11550g 
  
1.90 5.38 
 
2.00 31.09 Protein of unknown function 
CAGL0M07293g PDR12 1.90 2.14 1.67 -3.52 Putative ABC transporter of weak organic acids; gene is 
downregulated in azole-resistant strain 
CAGL0M04257g 
 
DCN1 1.88 2.62 
 
1.21 1.02 Ortholog(s) have NEDD8 transferase activity, cullin family 
protein binding, protein binding, bridging, ubiquitin binding, 
ubiquitin conjugating enzyme binding activity 
CAGL0L05786g 
 
CMR3 1.87 1.60 
 
1.97 1.08 Ortholog(s) have sequence-specific DNA binding activity 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0M00154g CYN1 
 
1.87 3.46 
 
1.64 1.78 Plasma membrane high affinity cystine specific transporter; present 
only in pathogenic yeasts; confers the ability to utilize cystine as a 
sulfur source 
CAGL0I01144g 
 
YPT35 1.87 1.64 
 
1.81 3.16 Ortholog(s) have phosphatidylinositol-3-phosphate binding activity 
and endosome localization 
CAGL0K12518g 
 
AGX1 1.86 2.77 
 
1.52 7.48 Ortholog(s) have alanine-glyoxylate transaminase activity, role in 
glycine biosynthetic process, by transamination of glyoxylate and 
mitochondrion localization 
CAGL0C05461g 
 
OST4 1.86 1.85 
 
2.43 -1.63 Ortholog(s) have dolichyl-diphosphooligosaccharide-protein 
glycotransferase activity, protein binding, bridging activity, role 
in protein N-linked glycosylation and oligosaccharyltransferase 
complex localization 
CAGL0J04004g 
 
MCP1 1.86 1.60 
 
1.46 10.41 Ortholog(s) have role in lipid homeostasis, mitochondrion 
organization and integral component of mitochondrial 
membrane, mitochondrial outer membrane localization 
CAGL0B02860g 
  
1.85 2.08 
 
2.24 6.67 Protein of unknown function 
CAGL0L10318g 
 
LPL1 1.82 3.32 
 
1.57 3.16 Putative protein; gene is upregulated in azole-resistant strain 
CAGL0J03762g MET7 MET7 1.80 3.69 
 
2.01 1.43 Ortholog(s) have tetrahydrofolylpolyglutamate synthase 
activity, role in one-carbon metabolic process, regulation of 
DNA methylation and cytosol, mitochondrion, nucleus 
localization 
CAGL0I02178g 
 
MPC2 1.80 1.84 
 
1.42 1.88 Ortholog(s) have pyruvate transmembrane transporter activity, 
role in mitochondrial pyruvate transport and integral 
component of mitochondrial inner membrane localization 
CAGL0L10142g RSB1 RSB1 1.79 1.87 
 
1.22 -3.35 Putative sphingolipid flippase; gene is upregulated in azole-
resistant strain 
CAGL0I04928g AIM11 1.79 2.84 -1.17 1.52 Ortholog of S. cerevisiae : AIM11, C. albicans SC5314 : 
C3_00840C_A, C. dubliniensis CD36 : Cd36_80770, C. 
parapsilosis CDC317 : CPAR2_102260 and Candida tenuis 
NRRL Y-1498 : CANTEDRAFT_114262 
CAGL0A01694g 
 
YGL036W 1.78 2.47 
 
1.45 2.63 Ortholog(s) have cytoplasm localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0B03465g 
 
SYM1 1.78 1.70 
 
1.58 2.09 Ortholog(s) have role in ethanol metabolic process and 
mitochondrial inner membrane localization 
CAGL0L13299g EPA11 
 
1.78 1.91 
 
1.98 1.81 Putative adhesin; belongs to adhesin cluster I 
CAGL0K00715g RTA1 YLR046C 1.77 2.45 
 
-1.20 -1.27 Putative protein involved in 7-aminocholesterol resistance; gene 
is upregulated in azole-resistant strain 
CAGL0J05544g 
 
END3 1.77 1.61 
 
1.45 2.65 Ortholog(s) have protein binding, bridging activity, role in 
ascospore wall assembly, endocytosis and mating projection tip 
localization 
CAGL0A02728g 
 
SEM1 1.77 2.07 
 
1.05 1.45 Ortholog(s) have role in SAGA complex localization to 
transcription regulatory region, exocytosis, filamentous growth, 
histone deubiquitination and mRNA export from nucleus, more 
CAGL0F03025g 
 
ARO80 1.76 2.84 
 
1.47 2.19 Ortholog(s) have sequence-specific DNA binding, sequence-
specific DNA binding RNA polymerase II transcription factor 
activity 
CAGL0D03894g PRO1 YHR033W 1.76 2.04 
 
1.44 2.44 Putative gamma-glutamyl phosphate reductase 
CAGL0J05632g 
 
RHO2 1.76 1.55 
 
1.18 1.83 Ortholog(s) have GTPase activity and role in establishment or 
maintenance of actin cytoskeleton polarity, establishment or 
maintenance of cell polarity regulating cell shape, regulation of 
alpha-glucan biosynthetic process 
CAGL0L01067g 
 
PAR32 1.76 1.80 
 
1.56 1.90 Ortholog(s) have cytoplasm localization 
CAGL0L04664g HEM15 HEM15 1.76 2.03 
 
1.91 2.72 Ortholog(s) have ferrochelatase activity, role in heme biosynthetic 
process and cytosol, mitochondrial inner membrane, nucleus 
localization 
CAGL0J03190g 
 
TDA2 1.76 2.04 
 
1.50 2.52 Ortholog(s) have cytoplasm, mating projection tip localization 
CAGL0G08844g 
 
ASG1 1.74 1.91 
 
1.28 1.37 Ortholog(s) have sequence-specific DNA binding activity 
CAGL0J05984g AAH1 1.74 2.08 1.56 -1.76 Ortholog(s) have adenine deaminase activity, role in adenine 
catabolic process, cell-abiotic substrate adhesion, hypoxanthine 
salvage and cytosol, nucleus localization 
CAGL0H07337g 
  
1.73 2.07 
 
2.13 1.08 Protein of unknown function 
CAGL0L03846g 
 
DBP2 1.73 3.18 
 
1.41 -1.41 Ortholog(s) have ATP-dependent RNA helicase activity 
CAGL0A02772g 
 
CDC40 1.73 1.53 
 
1.13 -1.18 Ortholog(s) have second spliceosomal transesterification activity 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0J10846g 
 
PCL5 1.73 3.79 
 
1.58 2.40 Ortholog(s) have cyclin-dependent protein serine/threonine kinase 
regulator activity 
CAGL0K01947g 
 
YER137C 1.73 1.74 
 
-1.47 1.22 Has domain(s) with predicted nucleic acid binding, zinc ion 
binding activity 
CAGL0H06699g 
 
GUT2 1.72 2.34 
 
1.40 3.22 Ortholog(s) have glycerol-3-phosphate dehydrogenase activity, 
role in NADH oxidation, glycerol metabolic process, replicative 
cell aging and integral component of mitochondrial outer 
membrane, plasma membrane localization 
CAGL0L09911g 
 
CSS1 1.72 1.75 
 
1.65 1.41 Putative adhesin-like cell wall protein; 5 tandem repeats; 
predicted GPI-anchor 
CAGL0F01419g AUS1 AUS1 1.72 1.90 
 
1.76 1.18 ATP-binding cassette transporter involved in sterol uptake 
CAGL0H02387g 
  
1.72 1.56 
 
1.81 7.46 Putative trehalose-6-phosphate synthase/phosphatase subunit; gene 
is upregulated in azole-resistant strain 
CAGL0I05874g 
  
1.71 3.92 
 
1.32 3.54 Haloacid dehalogenase-like hydrolase 
CAGL0K04697g 
 
STP3 1.71 1.63 
 
1.20 1.48 Ortholog(s) have sequence-specific DNA binding activity, role in 
filamentous growth and nucleus localization 
CAGL0D06512g 
 
CDC25 1.70 2.01 
 
1.69 3.70 Putative membrane bound guanine nucleotide exchange factor; gene 
is upregulated in azole-resistant strain 
CAGL0J08316g 
 
MET2 1.70 2.86 
 
1.68 4.52 Ortholog(s) have homoserine O-acetyltransferase activity, role in 
homoserine metabolic process, methionine biosynthetic process, 
regulation of DNA methylation and cytosol localization 
CAGL0K09680g 
 
FYV6 1.69 1.55 
 
1.77 1.14 Ortholog(s) have role in double-strand break repair via 
nonhomologous end joining and nucleus localization 
CAGL0F06897g 
 
YIR035C 1.69 1.67 
 
1.56 1.05 Putative protein with alcohol dehydrogenase domain; gene is 
downregulated in azole-resistant strain 
CAGL0M05665g PBI2 1.69 1.94 1.10 3.43 Ortholog(s) have endopeptidase inhibitor activity, role in 
regulation of proteolysis, vacuole fusion, non-autophagic and 
fungal-type vacuole, nucleus localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0D04246g 
 
VPS20 1.69 2.43 
 
1.43 1.90 Ortholog(s) have role in cellular response to lithium ion, cellular 
response to pH, filamentous growth of a population of 
unicellular organisms in response to neutral pH and 
intralumenal vesicle formation, more 
CAGL0L02453g 
  
1.69 1.52 
 
1.26 1.67 Protein of unknown function 
CAGL0M02343g 
 
ATG5 1.68 2.37 
 
1.69 1.83 Ortholog(s) have Atg8 ligase activity, enzyme activator activity 
CAGL0E03762g 
 
RIM101 1.68 2.11 
 
1.83 2.24 Ortholog(s) have RNA polymerase II core promoter proximal region 
sequence-specific DNA binding transcription factor activity 
involved in negative regulation of transcription, sequence-specific 
DNA binding activity 
CAGL0H10384g 
 
RRP42 1.68 1.58 
 
1.64 1.05 Ortholog(s) have role in exonucleolytic trimming to generate 
mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript 
(SSU-rRNA, 5.8S rRNA, LSU-rRNA), nuclear polyadenylation-
dependent tRNA catabolic process, rRNA catabolic process 
CAGL0J00429g COX6 COX6 1.68 2.34 
 
1.38 2.82 Cytochrome c oxidase subunit VI 
CAGL0F03047g 
 
SIP1 1.68 2.61 
 
1.52 3.12 Ortholog(s) have AMP-activated protein kinase activity, receptor 
signaling complex scaffold activity 
CAGL0C02623g 
 
COX8 1.68 3.17 
 
2.79 3.13 Ortholog(s) have cytochrome-c oxidase activity, role in 
mitochondrial electron transport, cytochrome c to oxygen and 
mitochondrial respiratory chain complex IV, plasma membrane 
localization 
CAGL0A00451g PDR1 PDR1 1.68 2.66 
 
-10.23 -5.16 Zinc finger transcription factor, activator of drug resistance 
genes via pleiotropic drug response elements (PDRE); regulates 
drug efflux pumps and controls multi-drug resistance; gene 
upregulated and/or mutated in azole-resistant strains 
CAGL0L07238g RPN6 1.67 2.21 1.23 1.68 Ortholog(s) have structural molecule activity, role in 
proteasome assembly, ubiquitin-dependent protein catabolic 
process and nucleus, proteasome regulatory particle, lid 
subcomplex, proteasome storage granule localization 
CAGL0G02717g 
 
SGA1 1.67 1.75 
 
1.60 2.72 Ortholog(s) have glucan 1,4-alpha-glucosidase activity, role in 
glycogen catabolic process and Golgi apparatus, endoplasmic 
reticulum, fungal-type vacuole, prospore membrane localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0D01837g 
  
1.67 3.00 
 
-1.50 2.50 Unknown 
CAGL0J06088g 
 
YNL162W-A 1.67 2.20 
 
1.44 2.60 Ortholog(s) have cytoplasm, nucleus localization 
CAGL0E04004g 
 
MUP3 1.66 2.17 
 
1.41 3.03 Ortholog(s) have L-methionine transmembrane transporter 
activity and role in methionine import 
CAGL0J08184g 
 
CAN1 1.66 1.67 
 
1.28 2.51 Ortholog(s) have arginine transmembrane transporter activity, 
role in arginine transport, transmembrane transport and 
membrane raft, mitochondrion, plasma membrane localization 
CAGL0D05082g 
 
UBI4 1.65 1.82 
 
1.24 8.37 Ortholog(s) have protein tag activity and role in cell 
morphogenesis, cellular response to heat, filamentous growth of 
a population of unicellular organisms, pathogenesis, phenotypic 
switching, protein ubiquitination 
CAGL0G01969g 
 
VHS3 1.65 1.63 
 
1.38 -1.85 Ortholog(s) have phosphopantothenoylcysteine decarboxylase 
activity, protein phosphatase inhibitor activity and role in 
cellular monovalent inorganic cation homeostasis 
CAGL0I03366g 
 
FAP7 1.65 1.93 
 
1.78 -1.50 Ortholog(s) have ATP binding, nucleoside-triphosphatase 
activity 
CAGL0D02420g 
 
SRN2 1.65 1.68 
 
1.38 2.44 Ortholog(s) have role in protein targeting to membrane, protein 
targeting to vacuole and ESCRT I complex localization 
CAGL0I00110g 
  
1.64 1.56 
 
1.65 2.31 Putative adhesin-like with multiple tandem repeats; ORF appears 
artificially broken into fragments due to sequencing errors; belongs 
to adhesin cluster III; predicted GPI-anchor 
CAGL0H02343g 
 
SAP30 1.64 2.09 
 
1.73 2.05 Ortholog(s) have histone deacetylase activity 
CAGL0L10186g 
 
TMC1 1.64 3.33 
 
1.82 6.54 Putative stress-induced protein; gene is upregulated in azole-
resistant strain 
CAGL0L00935g APQ12 APQ12 1.64 1.86 1.48 1.61 Ortholog(s) have role in cellular lipid metabolic process, mRNA 
export from nucleus, nuclear envelope organization and 
endoplasmic reticulum, nuclear envelope localization 
CAGL0A02233g HXT4/6/7 
 
1.64 3.14 
 
1.12 3.04 Has domain(s) with predicted substrate-specific transmembrane 
transporter activity, transmembrane transporter activity, role in 
transmembrane transport and integral component of 
membrane, membrane localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0K04257g 
 
RME1|VMA9 1.63 2.55 
 
1.83 4.43 Ortholog(s) have ATPase activity, coupled to transmembrane 
movement of ions, RNA polymerase II core promoter proximal 
region sequence-specific DNA binding, sequence-specific DNA 
binding RNA polymerase II transcription factor activity 
CAGL0A02211g HXT6/7 
 
1.62 2.42 
 
1.02 2.87 Has domain(s) with predicted substrate-specific transmembrane 
transporter activity, transmembrane transporter activity, role in 
transmembrane transport and integral component of 
membrane, membrane localization 
CAGL0H09328g 
 
QCR9 1.62 2.36 
 
-1.03 3.02 Ortholog(s) have ubiquinol-cytochrome-c reductase activity and 
role in aerobic respiration, iron-sulfur cluster assembly, 
mitochondrial electron transport, ubiquinol to cytochrome c 
CAGL0E05456g 
  
1.62 1.90 
 
1.77 -3.60 Has domain(s) with predicted DNA binding activity 
CAGL0J09306g 
 
VCX1 1.62 1.68 
 
1.33 2.78 Ortholog(s) have calcium:proton antiporter activity, 
potassium:proton antiporter activity and role in calcium ion 
transport, cellular calcium ion homeostasis, transmembrane 
transport 
CAGL0G03531g 
 
SPR6 1.62 1.61 
 
1.32 -1.01 Ortholog(s) have mitochondrion localization 
CAGL0L09086g 
 
CIT3 1.61 1.76 
 
1.13 1.50 Ortholog(s) have 2-methylcitrate synthase activity, citrate (Si)-
synthase activity, role in propionate catabolic process, 2-
methylcitrate cycle, tricarboxylic acid cycle and mitochondrion 
localization 
CAGL0L09185g 
 
YFR006W 1.61 2.15 
 
1.15 1.66 Ortholog(s) have cytoplasm localization 
CAGL0D05522g 
 
EMC6 1.60 1.96 
 
1.06 1.30 Ortholog(s) have role in protein folding in endoplasmic 
reticulum and ER membrane protein complex localization 
CAGL0L01485g GSF2 1.60 2.52 1.19 2.54 Putative protein of the ER membrane involved in hexose 
transporter secretion; gene is upregulated in azole-resistant 
strain 
CAGL0H00286g 
 
YPR172W 1.60 2.28 
 
1.10 1.29 Ortholog(s) have cytoplasm, nucleus localization 
CAGL0K10604g 
 
CMK2 1.60 2.03 
 
1.25 2.00 Ortholog(s) have calmodulin-dependent protein kinase activity, 
role in cellular response to oxidative stress, fungal-type cell wall 
organization, protein phosphorylation and cytoplasm 
localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0C02233g 
 
MXR1 1.60 3.51 
 
1.84 3.86 Ortholog(s) have L-methionine-(S)-S-oxide reductase activity, 
peptide-methionine (S)-S-oxide reductase activity and role in L-
methionine biosynthetic process from methionine sulphoxide, 
cellular response to hydrogen peroxide 
CAGL0F03135g 
 
RPN9 1.60 2.26 
 
1.52 2.33 Ortholog(s) have structural molecule activity, role in proteasome 
assembly, ubiquitin-dependent protein catabolic process and 
nucleus, proteasome regulatory particle, lid subcomplex, proteasome 
storage granule localization 
CAGL0M11473g 
  
1.60 2.22 
 
1.40 -2.25 Unknown 
CAGL0M08404g 
 
TPK3 1.60 2.02 
 
1.46 -1.18 Ortholog(s) have cAMP-dependent protein kinase activity and 
role in Ras protein signal transduction, mitochondrion 
organization, protein kinase A signaling, protein 
phosphorylation 
CAGL0G05467g 
 
GCR2 1.59 1.79 
 
1.14 2.87 Ortholog(s) have RNA polymerase II activating transcription 
factor binding, RNA polymerase II transcription factor binding 
transcription factor activity 
CAGL0A04829g 
  
1.59 3.18 
 
1.20 5.49 Putative hexokinase isoenzyme 2; protein differentially 
expressed in azole-resistant strain 
CAGL0G04807g 
 
VAM3 1.58 1.68 
 
1.17 2.11 Ortholog(s) have SNAP receptor activity 
CAGL0L06204g 
 
COX13 1.58 1.90 
 
1.18 2.36 Ortholog(s) have cytochrome-c oxidase activity, enzyme 
regulator activity, role in aerobic respiration, mitochondrial 
respiratory chain supercomplex assembly and mitochondrial 
respiratory chain complex IV, plasma membrane localization 
CAGL0H08844g 
 
DDR48 1.58 1.66 
 
1.60 15.23 Putative adhesin-like protein 
CAGL0F04477g PRE7 1.58 2.17 1.49 2.21 Ortholog(s) have role in proteasomal ubiquitin-independent 
protein catabolic process, proteasome-mediated ubiquitin-
dependent protein catabolic process and cytosol, nucleus, 
proteasome core complex, beta-subunit complex localization 
CAGL0C05489g 
 
GYP7 1.57 1.75 
 
1.29 2.36 Ortholog(s) have GTPase activator activity, role in regulation of 
vacuole fusion, non-autophagic, vesicle-mediated transport and 
cytosol, nucleus localization 
CAGL0C03916g 
  
1.57 1.65 
 
1.31 2.13 Has domain(s) with predicted role in protein glycosylation 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0H07997g KNH1 KNH1 1.57 1.83 
 
1.50 1.42 Protein involved in cell wall beta 1,6-glucan synthesis, similar to 
Kre9p 
CAGL0B00858g 
 
STE50 1.57 3.01 
 
1.54 3.77 Ortholog(s) have SAM domain binding, protein kinase regulator 
activity 
CAGL0J07216g 
 
RAD17 1.57 2.11 
 
1.25 1.75 Ortholog(s) have double-stranded DNA binding activity and 
role in double-strand break repair, intra-S DNA damage 
checkpoint, mitotic DNA replication checkpoint, mitotic G2 
DNA damage checkpoint, reciprocal meiotic recombination 
CAGL0G04543g 
 
VPS60 1.57 1.93 
 
1.70 1.78 Ortholog(s) have role in cellular response to drug, filamentous 
growth, late endosome to vacuole transport via multivesicular body 
sorting pathway and fungal-type vacuole membrane localization 
CAGL0L06754g 
 
SUP45 1.56 1.72 
 
1.39 -1.25 Ortholog(s) have translation release factor activity, codon 
specific activity and role in DNA-templated transcription, 
termination, asexual sporulation resulting in formation of a 
cellular spore, cytoplasmic translational termination 
CAGL0D06688g ALD4 ALD4 1.56 2.12 
 
1.27 3.89 Ortholog(s) have aldehyde dehydrogenase (NAD) activity, 
aldehyde dehydrogenase [NAD(P)+] activity and role in NADPH 
regeneration, acetate biosynthetic process, ethanol metabolic 
process, pyruvate metabolic process 
CAGL0I00836g 
  
1.56 1.59 
 
1.29 3.38 Ortholog(s) have Golgi apparatus, endoplasmic reticulum, 
fungal-type vacuole membrane localization 
CAGL0G02893g 
 
POS5 1.55 1.69 
 
1.55 1.95 Ortholog(s) have NADH kinase activity, role in NADP biosynthetic 
process, cellular response to oxidative stress and mitochondrial 
matrix localization 
CAGL0D06402g MET15 MET17 1.55 2.23 1.81 6.58 O-acetyl homoserine sulfhydrylase (OAHSH), ortholog of S. 
cerevisiae MET17; required for utilization of inorganic sulfate as 
sulfur source; able to utilize cystine as a sulfur source while S. 
cerevisiae met15 mutants are unable to do so 
CAGL0F06941g PYC1 
 
1.55 2.89 
 
1.60 4.48 Putative pyruvate carboxylase isoform; gene is upregulated in azole-
resistant strain 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0K04103g 
 
CAX4 1.55 1.70 
 
1.17 1.27 Ortholog(s) have dolichyldiphosphatase activity, role in lipid 
biosynthetic process, protein N-linked glycosylation and integral 
component of endoplasmic reticulum membrane localization 
CAGL0I09702g 
 
MCH5 1.55 1.76 
 
1.70 1.14 Ortholog(s) have riboflavin transporter activity, role in 
riboflavin transport and plasma membrane localization 
CAGL0L03289g 
  
1.55 1.87 
 
1.37 -1.15 Protein of unknown function 
CAGL0K10868g CTA1 CTA1 1.54 1.64 
 
1.97 4.66 Putative catalase A; gene is downregulated in azole-resistant strain; 
regulated by oxidative stress and glucose starvation; protein 
abundance increased in ace2 mutant cells 
CAGL0E01881g YPS11 
 
1.54 1.97 
 
1.50 3.48 Putative aspartic protease; member of a YPS gene cluster that is 
required for virulence in mice; induced in response to low pH and 
high temperature 
CAGL0F01243g 
 
MDM38 1.53 2.05 
 
1.24 2.67 Ortholog(s) have ribosome binding activity 
CAGL0M05445g 
 
COS111 1.53 1.59 
 
1.30 2.99 Ortholog(s) have role in signal transduction and mitochondrion 
localization 
CAGL0H05379g 
 
GCR1 1.53 1.82 
 
1.10 -1.46 Ortholog(s) have RNA polymerase II core promoter proximal 
region sequence-specific DNA binding, more 
CAGL0B03443g 
 
MCP2 1.53 1.68 
 
1.35 3.50 Ortholog(s) have role in lipid homeostasis, mitochondrion 
organization and integral component of mitochondrial 
membrane, mitochondrial inner membrane localization 
CAGL0D02156g 
 
GNA1 1.53 1.92 
 
1.20 2.24 Ortholog(s) have glucosamine 6-phosphate N-acetyltransferase 
activity, role in UDP-N-acetylglucosamine biosynthetic process, 
pathogenesis and cytosol, nucleus localization 
CAGL0J02530g 
  
1.53 2.27 
 
1.92 4.41 Putative adhesion protein; predicted GPI-anchor; belongs to adhesin 
cluster VI 
CAGL0F00605g GLK1 EMI2 1.53 2.89 
 
1.16 7.91 Aldohexose specific glucokinase 
CAGL0J04048g 1.53 1.67 1.47 1.83 Has domain(s) with predicted iron ion binding, iron-sulfur 
cluster binding activity and role in iron-sulfur cluster assembly 
CAGL0L08932g LSP1 LSP1 1.53 1.89 
 
1.29 2.90 Long chain base-responsive inhibitor of protein kinases; protein 
abundance decreased in ace2 mutant cells 
CAGL0L04378g 
 
PNS1 1.53 1.50 
 
1.36 2.09 Ortholog(s) have plasma membrane localization 
 
 130 
Table B-1. (Continued). 
 
C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0K06985g 
 
ERT1 1.53 2.17 
 
1.58 1.09 Ortholog(s) have RNA polymerase II core promoter proximal 
region sequence-specific DNA binding transcription factor 
activity involved in negative regulation of transcription, more 
CAGL0J04554g 
  
1.53 4.11 
 
1.77 5.72 Has domain(s) with predicted catalytic activity, pyridoxal phosphate 
binding, transaminase activity and role in biosynthetic process, 
cellular amino acid metabolic process 
CAGL0F04741g 
  
1.53 1.67 
 
1.32 3.32 Ortholog(s) have calmodulin binding, calmodulin-dependent 
protein kinase activity 
CAGL0K10824g 
 
YLR149C 1.52 1.52 
 
1.11 2.58 Ortholog of S. cerevisiae : YLR149C, C. albicans SC5314 : 
C7_03280C_A, C. dubliniensis CD36 : Cd36_72930, C. 
parapsilosis CDC317 : CPAR2_704080 and Candida tenuis 
NRRL Y-1498 : CANTEDRAFT_112372 
CAGL0H09768g 
 
FMP52 1.52 2.79 
 
1.13 1.73 Ortholog(s) have endoplasmic reticulum, mitochondrial outer 
membrane localization 
CAGL0F02717g PDH1 PDR15 1.51 2.15 
 
-1.17 5.10 Multidrug transporter, predicted plasma membrane ATP-
binding cassette (ABC) transporter; regulated by Pdr1p; 
involved in fluconazole resistance 
CAGL0M12837g 
 
SER33 1.51 1.77 
 
1.58 2.09 Ortholog(s) have phosphoglycerate dehydrogenase activity, role in 
serine family amino acid biosynthetic process and cytosol 
localization 
CAGL0D00198g 
 
BDH1 1.51 2.46 
 
1.08 4.59 Ortholog(s) have (R,R)-butanediol dehydrogenase activity, role 
in butanediol biosynthetic process and cytoplasm localization 
CAGL0G01672g 
 
RPN7 1.51 1.56 
 
1.35 1.95 Ortholog(s) have structural molecule activity, role in positive 
regulation of mitotic metaphase/anaphase transition and cytosol, 
nucleus, proteasome regulatory particle, lid subcomplex 
localization 
CAGL0L05390g ARC19 1.51 1.77 1.46 2.43 Ortholog(s) have structural molecule activity and role in Arp2/3 
complex-mediated actin nucleation, actin cortical patch 
assembly, cellular response to drug, spore germination 
CAGL0E00231g 
  
1.51 2.26 
 
1.60 -1.06 Putative adhesin-like protein; contains tandem repeats and a 
predicted GPI-anchor; belongs to adhesin cluster III 
CAGL0D03234g 
  
1.50 1.97 
 
1.15 2.50 Has domain(s) with predicted phosphatase activity 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0B03047g ILV5 ILV5 1.50 1.76 
 
1.44 3.06 Ketol-acid reducto-isomerase; mass spectrometry data indicates 
this gene is likely to be protein-coding 
CAGL0I10200g PWP3 
 
1.50 1.93 
 
1.33 2.58 Protein with tandem repeats; putative adhesin-like protein; 
belongs to adhesin cluster II 
CAGL0K06380g 
  
1.50 3.08 
 
1.64 5.25 Unknown 
CAGL0E02937g 
 
CGR1 1.50 2.75 
 
1.92 1.75 Ortholog(s) have role in cellular response to drug, rRNA processing 
and nucleolus, preribosome, large subunit precursor localization 
CAGL0B00374g 
 
ADF1 1.50 2.67 
 
1.50 1.17 Ortholog(s) have RNA polymerase II regulatory region DNA 
binding activity 
CAGL0I05434g 
 
TOA2 1.50 2.41 
 
-1.56 -1.55 Ortholog(s) have TBP-class protein binding, TBP-class protein 
binding RNA polymerase II transcription factor activity 
involved in preinitiation complex assembly activity 
 
Notes: Fold change is defined as the ratio of gene expression in SM1∆jjj1 compared to SM1 in two independent RNA-seq 
experiments. Bolded rows indicate genes whose up-regulation is dependent on PDR1 expression. 
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Table B-2. Genes down-regulated by at least 1.5-fold in SM1∆jjj1 versus SM1. 
 
C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0J07370g 
 
JJJ1 -19.95 -12.84 
 
-12.67 -11.37 Ortholog(s) have ATPase activator activity and role in 
endocytosis, rRNA processing, regulation of cell size, ribosomal 
large subunit biogenesis, ribosomal large subunit export from 
nucleus 
CAGL0B02651g 
 
MET31 -10.00 -1.57 
 
-3.33 -1.83 Ortholog(s) have core promoter proximal region sequence-specific 
DNA binding, sequence-specific transcription regulatory region 
DNA binding RNA polymerase II transcription factor recruiting 
transcription factor activity 
CAGL0L01023g 
  
-8.00 -2.33 
 
-2.00 1.29 Protein of unknown function 
CAGL0B02475g PHO84 PHO84 -7.70 -3.75 
 
-2.99 -1.12 Ortholog(s) have inorganic phosphate transmembrane 
transporter activity, manganese ion transmembrane 
transporter activity, phosphate:proton symporter activity, 
selenite:proton symporter activity 
CAGL0M07359g 
 
LEE1 -7.00 -1.71 
 
1.14 1.08 Has domain(s) with predicted nucleic acid binding, zinc ion 
binding activity 
CAGL0F00116g 
  
-6.00 -1.80 
 
-2.00 -2.25 Protein of unknown function 
CAGL0L11990g 
 
GRX4 -5.46 -2.90 
 
-2.37 2.36 Ortholog(s) have RNA polymerase II activating transcription 
factor binding, disulfide oxidoreductase activity 
CAGL0M10912g 
 
HUB1 -5.00 -1.50 
 
-1.67 1.17 Ortholog(s) have protein tag activity, role in cell 
morphogenesis involved in conjugation with cellular fusion, 
cellular protein modification process, mRNA cis splicing, via 
spliceosome and cytosol, mating projection, nucleus 
localization 
CAGL0I01936g 
 
SPO16 -4.67 -4.67 
 
-1.75 -1.40 Ortholog(s) have role in ascospore formation, positive 
regulation of protein sumoylation, regulation of reciprocal 
meiotic recombination, synaptonemal complex assembly and 
condensed nuclear chromosome localization 
CAGL0J00451g -4.61 -2.04 -2.64 1.81 Putative glyceraldehyde-3-phosphate dehydrogenase; protein 
differentially expressed in azole-resistant strain; expression 
downregulated in biofilm vs planktonic cell culture 
CAGL0K01529g 
 
SLM3 -4.41 -2.62 
 
-2.27 -1.74 Ortholog(s) have tRNA (5-methylaminomethyl-2-thiouridylate)-
methyltransferase activity, role in mitochondrial tRNA thio-
modification and mitochondrion localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0G00105g 
  
-4.33 -1.50 
 
-1.30 -3.75 Protein of unknown function 
CAGL0G08734g 
 
RPL9B -4.27 -4.10 
 
-4.02 -3.89 Ortholog(s) have structural constituent of ribosome activity, role in 
cytoplasmic translation and cytosolic large ribosomal subunit, 
nucleus localization 
CAGL0A03102g ARO10 ARO10 -4.17 -3.41 
 
-2.15 -3.11 Ortholog(s) have phenylpyruvate decarboxylase activity 
CAGL0M00308g 
  
-4.00 -6.00 
 
-2.00 1.00 Protein of unknown function 
CAGL0D00105g 
  
-4.00 -2.00 
 
-1.71 -1.14 Protein of unknown function 
CAGL0D00869g 
  
-4.00 -1.75 
 
1.00 -3.50 Unknown 
CAGL0F09141g 
  
-4.00 -1.67 
 
-4.00 1.40 Protein of unknown function 
CAGL0G06050g 
  
-3.95 -3.59 
 
-1.79 3.97 Protein of unknown function 
CAGL0L13431g 
  
-3.92 -2.38 
 
-2.32 -7.13 Unknown 
CAGL0H06809g 
 
VPS51 -3.75 -2.14 
 
1.07 1.33 Putative component of Golgi-associated retrograde protein 
complex; gene is upregulated in azole-resistant strain 
CAGL0M00792g 
  
-3.71 -1.90 
 
-1.86 -2.11 Protein of unknown function 
CAGL0J09174g 
 
YDL186W -3.50 -2.00 
 
-1.75 -1.33 Ortholog of S. cerevisiae : YDL186W and Saccharomyces 
cerevisiae S288C : YDL186W 
CAGL0A00627g 
 
ERP6 -3.42 -2.69 
 
-2.93 -2.06 Ortholog(s) have role in ER to Golgi vesicle-mediated transport 
and mitochondrion localization 
CAGL0G00946g 
 
ERV1 -3.30 -9.75 
 
-1.43 -3.90 Ortholog(s) have flavin-linked sulfhydryl oxidase activity and 
role in cellular iron ion homeostasis, cellular response to 
oxidative stress, protein import into mitochondrial 
intermembrane space 
CAGL0C00110g EPA6 -3.08 -1.55 -3.35 1.11 Sub-telomerically encoded adhesin with a role in cell adhesion; 
binds to ligands containing a terminal galactose residue; 
expressed during murine urinary tract infection, biofilm-
upregulated; belongs to adhesin cluster I 
CAGL0I03520g 
 
YDL157C -3.00 -2.20 
 
-1.29 1.00 Ortholog(s) have mitochondrion localization 
CAGL0I02068g 
 
REC104 -3.00 -2.00 
 
1.17 1.17 Ortholog(s) have role in reciprocal meiotic recombination and 
condensed nuclear chromosome localization 
CAGL0I10010g 
 
CUR1 -2.91 -3.70 
 
-1.60 1.00 Ortholog(s) have chaperone binding activity, role in cellular 
response to heat, intracellular protein transport, protein 
folding, protein localization to nucleus and nucleus localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0F08767g 
  
-2.88 -1.81 
 
-3.29 -1.71 Protein of unknown function 
CAGL0E04092g SIT1 ARN1 -2.85 -5.53 
 
-2.11 -2.94 Putative siderophore-iron transporter with 14 transmembrane 
domains; required for iron-dependent survival in macrophages; 
mRNA levels elevated under iron deficiency conditions; plasma 
membrane localized 
CAGL0I01914g 
  
-2.80 -3.00 
 
-1.40 1.13 Protein of unknown function 
CAGL0D00116g 
  
-2.80 -2.38 
 
-1.40 -1.58 Protein of unknown function 
CAGL0A04389g 
 
CMC2 -2.78 -1.95 
 
-1.61 1.68 Ortholog(s) have role in mitochondrial respiratory chain 
complex assembly and mitochondrial intermembrane space, 
nucleus localization 
CAGL0F07755g CEP3 CEP3 -2.72 -1.60 
 
1.03 -1.89 Centromere binding factor 3b; inner kinetochore protein 
CAGL0J11979g 
  
-2.67 -2.83 
 
1.00 -1.89 Protein of unknown function 
CAGL0M04620g 
  
-2.67 -2.40 
 
-1.14 1.25 Unknown 
CAGL0L13376g 
  
-2.66 -6.68 
 
-2.69 -2.14 Unknown 
CAGL0A01243g GIT1 
 
-2.65 -3.09 
 
-2.29 1.01 Has domain(s) with predicted transmembrane transporter 
activity, role in transmembrane transport and integral 
component of membrane localization 
CAGL0I01232g 
 
ERP5 -2.60 -5.88 
 
-2.29 -5.88 Has domain(s) with predicted role in transport and integral 
component of membrane localization 
CAGL0L11286g 
 
SMA2 -2.57 -1.62 
 
-1.29 -1.42 Ortholog(s) have role in ascospore wall assembly, spore 
membrane bending pathway and cytoplasm, prospore 
membrane localization 
CAGL0F00176g 
  
-2.50 -3.00 
 
-1.36 1.00 Unknown 
CAGL0H08624g 
 
MCM16 -2.50 -2.67 
 
-1.88 -1.28 Ortholog(s) have role in establishment of mitotic sister 
chromatid cohesion and condensed nuclear chromosome 
kinetochore localization 
CAGL0F05709g ATC1 -2.50 -1.78 -2.36 -1.63 Ortholog(s) have role in bipolar cellular bud site selection, cellular 
cation homeostasis and cytoplasm, nucleus localization 
CAGL0C04917g 
 
CPA2 -2.49 -2.19 
 
-2.18 1.07 Ortholog(s) have carbamoyl-phosphate synthase (glutamine-
hydrolyzing) activity, role in arginine biosynthetic process and 
carbamoyl-phosphate synthase complex, mitochondrion 
localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0I09856g 
 
SFG1 -2.40 -2.93 
 
-2.73 -2.12 Ortholog(s) have role in mitotic cell cycle, pseudohyphal growth 
and cytoplasm, nucleus localization 
CAGL0F05951g 
 
IMP2 -2.38 -1.65 
 
-1.29 -1.22 Ortholog(s) have endopeptidase activity, role in protein 
processing involved in protein targeting to mitochondrion and 
mitochondrial inner membrane peptidase complex localization 
CAGL0H07139g 
 
MCM21 -2.36 -1.57 
 
-1.51 1.29 Ortholog(s) have role in establishment of mitotic sister 
chromatid cohesion and COMA complex localization 
CAGL0G02387g 
 
PXL1 -2.36 -2.55 
 
-1.33 -1.88 Ortholog(s) have Rho GDP-dissociation inhibitor activity and 
role in maintenance of cell polarity, regulation of Rho protein 
signal transduction 
CAGL0A03740g 
 
POX1 -2.36 -1.61 
 
-1.82 1.14 Ortholog(s) have role in fatty acid beta-oxidation, long-chain 
fatty acid catabolic process and peroxisomal matrix 
localization 
CAGL0F00110g AWP10 
 
-2.35 -1.68 
 
-2.30 -1.25 Putative adhesin-like protein; GPI-anchored; belongs to 
adhesin cluster V; ORF appears artificially broken into 
fragments due to sequencing errors but the gene is likely 
protein-coding based on mass spectrometry data 
CAGL0K08602g 
 
SLD2 -2.33 -2.50 
 
-1.93 -1.25 Ortholog(s) have DNA replication origin binding, single-
stranded DNA binding activity 
CAGL0F02849g 
 
RRP17 -2.33 -2.29 
 
-1.91 -2.00 Ortholog(s) have role in rRNA processing and cytoplasm 
localization 
CAGL0M05533g DUR1,2 DUR1,2 -2.31 -1.98 
 
-2.43 -1.40 Ortholog(s) have allophanate hydrolase activity, urea 
carboxylase activity, role in cellular response to alkaline pH, 
nitrogen utilization, pathogenesis, urea catabolic process and 
cytoplasm localization 
CAGL0K00781g 
 
YGR210C -2.29 -2.35 
 
-2.83 -10.80 Ortholog(s) have cytosol, nucleus localization 
CAGL0H03025g PAN2 -2.28 -2.25 -2.84 -1.32 Ortholog(s) have poly(A)-specific ribonuclease activity, role in 
nuclear-transcribed mRNA poly(A) tail shortening, 
postreplication repair and PAN complex localization 
CAGL0A03828g 
 
RAX1 -2.27 -3.09 
 
-1.37 -1.42 Ortholog(s) have role in cellular bud site selection and cellular 
bud neck, endoplasmic reticulum localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0M06193g 
 
SWD3 -2.26 -2.23 
 
-1.43 -1.98 Ortholog(s) have histone methyltransferase activity (H3-K4 
specific) activity, role in chromatin silencing at telomere, 
histone H3-K4 methylation, telomere maintenance and 
Set1C/COMPASS complex localization 
CAGL0D06336g 
 
TYW3 -2.25 -2.15 
 
-1.13 -1.65 Ortholog(s) have tRNA methyltransferase activity, role in 
tRNA methylation, wybutosine biosynthetic process and 
cytosol, nucleus localization 
CAGL0K03619g 
 
SPC24 -2.25 -2.13 
 
-2.25 -1.42 Ortholog(s) have structural constituent of cytoskeleton 
activity, role in chromosome segregation, microtubule 
nucleation and Ndc80 complex, condensed nuclear 
chromosome kinetochore localization 
CAGL0C02211g UTR2 UTR2 -2.22 -3.18 
 
-2.28 -2.27 Putative glycoside hydrolase of the Crh family; predicted GPI-
anchor 
CAGL0C05115g ARG1 ARG1 -2.19 -1.86 
 
-2.10 -1.08 Argininosuccinate synthetase 
CAGL0B04675g 
 
YCL001W-B -2.19 -4.43 
 
-3.13 1.12 Has domain(s) with predicted role in RNA surveillance, 
nuclear-transcribed mRNA catabolic process, no-go decay, 
nuclear-transcribed mRNA catabolic process, non-stop decay 
CAGL0K09570g 
  
-2.17 -1.70 
 
-1.67 -2.50 Has domain(s) with predicted phosphotransferase activity, for 
other substituted phosphate groups activity, role in phospholipid 
biosynthetic process and membrane localization 
CAGL0I08613g DUR3 
 
-2.15 -3.10 
 
-2.17 -5.69 Putative plasma membrane polyamine transporter 
CAGL0J06402g 
  
-2.14 -1.77 
 
-1.55 1.04 Has domain(s) with predicted catalytic activity, homocitrate 
synthase activity and role in lysine biosynthetic process via 
aminoadipic acid 
CAGL0L12782g 
 
DIG1 -2.12 -1.59 
 
-1.85 -5.36 Ortholog(s) have DNA binding, transcription factor binding 
activity 
CAGL0B02717g ACS2 -2.11 -2.52 -1.96 -2.36 Ortholog(s) have acetate-CoA ligase activity, acid-ammonia (or 
amide) ligase activity and role in acetate catabolic process, acetyl-
CoA biosynthetic process, carbon utilization, histone acetylation, 
replicative cell aging 
CAGL0L01243g 
 
GDA1 -2.11 -1.92 
 
-2.01 -4.86 Ortholog(s) have guanosine-diphosphatase activity, uridine-
diphosphatase activity 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0L10648g 
 
CLN2 -2.10 -3.71 
 
-1.91 -1.39 Ortholog(s) have cyclin-dependent protein serine/threonine 
kinase regulator activity 
CAGL0J00968g 
  
-2.09 -2.69 
 
-1.71 -1.75 Unknown 
CAGL0M08602g 
 
CCC2 -2.09 -1.63 
 
-1.78 -1.38 Ortholog(s) have cation-transporting ATPase activity, copper 
ion binding activity and role in cellular iron ion homeostasis, 
copper ion export, pigment metabolic process involved in 
developmental pigmentation 
CAGL0F08019g PEX21 
 
-2.06 -2.19 
 
-2.85 -1.67 Protein of unknown function 
CAGL0M09383g 
 
SEA4 -2.03 -1.91 
 
-1.22 -1.22 Ortholog(s) have Seh1-associated complex, cytosol, extrinsic 
component of fungal-type vacuolar membrane localization 
CAGL0M03311g 
 
GTT3 -2.02 -2.11 
 
-2.26 -2.20 Ortholog(s) have plasma membrane localization 
CAGL0L09581g 
 
DUT1 -2.01 -1.80 
 
-1.96 -3.79 Ortholog(s) have dITP diphosphatase activity, dUTP 
diphosphatase activity, role in dITP catabolic process, dUTP 
catabolic process and cytoplasm, nucleus localization 
CAGL0M07854g 
 
LSM8 -2.00 -7.00 
 
1.00 -1.75 Ortholog(s) have RNA binding activity, role in mRNA splicing, 
via spliceosome and U4/U6 x U5 tri-snRNP complex, U6 
snRNP, nucleolus localization 
CAGL0L09999g 
 
BSC2 -2.00 -3.67 
 
-2.00 1.27 Ortholog(s) have lipid particle localization 
CAGL0M00110g AWP11 
 
-2.00 -2.33 
 
-2.67 -1.75 Putative adhesin-like protein; GPI-anchored; belongs to adhesin 
cluster V; ORF appears artificially broken into fragments due to 
sequencing errors but the gene is likely protein-coding based on 
mass spectrometry data 
CAGL0L06050g 
 
MND1 -2.00 -2.30 
 
-2.67 -2.56 Ortholog(s) have double-stranded DNA binding activity, role in 
reciprocal meiotic recombination and condensed nuclear 
chromosome localization 
CAGL0J06006g GIM3 -2.00 -2.00 -2.00 1.13 Ortholog(s) have tubulin binding activity, role in positive 
regulation of transcription elongation from RNA polymerase 
II promoter, tubulin complex assembly and cytoplasm, 
prefoldin complex localization 
CAGL0G03289g SSA3 SSA4 -2.00 -1.54 
 
-1.69 1.66 Heat shock protein of the HSP70 family 
CAGL0E01969g 
 
SMF1 -2.00 -2.58 
 
-2.09 -1.71 Ortholog(s) have inorganic cation transmembrane transporter 
activity, solute:proton symporter activity 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0D06314g 
  
-1.99 -1.64 
 
-1.53 -1.07 Has domain(s) with predicted DNA binding, RNA binding 
activity and role in RNA metabolic process 
CAGL0B02145g 
 
SKG6 -1.98 -6.24 
 
-1.67 -3.60 Ortholog(s) have cell cortex, cellular bud neck, cellular bud tip, 
incipient cellular bud site, integral component of membrane 
localization 
CAGL0J00517g 
 
RRM3 -1.98 -2.32 
 
-1.76 -1.73 Ortholog(s) have ATP-dependent DNA helicase activity and role 
in DNA replication, G-quadruplex DNA unwinding, mitochondrial 
genome maintenance, replication fork progression beyond 
termination site 
CAGL0I04818g 
 
CHS2 -1.98 -1.72 
 
-1.71 -1.24 Ortholog(s) have chitin synthase activity 
CAGL0I10791g 
 
ARG3 -1.98 -2.09 
 
-1.53 1.19 Ortholog(s) have ornithine carbamoyltransferase activity, role 
in arginine biosynthetic process via ornithine, asexual 
sporulation and cytosol, mitochondrial matrix localization 
CAGL0F04323g 
 
POL12 -1.97 -3.26 
 
-1.71 -2.36 Ortholog(s) have DNA-directed DNA polymerase activity, role in 
DNA replication initiation, telomere capping and alpha DNA 
polymerase:primase complex, cytosol, nuclear envelope 
localization 
CAGL0B04851g 
 
BUD3 -1.95 -2.04 
 
-1.94 -1.11 Ortholog(s) have role in axial cellular bud site selection, 
cytogamy and cellular bud neck contractile ring localization 
CAGL0M00682g 
 
YLR446W -1.94 -2.53 
 
1.03 -1.09 Has domain(s) with predicted ATP binding, 
phosphotransferase activity, alcohol group as acceptor activity 
and role in carbohydrate metabolic process 
CAGL0L01793g 
 
SPC42 -1.94 -1.88 
 
-1.14 -1.69 Ortholog(s) have structural constituent of cytoskeleton 
activity, role in microtubule nucleation, spindle pole body 
duplication and central plaque of spindle pole body, 
intermediate layer of spindle pole body localization 
CAGL0L01551g SUR7 -1.93 -2.04 -1.88 -2.60 Ortholog(s) have role in ascospore formation, cellular response to 
biotic stimulus, cellular response to chemical stimulus, cellular 
response to glucose starvation and cellular response to neutral pH, 
more 
CAGL0D03256g 
  
-1.92 -1.97 
 
-1.61 -1.50 Has domain(s) with predicted role in lipid metabolic process 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0I03784g 
 
CRD1 -1.92 -1.92 
 
1.03 1.49 Ortholog(s) have cardiolipin synthase activity, role in cellular 
ion homeostasis, lipid biosynthetic process, mitochondrial 
membrane organization and mitochondrion localization 
CAGL0J05104g 
 
YHC3 -1.92 -2.69 
 
-1.14 1.28 Ortholog(s) have role in actin cortical patch localization, 
arginine transport, cellular protein localization, endocytosis, 
late endosome to vacuole transport and lysine transport, more 
CAGL0A04081g 
 
YLR194C -1.91 -2.45 
 
-1.81 -1.71 Predicted GPI-linked cell wall protein 
CAGL0L08184g FEN1 
 
-1.90 -1.92 
 
-1.75 -4.57 Predicted fatty acid elongase with role in sphingolipid biosynthetic 
process; mutants show reduced sensitivity to caspofungin and 
increased sensitivity to micafungin 
CAGL0D05918g ATF2 ATF2 -1.90 -2.29 
 
-1.46 -2.89 Putative alcohol acetyltransferase involved in steroid 
detoxification; gene is upregulated in azole-resistant strain 
CAGL0E04818g 
 
MFB1 -1.89 -1.53 
 
-1.79 -1.98 Ortholog(s) have role in mitochondrion organization and extrinsic 
component of mitochondrial outer membrane localization 
CAGL0F08591g 
 
NKP2 -1.89 -2.78 
 
-1.55 -2.08 Ortholog(s) have role in chromosome segregation and kinetochore, 
spindle pole body localization 
CAGL0F07843g 
 
GPI10 -1.87 -1.84 
 
-2.05 -1.98 Ortholog(s) have dolichyl-phosphate-mannose-glycolipid alpha-
mannosyltransferase activity, role in GPI anchor biosynthetic 
process and endoplasmic reticulum localization 
CAGL0M11550g 
 
CDC45 -1.86 -2.71 
 
-1.77 -2.11 Ortholog(s) have DNA replication origin binding, chromatin 
binding, single-stranded DNA binding activity 
CAGL0K03355g 
 
SRT1 -1.86 -2.29 
 
1.31 1.13 Ortholog(s) have dehydrodolichyl diphosphate synthase 
activity, role in isoprenoid biosynthetic process, protein 
glycosylation and lipid particle localization 
CAGL0H08712g -1.85 -3.87 -1.69 -2.54 Has domain(s) with predicted phosphatidylinositol binding activity 
and role in cell communication 
CAGL0G03685g 
  
-1.85 -1.65 
 
1.39 -1.39 Protein of unknown function 
CAGL0M09207g 
 
STE18 -1.85 -1.50 
 
-2.18 1.42 Ortholog(s) have signal transducer activity 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0L07348g 
 
POL3 -1.84 -1.77 
 
-1.14 -3.09 Ortholog(s) have 3'-5'-exodeoxyribonuclease activity, DNA-
directed DNA polymerase activity and role in DNA replication, 
removal of RNA primer, DNA-dependent DNA replication 
maintenance of fidelity, RNA-dependent DNA replication 
CAGL0M06677g 
 
HHF2 -1.84 -9.42 
 
-1.89 -3.23 Ortholog(s) have role in histone H3-K79 methylation, sexual 
sporulation resulting in formation of a cellular spore and nucleus 
localization 
CAGL0D01716g 
 
POL30 -1.84 -2.37 
 
-1.57 -2.83 Ortholog(s) have DNA polymerase processivity factor activity 
CAGL0D00528g 
 
FAS1 -1.83 -1.77 
 
-1.83 -1.49 Ortholog(s) have 3-hydroxyacyl-[acyl-carrier-protein] 
dehydratase activity, [acyl-carrier-protein] S-acetyltransferase 
activity and [acyl-carrier-protein] S-malonyltransferase 
activity, more 
CAGL0F01793g ERG3 ERG3 -1.83 -1.64 
 
-1.20 -4.84 Delta 5,6 sterol desaturase; C-5 sterol desaturase; predicted 
transmembrane domain and endolasmic reticulum (ER) 
binding motif; gene used for molecular typing of C. glabrata 
strain isolates 
CAGL0K05599g 
 
DIA2 -1.83 -1.53 
 
-1.71 -1.70 Ortholog(s) have DNA replication origin binding, ubiquitin-
protein transferase activity 
CAGL0F00363g OPI3 OPI3 -1.82 -1.61 
 
-1.77 1.77 Ortholog(s) have phosphatidyl-N-dimethylethanolamine N-
methyltransferase activity, phosphatidyl-N-
methylethanolamine N-methyltransferase activity and role in 
cleistothecium development, phosphatidylcholine biosynthetic 
process 
CAGL0K05973g HSP60 HSP60 -1.82 -2.32 
 
-1.97 -1.22 Heat shock protein 60, mitochondrial precursor; putative 
chaperonin 
CAGL0H10054g YBR053C -1.80 -1.53 -1.70 1.08 Ortholog of S. cerevisiae : YBR053C, C. albicans SC5314 : 
C4_02760C_A/CGR1, C. dubliniensis CD36 : Cd36_42630, C. 
parapsilosis CDC317 : CPAR2_400280 and Candida tenuis 
NRRL Y-1498 : CANTEDRAFT_113139 
CAGL0H09482g 
  
-1.80 -2.67 
 
-1.80 -1.14 Protein of unknown function 
CAGL0J11572g NUF2 NUF2 -1.80 -1.81 
 
1.00 -1.40 Putative spindle pole body protein 
CAGL0I02134g PEX21B PEX18 -1.80 -1.70 
 
-1.27 -1.39 Ortholog(s) have role in protein import into peroxisome 
matrix and cytosol, peroxisome localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0M09086g 
 
BUD4 -1.80 -2.29 
 
-1.72 -1.59 Ortholog(s) have GTP binding, cell adhesion molecule binding 
activity 
CAGL0G08668g 
 
SUN4 -1.79 -6.64 
 
-1.53 -5.64 Ortholog(s) have glucan endo-1,3-beta-D-glucosidase activity 
CAGL0F05533g 
 
CBS2 -1.79 -2.00 
 
-1.83 1.45 Ortholog(s) have translation regulator activity and role in 
mitochondrial respiratory chain complex III biogenesis, 
positive regulation of mitochondrial translation 
CAGL0M11858g 
 
SPC25 -1.79 -2.42 
 
-1.79 -2.23 Ortholog(s) have structural constituent of cytoskeleton activity, 
role in chromosome segregation, microtubule nucleation and 
Ndc80 complex, condensed nuclear chromosome kinetochore 
localization 
CAGL0J03740g 
 
SSP2 -1.79 -1.71 
 
-2.00 -1.03 Ortholog(s) have role in ascospore wall assembly, positive 
regulation of protein autophosphorylation and ascospore wall, 
prospore membrane localization 
CAGL0A04169g 
 
MMR1 -1.79 -1.51 
 
-1.60 -1.57 Ortholog(s) have role in mitochondrion inheritance and cellular 
bud neck, incipient cellular bud site, mitochondrial outer 
membrane localization 
CAGL0E01023g 
 
CWC15 -1.78 -1.66 
 
-1.05 -1.66 Ortholog(s) have RNA binding activity, role in mRNA cis 
splicing, via spliceosome and Prp19 complex, U2-type 
spliceosomal complex localization 
CAGL0B00242g 
 
HMLALPHA1 -1.78 -1.91 
 
-1.60 -1.31 Alpha-domain mating-type protein alpha1p 
CAGL0J11638g 
 
CDC5 -1.78 -1.62 
 
-1.53 -1.07 Ortholog(s) have enzyme activator activity, protein kinase 
activity 
CAGL0F02585g 
 
URH1 -1.78 -2.79 
 
-2.49 -1.07 Ortholog(s) have nicotinamide riboside hydrolase activity, 
nicotinic acid riboside hydrolase activity, uridine nucleosidase 
activity 
CAGL0G09801g DPB2 -1.78 -3.35 -1.12 -2.03 Ortholog(s) have DNA-directed DNA polymerase activity, 
double-stranded DNA binding, single-stranded DNA binding 
activity 
CAGL0K06457g 
 
RMT2 -1.77 -1.57 
 
1.11 -1.60 Ortholog(s) have protein-arginine N5-methyltransferase 
activity, role in peptidyl-arginine methylation and cytosol, 
nucleus localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0F05731g 
 
PLP1 -1.75 -1.67 
 
-1.75 1.03 Ortholog(s) have G-protein beta/gamma-subunit complex 
binding activity, role in positive regulation of transcription 
from RNA polymerase II promoter by pheromones, protein 
folding and cytosol, nucleus localization 
CAGL0K07876g 
 
MDM36 -1.75 -2.57 
 
-1.00 1.31 Ortholog(s) have role in mitochondrial fission, mitochondrion 
inheritance and mitochondrion localization 
CAGL0I05940g 
 
SFH5 -1.75 -3.15 
 
-1.32 -1.68 Ortholog(s) have phosphatidylinositol transporter activity 
CAGL0I09328g 
 
TSC10 -1.74 -1.96 
 
-1.83 -2.15 Ortholog(s) have 3-dehydrosphinganine reductase activity, role in 
3-keto-sphinganine metabolic process, sphingolipid biosynthetic 
process and endoplasmic reticulum, lipid particle, mitochondrial 
outer membrane localization 
CAGL0E01331g SWI5 
 
-1.74 -2.07 
 
-1.92 -1.69 Transcription factor; mutants display increased fungal burdens in 
mouse lungs and brain 
CAGL0E04268g 
 
YML037C -1.74 -2.13 
 
1.06 -1.34 Ortholog(s) have clathrin-coated vesicle localization 
CAGL0B04873g 
 
DCC1 -1.73 -2.38 
 
-2.00 -1.58 Ortholog(s) have role in attachment of spindle microtubules to 
kinetochore involved in homologous chromosome segregation, 
cellular response to DNA damage stimulus, maintenance of DNA 
trinucleotide repeats, mitotic sister chromatid cohesion 
CAGL0G04851g SUR4 ELO3 -1.72 -1.88 
 
-1.75 -4.01 Predicted fatty acid elongase involved in production of very long 
chain fatty acids for sphingolipid biosynthesis; mutants show 
reduced sensitivity to caspofungin and increased sensitivity to 
micafungin 
CAGL0I04422g 
 
KIN3 -1.72 -1.86 
 
-1.16 -1.57 Putative protein kinase; gene is upregulated in azole-resistant 
strain 
CAGL0B01243g MATalpha1 MATALPHA1 -1.72 -2.11 
 
-1.63 -1.19 Alpha-domain mating-type protein alpha1p; expressed in all 
MTLalpha strains and not in MTLa strains 
CAGL0H07161g HIM1 -1.72 -1.62 -1.63 -1.97 Ortholog(s) have role in DNA repair 
CAGL0M04499g 
 
PUT1 -1.72 -1.79 
 
-1.53 1.32 Ortholog(s) have proline dehydrogenase activity, role in 
proline catabolic process to glutamate and mitochondrion 
localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0B04543g 
 
CRC1 -1.71 -1.98 
 
-1.59 -1.12 Ortholog(s) have carnitine transmembrane transporter 
activity, carnitine:acyl carnitine antiporter activity and role in 
acetate catabolic process, carbon utilization, carnitine 
transport, fatty acid metabolic process 
CAGL0M13805g MP65 SCW10 -1.71 -2.77 
 
-1.51 -2.26 65 kDa mannoprotein 
CAGL0I02464g 
 
SPC97 -1.71 -1.76 
 
-1.50 -1.73 Putative component of microtubule-nucleating complex; gene is 
upregulated in azole-resistant strain 
CAGL0M06655g 
 
HHT2 -1.71 -2.90 
 
-1.75 -3.14 Ortholog(s) have role in DNA methylation, global genome 
nucleotide-excision repair, mitotic spindle assembly checkpoint, 
rRNA transcription, regulation of DNA methylation, sexual 
sporulation resulting in formation of a cellular spore 
CAGL0G02409g 
 
SRP40 -1.71 -2.83 
 
-1.40 -3.08 Ortholog(s) have nucleolus localization 
CAGL0M05621g 
  
-1.71 -1.60 
 
-1.58 -1.65 Ortholog(s) have role in endocytosed protein transport to vacuole, 
endocytosis, mannosyl-inositol phosphorylceramide biosynthetic 
process and cis-Golgi network membrane, trans-Golgi network 
membrane localization 
CAGL0H01683g 
 
URC2 -1.71 -4.29 
 
-1.05 -1.26 Ortholog(s) have sequence-specific DNA binding activity and 
cytoplasm, nucleus localization 
CAGL0C02431g 
 
FIR1 -1.71 -3.44 
 
-1.47 -1.95 Ortholog(s) have role in mRNA polyadenylation and cellular 
bud neck localization 
CAGL0E04906g 
 
AHA1 -1.70 -2.04 
 
-1.37 -1.13 Ortholog(s) have ATPase activator activity, chaperone binding 
activity, role in cellular response to heat, protein folding and 
cytosol localization 
CAGL0F04092g 
  
-1.70 -1.83 
 
1.06 1.04 Unknown 
CAGL0J08822g 
 
CLB4 -1.70 -1.61 
 
-1.32 -1.82 Ortholog(s) have cyclin-dependent protein serine/threonine 
kinase regulator activity 
CAGL0M06237g EEB1 -1.70 -1.55 -1.56 -1.86 Ortholog(s) have alcohol O-octanoyltransferase activity, short-
chain carboxylesterase activity and role in medium-chain fatty acid 
biosynthetic process, medium-chain fatty acid catabolic process 
CAGL0E01243g 
 
TIS11 -1.68 -1.75 
 
-1.26 1.55 Ortholog(s) have mRNA binding activity, role in cellular iron 
ion homeostasis, nuclear-transcribed mRNA catabolic process, 
regulation of mRNA catabolic process and cytoplasm, nucleus 
localization 
 144 
Table B-2. (Continued). 
 
C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0D02948g KAR2 KAR2 -1.68 -1.71 
 
-1.75 -1.79 Protein with a predicted role in nuclear fusion 
CAGL0G06666g 
 
POL1 -1.68 -1.85 
 
-1.35 -2.32 Ortholog(s) have DNA replication origin binding, DNA-
directed DNA polymerase activity, chromatin binding, single-
stranded DNA binding activity 
CAGL0L01969g 
 
YKL033W-A -1.68 -1.74 
 
-2.28 -1.33 Ortholog(s) have cytosol, nucleus localization 
CAGL0K02387g 
 
ROK1 -1.68 -1.87 
 
-1.37 -2.89 Ortholog(s) have ATP-dependent RNA helicase activity 
CAGL0G03795g SSA1 SSA2 -1.67 -2.98 
 
-1.78 -3.15 Heat shock protein of the HSP70 family 
CAGL0M08096g 
  
-1.67 -3.20 
 
-1.15 -4.00 Protein of unknown function 
CAGL0C01727g 
 
ALG7 -1.66 -1.80 
 
-1.83 -1.69 Ortholog(s) have UDP-N-acetylglucosamine-dolichyl-phosphate 
N-acetylglucosaminephosphotransferase activity and role in N-
glycan processing, aerobic respiration, cellular response to drug, 
dolichyl diphosphate biosynthetic process 
CAGL0J11110g 
 
MRX12 -1.66 -2.64 
 
-1.29 -2.07 Ortholog(s) have mitochondrion localization 
CAGL0C03135g 
 
YCS4 -1.66 -1.60 
 
-1.49 -1.20 Ortholog(s) have chromatin binding activity 
CAGL0I03740g 
 
YDL144C -1.66 -2.12 
 
-1.50 -2.46 Ortholog(s) have cytoplasm, nucleus localization 
CAGL0A02431g YPS7 YPS7 -1.66 -1.66 
 
-1.79 -2.96 Putative aspartic protease; predicted GPI-anchor; expression 
induced at high temperature 
CAGL0I02508g 
 
CTR2 -1.65 -3.81 
 
-1.54 -1.26 Ortholog(s) have copper uptake transmembrane transporter 
activity and role in cellular copper ion homeostasis, copper ion 
import, copper ion transmembrane transport, intracellular 
copper ion transport 
CAGL0J01287g AIP1 AIP1 -1.65 -1.91 
 
-1.60 -1.09 Putative actin cytoskeleton component 
CAGL0G08085g -1.63 -1.80 -1.46 -1.97 Has domain(s) with predicted ATP binding, cation-
transporting ATPase activity, magnesium ion binding, metal 
ion binding, nucleotide binding, phospholipid-translocating 
ATPase activity and role in cation transport, phospholipid 
transport 
CAGL0C03575g 
 
AGA1 -1.63 -2.29 
 
-1.11 -1.22 Predicted GPI-linked protein; putative adhesin-like protein 
CAGL0K02981g 
 
NAT4 -1.63 -2.93 
 
-1.20 -1.07 Ortholog(s) have histone acetyltransferase activity, role in 
histone acetylation, phenotypic switching, regulation of 
chromatin silencing at rDNA and cell division site, cytosol, 
nucleus localization 
CAGL0G04939g 
 
MDM30 -1.63 -1.73 
 
1.08 -1.63 Ortholog(s) have ubiquitin-protein transferase activity 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0I03630g 
 
RPC53 -1.62 -2.66 
 
-1.32 -2.72 Ortholog(s) have RNA polymerase III activity, role in tRNA 
transcription from RNA polymerase III promoter and DNA-
directed RNA polymerase III complex, cytosol localization 
CAGL0G07249g 
 
YOX1 -1.61 -1.51 
 
-1.10 -3.10 Ortholog(s) have RNA polymerase II regulatory region 
sequence-specific DNA binding, RNA polymerase II 
transcription factor binding transcription factor activity 
involved in negative regulation of transcription activity 
CAGL0L07898g 
 
MAK32 -1.61 -1.88 
 
-1.45 2.67 Ortholog(s) have role in interspecies interaction between 
organisms 
CAGL0L10340g 
 
SLD7 -1.61 -3.58 
 
1.11 -2.15 Ortholog(s) have role in regulation of DNA-dependent DNA 
replication initiation and DNA replication preinitiation 
complex, chromosome, centromeric region, endoplasmic 
reticulum, nuclear envelope, spindle pole body localization 
CAGL0G09581g 
 
TUF1 -1.61 -1.64 
 
-1.68 1.17 Ortholog(s) have GTPase activity, translation elongation 
factor activity, role in mitochondrial translational elongation 
and mitochondrion localization 
CAGL0D05940g ERG1 ERG1 -1.60 -1.53 
 
-1.39 -2.55 Squalene epoxidase with a role in ergosterol synthesis; 
involved in growth under conditions of low oxygen tension 
CAGL0J05236g 
 
LAS21 -1.60 -1.65 
 
-1.52 -2.01 Ortholog(s) have mannose-ethanolamine phosphotransferase 
activity 
CAGL0J07480g 
 
BNI4 -1.60 -1.68 
 
-1.44 -1.29 Ortholog(s) have role in asymmetric protein localization, 
barrier septum assembly, cellular response to biotic stimulus, 
cellular response to starvation and chitin biosynthetic process, 
more 
CAGL0I01166g TRR1 
 
-1.60 -1.64 
 
-1.47 -6.19 Thioredoxin reductase (NADPH) 
CAGL0M02321g 
  
-1.59 -1.51 
 
-1.21 -1.77 Protein of unknown function 
CAGL0I09746g SLY41 -1.59 -1.95 -1.57 -1.82 Ortholog(s) have phosphoenolpyruvate transmembrane transporter 
activity, role in ER to Golgi vesicle-mediated transport, 
phosphoenolpyruvate transmembrane import into Golgi lumen and 
Golgi apparatus, endoplasmic reticulum localization 
CAGL0G00682g 
  
-1.58 -1.66 
 
-1.31 -1.26 Ortholog(s) have Golgi apparatus, endoplasmic reticulum 
localization 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0K11418g ADK1 ADK1 -1.58 -1.73 
 
-1.41 -1.45 Putative adenylate kinase; protein differentially expressed in 
azole-resistant strain 
CAGL0L03454g 
 
SRS2 -1.58 -1.90 
 
-1.35 -2.87 Ortholog(s) have DNA helicase activity 
CAGL0G06226g 
 
LTE1 -1.57 -1.98 
 
-1.60 -1.53 Ortholog(s) have role in vesicle-mediated transport and cellular 
bud localization 
CAGL0F07601g CWP1.1 CWP2 -1.57 -1.71 
 
-1.23 1.06 GPI-linked cell wall protein 
CAGL0H09438g 
 
BIM1 -1.57 -2.22 
 
-1.61 -2.84 Ortholog(s) have ATPase activator activity, microtubule plus-end 
binding, protein homodimerization activity, structural constituent 
of cytoskeleton activity 
CAGL0K02739g 
  
-1.57 -2.72 
 
-1.46 -2.40 Ortholog(s) have sphingosine N-acyltransferase activity and 
role in ceramide biosynthetic process 
CAGL0M05599g 
 
TOS1 -1.57 -1.91 
 
-1.51 -2.46 Ortholog(s) have cell surface, endoplasmic reticulum, extracellular 
region, fungal-type vacuole, hyphal cell wall localization 
CAGL0F01287g GAS5 GAS5 -1.57 -2.07 
 
-1.36 -2.04 Putative transglycosidase with a predicted role in the 
elongation of 1,3-beta-glucan 
CAGL0E01727g YPS3 
 
-1.56 -2.69 
 
-1.51 -2.68 Putative aspartic protease; predicted GPI-anchor; member of a 
YPS gene cluster that is required for virulence in mice 
CAGL0D02596g 
 
PSF3 -1.56 -1.85 
 
-1.81 -2.28 Ortholog(s) have role in GINS complex assembly, double-strand 
break repair via break-induced replication, mitotic DNA 
replication initiation, mitotic DNA replication preinitiation 
complex assembly 
CAGL0J09702g 
 
ACK1 -1.56 -1.88 
 
-1.52 -1.65 Ortholog(s) have role in fungal-type cell wall organization, 
positive regulation of signal transduction and mitochondrion 
localization 
CAGL0I01958g 
  
-1.56 -1.84 
 
1.08 -1.19 Protein of unknown function 
CAGL0M08448g MCD4 -1.56 -2.78 -1.47 -2.54 Ortholog(s) have mannose-ethanolamine phosphotransferase 
activity and role in ATP transport, GPI anchor biosynthetic 
process, conidium formation, fungal-type cell wall 
organization or biogenesis, regulation of growth rate 
CAGL0F01485g TIR2 TIR4 -1.55 -1.90 
 
-1.30 -2.46 Putative GPI-linked cell wall mannoprotein of the 
Srp1p/Tip1p family 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0H02805g 
 
SMC3 -1.55 -1.56 
 
-1.28 -1.09 Ortholog(s) have role in ascospore formation, meiotic sister 
chromatid cohesion, mitotic sister chromatid cohesion, positive 
regulation of maintenance of mitotic sister chromatid cohesion 
and centromeric, more 
CAGL0I07249g 
 
BAG7 -1.54 -2.13 
 
-1.52 1.07 Putative GTPase-activating protein involved in cell wall and 
cytoskeleton homeostasis; gene is upregulated in azole-
resistant strain 
CAGL0L05610g 
 
SPT10 -1.54 -1.62 
 
-1.07 -2.11 Ortholog(s) have sequence-specific DNA binding activity 
CAGL0K11132g 
 
SNU56 -1.54 -1.53 
 
-1.12 -1.19 Ortholog(s) have mRNA binding activity, role in mRNA 
splicing, via spliceosome and U1 snRNP, U2-type 
prespliceosome, commitment complex localization 
CAGL0M00330g HOM6 HOM6 -1.54 -1.78 
 
-1.81 -1.59 Ortholog(s) have homoserine dehydrogenase activity, role in 
homoserine biosynthetic process, methionine biosynthetic process, 
threonine biosynthetic process and cytoplasm, nucleus localization 
CAGL0H00759g 
 
SGS1 -1.54 -1.58 
 
-1.07 -1.05 Ortholog(s) have ATP-dependent DNA helicase activity 
CAGL0L10714g ERG2 ERG2 -1.54 -2.26 
 
-1.68 -2.37 C-8 sterol isomerase 
CAGL0K04477g 
 
ERG25 -1.54 -3.14 
 
-1.06 -5.11 Ortholog(s) have C-4 methylsterol oxidase activity, role in 
ergosterol biosynthetic process and endoplasmic reticulum 
membrane, plasma membrane localization 
CAGL0M08514g PIR5 PIR3 -1.53 -2.03 
 
-1.26 -1.30 Pir protein family member, putative cell wall component 
CAGL0G08129g 
 
MSH6 -1.53 -3.01 
 
-1.35 -3.25 Ortholog(s) have ATP binding, ATPase activity, four-way 
junction DNA binding, guanine/thymine mispair binding, 
single base insertion or deletion binding activity 
CAGL0M13035g DEF1 -1.52 -2.77 -1.04 -1.66 Ortholog(s) have role in protein ubiquitination, telomere 
maintenance, transcription-coupled nucleotide-excision repair, 
ubiquitin-dependent protein catabolic process and nucleus 
localization 
CAGL0A03905g 
 
HMX1 -1.52 -1.54 
 
-1.01 1.40 Ortholog(s) have heme oxygenase (decyclizing) activity and 
role in cellular iron ion homeostasis, heme catabolic process, 
response to carbon monoxide, response to oxidative stress 
CAGL0M11528g 
 
APC9 -1.52 -2.67 
 
1.00 1.21 Ortholog(s) have ubiquitin-protein transferase activity, role in 
chromatin assembly, protein ubiquitination and anaphase-
promoting complex localization 
 148 
Table B-2. (Continued). 
 
C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0M08228g 
 
LST4 -1.51 -1.90 
 
-1.56 -1.10 Ortholog(s) have protein transporter activity, role in Golgi to 
plasma membrane transport, intracellular protein transport 
and vesicle coat localization 
CAGL0K11506g 
 
RAD27 -1.51 -4.79 
 
-1.05 -3.29 Ortholog(s) have 5'-flap endonuclease activity, single-stranded 
DNA 5'-3' exodeoxyribonuclease activity 
CAGL0L03333g 
 
UIP5 -1.51 -1.77 
 
-1.26 -2.13 Ortholog(s) have nuclear envelope localization 
CAGL0A00561g 
 
RPN14 -1.51 -1.56 
 
-1.42 -1.35 Ortholog(s) have role in proteasome regulatory particle 
assembly, ubiquitin-dependent protein catabolic process and 
cytosol, nucleus localization 
CAGL0F07557g 
 
YJU2 -1.50 -3.60 
 
-1.57 -1.64 Ortholog(s) have first spliceosomal transesterification activity, role 
in generation of catalytic spliceosome for first transesterification 
step and U2-type catalytic step 1 spliceosome localization 
CAGL0M08580g 
 
CUE5 -1.50 -2.92 
 
-1.86 -1.03 Ortholog(s) have protein binding, bridging, ubiquitin binding 
activity, role in ubiquitin-dependent protein catabolic process 
and cytoplasm localization 
CAGL0J04334g 
 
POP8 -1.50 -2.80 
 
1.17 -1.75 Ortholog(s) have ribonuclease MRP activity, ribonuclease P 
activity, role in intronic box C/D snoRNA processing, mRNA 
cleavage, tRNA processing and cytosol, nucleolar ribonuclease 
P complex, ribonuclease MRP complex localization 
CAGL0L10015g 
 
TOM6 -1.50 -1.94 
 
-1.38 1.09 Ortholog(s) have protein channel activity, role in 
mitochondrial outer membrane translocase complex assembly, 
protein import into mitochondrial matrix and mitochondrial 
outer membrane translocase complex localization 
CAGL0F04543g 
  
-1.50 -1.86 
 
1.33 -1.86 Protein of unknown function 
CAGL0I07997g MDM20 -1.50 -1.69 -1.05 -1.76 Ortholog(s) have peptide alpha-N-acetyltransferase activity, 
role in N-terminal peptidyl-methionine acetylation, 
cytoskeleton organization, mitochondrion inheritance and 
NatB complex localization 
CAGL0I09174g 
 
SHG1 -1.50 -1.65 
 
1.38 -2.00 Ortholog(s) have histone methyltransferase activity (H3-K4 
specific) activity, role in histone H3-K4 methylation and 
Set1C/COMPASS complex localization 
CAGL0M07744g 
  
-1.50 -1.50 
 
1.25 1.13 Protein of unknown function 
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Notes: Fold change is defined as the ratio of gene expression in SM1∆jjj1 compared to SM1 in two independent RNA-seq 
experiments. Bolded rows indicate genes whose down-regulation is dependent on PDR1 expression. 
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Table B-3. Adhesion related genes up-regulated by at least 1.5-fold in SM1∆jjj1 versus SM1. 
 
C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0K00170g EPA22 
 
7.06 2.98 
 
13.57 4.81 Putative adhesin-like protein; belongs to adhesin cluster I 
CAGL0E06688g EPA3 
 
5.21 3.96 
 
6.76 3.76 Epithelial adhesion protein; belongs to adhesin cluster I; GPI-
anchored 
CAGL0E06666g EPA2 
 
4.35 3.22 
 
6.57 4.38 Epithelial adhesion protein; predicted GPI-anchor; belongs to 
adhesin cluster I 
CAGL0I10147g PWP1 
 
3.83 5.07 
 
4.13 6.44 Protein with 32 tandem repeats; putative adhesin-like protein; 
belongs to adhesin cluster II 
CAGL0J05159g 
  
2.96 1.79 
 
2.70 1.49 Putative adhesin-like protein 
CAGL0E06644g EPA1 
 
2.90 4.56 
 
2.46 2.59 Sub-telomerically encoded adhesin with a role in cell adhesion; 
GPI-anchored cell wall protein; N-terminal ligand binding domain 
binds to ligands containing a terminal galactose residue; belongs to 
adhesin cluster I 
CAGL0L00157g 
  
2.73 6.48 
 
2.82 3.72 Putative adhesin-like protein; multiple tandem repeats; predicted 
GPI-anchor; belongs to adhesin cluster III 
CAGL0J01727g 
  
2.53 2.27 
 
2.21 1.89 Putative adhesion protein; predicted GPI-anchor; belongs to 
adhesin cluster VI 
CAGL0J01774g 
  
2.41 2.18 
 
2.80 2.62 Putative adhesin-like protein; has glycine and serine rich repeats; 
belongs to adhesin cluster VI 
CAGL0E00110g 
  
2.09 2.98 
 
3.01 2.30 Putative adhesin-like protein; ORF appears artificially broken into 
fragments due to sequencing errors; belongs to adhesin cluster III; 
predicted GPI anchor 
CAGL0L13299g EPA11 
 
1.78 1.91 
 
1.98 1.81 Putative adhesin; belongs to adhesin cluster I 
CAGL0L09911g 
 
CSS1 1.72 1.75 
 
1.65 1.41 Putative adhesin-like cell wall protein; 5 tandem repeats; 
predicted GPI-anchor 
CAGL0I00110g 1.64 1.56 1.65 2.31 Putative adhesin-like with multiple tandem repeats; ORF appears 
artificially broken into fragments due to sequencing errors; belongs 
to adhesin cluster III; predicted GPI-anchor 
CAGL0H08844g 
 
DDR48 1.58 1.66 
 
1.60 15.23 Putative adhesin-like protein 
CAGL0J02530g 
  
1.53 2.27 
 
1.92 4.41 Putative adhesion protein; predicted GPI-anchor; belongs to 
adhesin cluster VI 
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C. glabrata 
designation 
C. glabrata 
gene names 
S. cerevisiae 
orthologs 
SM1∆jjj1 vs SM1   SM1∆jjj1∆pdr1 vs SM1 
Description  Exp. 1 Exp. 2   Exp. 1 Exp. 2 
CAGL0E00231g 
  
1.51 2.26 
 
1.60 -1.06 Putative adhesin-like protein; contains tandem repeats and a 
predicted GPI-anchor; belongs to adhesin cluster III 
CAGL0I10200g PWP3 
 
1.50 1.93 
 
1.33 2.58 Protein with tandem repeats; putative adhesin-like protein; 
belongs to adhesin cluster II 
 
Notes: Fold change is defined as the ratio of gene expression in SM1∆jjj1 compared to SM1 in two independent RNA-seq 
experiments. Bolded rows indicate genes whose up-regulation is dependent on PDR1 expression. 
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